WO2021228135A1 - 制备抗原结合单元的方法 - Google Patents
制备抗原结合单元的方法 Download PDFInfo
- Publication number
- WO2021228135A1 WO2021228135A1 PCT/CN2021/093305 CN2021093305W WO2021228135A1 WO 2021228135 A1 WO2021228135 A1 WO 2021228135A1 CN 2021093305 W CN2021093305 W CN 2021093305W WO 2021228135 A1 WO2021228135 A1 WO 2021228135A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- abu
- less
- cells
- days
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 151
- 239000000427 antigen Substances 0.000 title claims description 526
- 108091007433 antigens Proteins 0.000 title claims description 526
- 102000036639 antigens Human genes 0.000 title claims description 526
- 230000027455 binding Effects 0.000 title claims description 392
- 238000009739 binding Methods 0.000 title claims description 390
- 241000711573 Coronaviridae Species 0.000 claims abstract description 63
- 210000004027 cell Anatomy 0.000 claims description 184
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 164
- 239000012634 fragment Substances 0.000 claims description 49
- 102100031673 Corneodesmosin Human genes 0.000 claims description 38
- 101710139375 Corneodesmosin Proteins 0.000 claims description 38
- 102100027207 CD27 antigen Human genes 0.000 claims description 18
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 18
- 108020003175 receptors Proteins 0.000 claims description 18
- 102000005962 receptors Human genes 0.000 claims description 18
- 230000002829 reductive effect Effects 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 238000010494 dissociation reaction Methods 0.000 claims description 16
- 230000005593 dissociations Effects 0.000 claims description 16
- 210000001806 memory b lymphocyte Anatomy 0.000 claims description 14
- 230000035772 mutation Effects 0.000 claims description 14
- 238000004458 analytical method Methods 0.000 claims description 13
- 230000003612 virological effect Effects 0.000 claims description 13
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 12
- 210000000822 natural killer cell Anatomy 0.000 claims description 9
- 230000007423 decrease Effects 0.000 claims description 8
- 210000004443 dendritic cell Anatomy 0.000 claims description 8
- 210000001616 monocyte Anatomy 0.000 claims description 8
- 238000012163 sequencing technique Methods 0.000 claims description 8
- 241000315672 SARS coronavirus Species 0.000 claims description 6
- 241001678559 COVID-19 virus Species 0.000 claims description 3
- 238000003306 harvesting Methods 0.000 claims description 3
- 101000629313 Severe acute respiratory syndrome coronavirus Spike glycoprotein Proteins 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 17
- 239000003814 drug Substances 0.000 abstract description 11
- 239000000203 mixture Substances 0.000 abstract description 11
- 238000002360 preparation method Methods 0.000 abstract description 10
- 230000002265 prevention Effects 0.000 abstract description 7
- 238000012216 screening Methods 0.000 abstract description 4
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 239000000032 diagnostic agent Substances 0.000 abstract description 2
- 229940039227 diagnostic agent Drugs 0.000 abstract description 2
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- 150000001413 amino acids Chemical class 0.000 description 123
- 238000012217 deletion Methods 0.000 description 102
- 230000037430 deletion Effects 0.000 description 102
- 238000006467 substitution reaction Methods 0.000 description 100
- 108090000765 processed proteins & peptides Proteins 0.000 description 88
- 102000004196 processed proteins & peptides Human genes 0.000 description 85
- 229920001184 polypeptide Polymers 0.000 description 79
- 230000006229 amino acid addition Effects 0.000 description 78
- 241000700605 Viruses Species 0.000 description 72
- 108090000623 proteins and genes Proteins 0.000 description 40
- 239000000523 sample Substances 0.000 description 35
- 230000003472 neutralizing effect Effects 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 28
- 244000052769 pathogen Species 0.000 description 27
- 108091033319 polynucleotide Proteins 0.000 description 27
- 102000040430 polynucleotide Human genes 0.000 description 27
- 239000002157 polynucleotide Substances 0.000 description 27
- 235000001014 amino acid Nutrition 0.000 description 26
- 238000010790 dilution Methods 0.000 description 25
- 239000012895 dilution Substances 0.000 description 25
- 230000001717 pathogenic effect Effects 0.000 description 25
- 238000007792 addition Methods 0.000 description 24
- 241001112090 Pseudovirus Species 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 238000006386 neutralization reaction Methods 0.000 description 16
- 239000013598 vector Substances 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 230000008707 rearrangement Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 208000001528 Coronaviridae Infections Diseases 0.000 description 10
- 241000699800 Cricetinae Species 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 108091008875 B cell receptors Proteins 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 206010035664 Pneumonia Diseases 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 239000006143 cell culture medium Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000005291 magnetic effect Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 230000009385 viral infection Effects 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 101710198474 Spike protein Proteins 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 6
- -1 antibodies Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 229940096437 Protein S Drugs 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000013357 binding ELISA Methods 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 230000001018 virulence Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000186226 Corynebacterium glutamicum Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000007857 nested PCR Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000186146 Brevibacterium Species 0.000 description 2
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241001467578 Microbacterium Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 231100000645 Reed–Muench method Toxicity 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 241000319304 [Brevibacterium] flavum Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 150000002344 gold compounds Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
- 229960004171 hydroxychloroquine Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 239000000367 immunologic factor Substances 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 229960001639 penicillamine Drugs 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 238000007861 thermal asymmetric interlaced PCR Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- VUAFHZCUKUDDBC-SCSAIBSYSA-N (2s)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid Chemical compound CC(C)(S)C(=O)N[C@H](CS)C(O)=O VUAFHZCUKUDDBC-SCSAIBSYSA-N 0.000 description 1
- AMFDITJFBUXZQN-KUBHLMPHSA-N (2s,3s,4r,5r)-2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol Chemical compound C=1NC=2C(N)=NC=NC=2C=1[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O AMFDITJFBUXZQN-KUBHLMPHSA-N 0.000 description 1
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- ZUXIYCHITJQXIU-UHFFFAOYSA-N 10-[3-[4-[2-(1,3-dioxan-2-yl)ethyl]piperazin-1-yl]propyl]phenothiazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CCCN(CC1)CCN1CCC1OCCCO1 ZUXIYCHITJQXIU-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241001533384 Circovirus Species 0.000 description 1
- 241000494545 Cordyline virus 2 Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241001517047 Corynebacterium acetoacidophilum Species 0.000 description 1
- 241000186145 Corynebacterium ammoniagenes Species 0.000 description 1
- 241001485655 Corynebacterium glutamicum ATCC 13032 Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 241000235646 Cyberlindnera jadinii Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100037931 Harmonin Human genes 0.000 description 1
- 101710132730 Harmonin Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000724675 Hepatitis E virus Species 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241001479210 Human astrovirus Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000046923 Human bocavirus Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- 241000829111 Human polyomavirus 1 Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 229940125583 Inovio COVID-19 vaccine Drugs 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241000144155 Microbacterium ammoniaphilum Species 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241000526636 Nipah henipavirus Species 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 241000311088 Schwanniomyces Species 0.000 description 1
- 241000235005 Schwanniomyces occidentalis var. occidentalis Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000881765 Serratia ficaria Species 0.000 description 1
- 241000218654 Serratia fonticola Species 0.000 description 1
- 241000607717 Serratia liquefaciens Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 241001634922 Tausonia pullulans Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 241000223230 Trichosporon Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229940119059 actemra Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000007844 allele-specific PCR Methods 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000007845 assembly PCR Methods 0.000 description 1
- 229960002118 asunaprevir Drugs 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 238000007846 asymmetric PCR Methods 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960000517 boceprevir Drugs 0.000 description 1
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229960004272 bucillamine Drugs 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- CLOMYZFHNHFSIQ-UHFFFAOYSA-N clonixin Chemical compound CC1=C(Cl)C=CC=C1NC1=NC=CC=C1C(O)=O CLOMYZFHNHFSIQ-UHFFFAOYSA-N 0.000 description 1
- 229960001209 clonixin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007847 digital PCR Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960000980 entecavir Drugs 0.000 description 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229950009614 gimsilumab Drugs 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229940015045 gold sodium thiomalate Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000007849 hot-start PCR Methods 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960003998 ifenprodil Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007852 inverse PCR Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000007855 methylation-specific PCR Methods 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 238000007856 miniprimer PCR Methods 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950000844 mizoribine Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 210000003720 plasmablast Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000004915 pus Anatomy 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 1
- 229960002063 sofosbuvir Drugs 0.000 description 1
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960002935 telaprevir Drugs 0.000 description 1
- 108010017101 telaprevir Proteins 0.000 description 1
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 description 1
- 229960005311 telbivudine Drugs 0.000 description 1
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- This article relates to the field of immunology and molecular virology, especially the diagnosis, prevention and treatment of the new coronavirus. Specifically, this article relates to antibodies against the novel coronavirus, and compositions containing the antibodies (for example, diagnostic agents and therapeutic agents). In addition, this article also relates to the screening, preparation and use of the antibody.
- the antibodies described herein can be used to diagnose, prevent, and/or treat a novel coronavirus infection and/or diseases caused by the infection (for example, novel coronavirus pneumonia).
- coronavirus SARS-CoV-2 is the pathogen that causes the new type of coronavirus pneumonia (COVID-19). It is a single-stranded RNA virus.
- MERS-CoV Middle East respiratory syndrome coronavirus
- Coronavirus particles are round or elliptical, and also pleomorphic, with a diameter of 50-200nm, which is a relatively large virus.
- Coronavirus is an enveloped virus. A lipid envelope is wrapped around the virus capsid, and a wide spike protein (Spike, S protein, SEQ ID No: 1460) is arranged on it, which is shaped like a sun halo.
- the new coronavirus SARS-CoV-2 has an S protein on the surface of the virus, which can bind to the host cell receptor angiotensin conversion through the receptor binding domain (RBD) contained in the virus in the process of infecting the host.
- Enzyme 2 (ACE2) molecule which initiates the fusion of the viral membrane with the host cell membrane, causing the host cell to infect the virus.
- a method of providing an antigen-binding unit for a predetermined antigen comprising (a) obtaining a blood sample from an individual, wherein the individual is confirmed to carry the antigen at the first time, and the The second time after the first time is confirmed not to carry the antigen or the amount of the antigen carried is reduced; (b) enriching the B cells in the blood sample; (c) for including multiple individuals VDJ sequencing of the single-cell transcriptome of a sample of enriched B cells is performed to provide clonotype information of the antigen-binding unit; and (d) confirming the antigen-binding unit for the antigen based on the clonotype information.
- the step (b) of the method further includes selecting memory B cells in the blood sample.
- the method before the step (c) further includes eliminating at least 30%, 40%, 50%, 60%, 70% by one, two, three, or four of the following steps: %, 80%, 90%, 95% of the enriched B cells: select CD27+ B cells; exclude naive B cells; exclude depleted B cells; exclude non-B cells; and select which can bind the antigen Cell.
- the method further comprises performing one, two, three, four, five or more of the following steps after step (c) to exclude at least 30%, 40%, 50% , 60%, 70%, 80%, 90%, 95% of antigen-binding unit clonotypes: select clonotypes with an enrichment frequency higher than 1; select or exclude those from the expression of IgA1, IgA2, IgD, IgM, IgG1, IgG2 , IgG3 and/or IgG4 B cell clonotypes; exclude non-B cell clonotypes through cell typing; exclude naive B cell clonotypes through cell typing; exclude untransformed B cells through cell typing; Type to exclude depleted B cell clonotypes; exclude monocytes through cell typing; exclude dendritic cells through cell typing; exclude T cells through cell typing; exclude natural killer cells through cell typing; and exclude variable The region mutation rate is less than 1%, 1.5% or 2% of clonotypes.
- the method further includes performing one, two, three, four, five or more of the following steps after step (c), so that at least about 10%, 20% %, 30%, 40%, 50%, 60%, 70%, 80% or 90% of the selected clonotypes are confirmed as the antigen binding unit in step (d): the frequency of selection enrichment is higher than 1
- the frequency of selection enrichment is higher than 1
- the method further includes performing light and heavy chain matching based on the obtained sequence information.
- the method further includes performing pedigree analysis based on the obtained sequence information.
- the second time is about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 20 days, 25 days, 30 days.
- the individual is confirmed not to carry the antigen at the second time. In some embodiments, the individual is confirmed not to carry the antigen or the amount of the antigen carried is reduced at the second time. In some embodiments, the individual is confirmed not to carry the antigen or the amount of the antigen carried is reduced at a plurality of different second times.
- the plurality of second time intervals are about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days , 13 days, 14 days, 15 days, 20 days, 25 days, 30 days.
- the amount of the antigen confirmed to be carried by the individual gradually decreases at a plurality of different second times.
- the antigen is a viral antigen. In some embodiments, the antigen is a novel coronavirus (SARS-CoV-2). In some embodiments, the antigen is the receptor binding domain (RBD) of the S protein of the novel coronavirus (SARS-CoV-2). In some embodiments, the method further includes comparing the clonotype information with one or more reference sequences. In some embodiments, the reference sequence is an antibody or fragment thereof that specifically binds to the antigen. In some embodiments, the reference sequence specifically binds SARS-CoV. In some embodiments, the reference sequence specifically binds to the receptor binding domain (RBD) of the SARS-CoV S protein.
- the reference sequence is an antibody or a fragment thereof
- the comparison includes predicting the CDR3H structure of the clonotype based on the transcriptome sequence information, and comparing the predicted CDR3H structure of the clonotype with the The CDR3H structure of the antibody or its fragment was compared.
- the method further comprises expressing the antigen binding unit in the host cell. In some embodiments, the method further includes purifying the antigen binding unit. In some embodiments, it further includes evaluating the ability of the antigen binding unit to bind the antigen.
- At least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the antigen binding unit binds to the antigen at a rate higher than that of The rate at which the antigen dissociates.
- At least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the antigen binding unit is less than 100 nM, less than 50 nM, less than 20 nM, An equilibrium dissociation constant (KD) of less than 15 nM, less than 10 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.1 nM, less than 0.05 nM, or less than 0.01 nM binds the antigen.
- KD equilibrium dissociation constant
- a method for preparing an antigen-binding unit against a predetermined antigen comprising identifying the antigen-binding unit against the antigen according to the method of any preceding claim, and expressing the antigen-binding unit against the antigen in a host cell Antigen-binding unit, and harvesting and purifying the antigen-binding unit.
- an antigen binding unit comprising a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprising VH CDR1, VH CDR2 and VH CDR3, the The light chain variable region includes VL CDR1, VL CDR2, and VL CDR3; wherein the VH CDR3 includes a sequence selected from SEQ ID NO: 1-360 and 2971-3005 or is similar to SEQ ID NO: 1-360 and 2971-3005 Compared with a sequence comprising one or more amino acid additions, deletions, or substitutions, and/or wherein the VL CDR3 comprises a sequence selected from SEQ ID NO: 361-720 and 3076-3110 or a sequence with SEQ ID NO: 361-720 and Compared with 3076-3110, a sequence containing one or more amino acid additions, deletions, or substitutions.
- the antigen binding unit is less than 100 nM, less than 50 nM, less than 20 nM, less than 15 nM, less than 10 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.1 nM,
- KD equilibrium dissociation constant
- the antigen binding unit is less than 20 ⁇ g/ml, less than 10 ⁇ g/ml, less than 9 ⁇ g/ml, less than 8 ⁇ g/ml, less than 7 ⁇ g/ml, less than 6 ⁇ g/ml, less than 5 ⁇ g/ml, less than 4 ⁇ g /ml, less than 3 ⁇ g/ml, less than 2 ⁇ g/ml, less than 1 ⁇ g/ml, less than 0.5 ⁇ g/ml, less than 0.25 ⁇ g/ml, less than 0.2 ⁇ g/ml, less than 0.1 ⁇ g/ml, less than 0.05 ⁇ g/ml, or less than The IC 50 of 0.001g/ml neutralizes the new coronavirus (SARS-CoV-2).
- SARS-CoV-2 new coronavirus
- the VH CDR1 of the antigen binding unit comprises a sequence selected from SEQ ID NOs: 1461-1820 and 2901-2935 or comprises one or more sequences compared with SEQ ID NOs: 1461-1820 and 2901-2935 A sequence of multiple amino acid additions, deletions, or substitutions.
- the VH CDR1 of the antigen binding unit comprises a sequence selected from SEQ ID NO: 1461-1820 and 2901-2935.
- the VH CDR1 of the antigen-binding unit includes an amino acid addition, deletion, or substitution of 5, 4, 3, 2 or 1 compared with SEQ ID NO: 1461-1820 and 2901-2935 sequence.
- the VH CDR1 of the antigen binding unit includes the same sequence as the CDR1 included in SEQ ID NOs: 721-1080 and 3111-3145.
- the VH CDR2 of the antigen binding unit includes a sequence selected from SEQ ID NO: 1821-2180 and 2936-2970 or includes one or more sequences compared with SEQ ID NO: 1821-2180 and 2936-2970. A sequence of multiple amino acid additions, deletions, or substitutions.
- the VH CDR2 of the antigen binding unit comprises a sequence selected from SEQ ID NO: 1821-2180 and 2936-2970.
- the VH CDR2 of the antigen-binding unit includes an amino acid addition, deletion, or substitution of 5, 4, 3, 2 or 1 compared with SEQ ID NO: 1821-2180 and 2936-2970. sequence.
- the VH CDR2 of the antigen binding unit comprises the same sequence as the CDR2 contained in SEQ ID NOs: 721-1080 and 3111-3145.
- the VL CDR1 of the antigen-binding unit comprises a sequence selected from SEQ ID NO: 2181-2540 and 3006-3040 or comprises one or more sequences compared with SEQ ID NO: 2181-2540 and 3006-3040. A sequence of multiple amino acid additions, deletions, or substitutions.
- the VL CDR1 of the antigen binding unit comprises a sequence selected from SEQ ID NO: 2181-2540 and 3006-3040.
- the VLCDR1 of the antigen binding unit comprises a sequence comprising 5, 4, 3, 2 or 1 amino acid addition, deletion, or substitution compared with SEQ ID NO: 2181-2540 and 3006-3040 .
- the VL CDR1 of the antigen binding unit includes the same sequence as the CDR1 included in SEQ ID NOs: 1081-1440 and 3146-3180.
- the VL CDR2 of the antigen binding unit comprises a sequence selected from SEQ ID NO: 2541-2900 and 3041-3075, or comprises one or more sequences compared with SEQ ID NO: 2541-2900 and 3041-3075. A sequence of multiple amino acid additions, deletions, or substitutions.
- the VL CDR2 of the antigen binding unit comprises a sequence selected from SEQ ID NO: 2541-2900 and 3041-3075.
- the VLCDR2 of the antigen binding unit comprises a sequence comprising 5, 4, 3, 2 or 1 amino acid addition, deletion, or substitution compared with SEQ ID NO: 2541-2900 and 3041-3075 .
- the VL CDR2 of the antigen binding unit includes the same sequence as the CDR2 included in SEQ ID NOs: 1081-1440 and 3146-3180.
- the VH of the antigen binding unit comprises a sequence selected from SEQ ID NO: 721-1080 and 3111-3145 or contains one or more sequences compared with SEQ ID NO: 721-1080 and 3111-3145.
- the VH of the antigen binding unit comprises a sequence selected from SEQ ID NO: 721-1080 and 3111-3145.
- the VH of the antigen binding unit includes 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 compared with SEQ ID NO: 721-1080 and 3111-3145.
- the VH of the antigen binding unit comprises a sequence selected from SEQ ID NO: 721-1080 and 3111-3145 that has at least 80%, 85%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98%, 99%, or 99% identity sequence.
- the VL of the antigen binding unit comprises a sequence selected from SEQ ID NO: 1081-1440 and 3146-3180 or contains one or more sequences compared with SEQ ID NO: 1081-1440 and 3146-3180.
- the VL of the antigen binding unit comprises a sequence selected from SEQ ID NO: 1081-1440 and 3146-3180.
- the VL of the antigen binding unit includes 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 compared with SEQ ID NOs: 1081-1440 and 3146-3180.
- the VL of the antigen binding unit comprises a sequence selected from SEQ ID NO: 1081-1440 and 3146-3180 that has at least 80%, 85%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98%, 99%, or 99% identity sequence.
- an antigen binding unit comprising a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprising VH CDR1, VH CDR2 and VH CDR3, so
- the light chain variable region includes VL CDR1, VL CDR2, and VL CDR3;
- the VH CDR1 includes a sequence selected from SEQ ID NO: 1461-1820 and 2901-2935, and SEQ ID NO: 1461-1820 and 2901-2935 Compared with a sequence containing one or more amino acid additions, deletions, or substitutions, or the same sequence as the CDR1 contained in SEQ ID NO: 721-1080 and 3111-3145
- the VH CDR2 includes a sequence selected from SEQ ID NO :1821-2180 and 2936-2970, compared with SEQ ID NO: 1821-2180 and 2936-2970, containing one or more amino acid additions, deletions, or substitutions, or with SEQ ID NO: 721-10
- an antigen binding unit comprising a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprising VH CDR1, VH CDR2 and VH CDR3, so
- the light chain variable region includes VL CDR1, VL CDR2, and VL CDR3;
- the VH CDR1 includes a sequence selected from SEQ ID NO: 1461-1820 and 2901-2935 or a sequence that is identical to SEQ ID NO: 1461-1820 and 2901-2935 Compared with a sequence comprising one or more amino acid additions, deletions, or substitutions
- the VH CDR2 comprises a sequence selected from SEQ ID NO: 1821-2180 and 2936-2970 or a sequence with SEQ ID NO: 1821-2180 and 2936 Compared with 2970, a sequence comprising one or more amino acid additions, deletions, or substitutions
- the VH CDR3 comprises a sequence selected from SEQ ID NO: 1-360 and 2971
- the VLCDR2 contains a sequence selected from SEQ ID NO: 2541-2900 and 3041-3075 or a sequence with SEQ ID NO: 2541- Compared with 3041-3075, 2900 contains one or more amino acid additions, deletions, or substitutions.
- the VL CDR3 contains a sequence selected from SEQ ID NO: 361-720 and 3076-3110 or a sequence with SEQ ID NO: 361- Compared with 3076-3110, 720 contains one or more amino acid additions, deletions, or substitutions.
- the VH of the antigen binding unit comprises a sequence selected from SEQ ID NO: 721-1080 and 3111-3145 or contains one or more sequences compared with SEQ ID NO: 721-1080 and 3111-3145.
- the VH of the antigen binding unit comprises a sequence selected from SEQ ID NO: 721-1080 and 3111-3145.
- the VH of the antigen binding unit includes 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 compared with SEQ ID NO: 721-1080 and 3111-3145.
- the VH of the antigen binding unit comprises a sequence selected from SEQ ID NO: 721-1080 and 3111-3145 that has at least 80%, 85%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98%, 99%, or 99% identity sequence.
- the VL of the antigen binding unit comprises a sequence selected from SEQ ID NO: 1081-1440 and 3146-3180 or contains one or more sequences compared with SEQ ID NO: 1081-1440 and 3146-3180.
- the VL of the antigen binding unit comprises a sequence selected from SEQ ID NO: 1081-1440 and 3146-3180.
- the VL of the antigen binding unit includes 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 compared with SEQ ID NOs: 1081-1440 and 3146-3180.
- the VL of the antigen binding unit comprises a sequence selected from SEQ ID NO: 1081-1440 and 3146-3180 that has at least 80%, 85%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98%, 99%, or 99% identity sequence.
- the antigen binding unit is less than 100 nM, less than 50 nM, less than 20 nM, less than 15 nM, less than 10 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.1 nM.
- KD equilibrium dissociation constant
- the equilibrium dissociation constant (KD) of less than 0.05nM, or less than 0.01nM binds to the receptor binding domain (RBD) of the new coronavirus (SARS-CoV-2) S protein.
- the antigen binding unit is less than 20 ⁇ g/ml, less than 10 ⁇ g/ml, less than 9 ⁇ g/ml, less than 8 ⁇ g/ml, less than 7 ⁇ g/ml, less than 6 ⁇ g/ml, less than 5 ⁇ g/ml, less than 4 ⁇ g /ml, less than 3 ⁇ g/ml, less than 2 ⁇ g/ml, less than 1 ⁇ g/ml, less than 0.5 ⁇ g/ml, less than 0.25 ⁇ g/ml, less than 0.2 ⁇ g/ml, less than 0.1 ⁇ g/ml, less than 0.05 ⁇ g/ml, or less than The IC50 of 0.001 ⁇ g/ml neutralizes the new coronavirus (SARS-CoV-2).
- SARS-CoV-2 new coronavirus
- an antigen binding unit which comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises a compound selected from SEQ ID NO: 721-1080 and 3111
- the sequence of 3145 has a sequence of at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99% identity, and / Or wherein the VL contains at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98%, 99%, or 99% identity sequence.
- the antigen binding unit is less than 100 nM, less than 50 nM, less than 20 nM, less than 15 nM, less than 10 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.1 nM.
- KD equilibrium dissociation constant
- the equilibrium dissociation constant (KD) of less than 0.05nM, or less than 0.01nM binds to the receptor binding domain (RBD) of the new coronavirus (SARS-CoV-2) S protein.
- the antigen binding unit is less than 20 ⁇ g/ml, less than 10 ⁇ g/ml, less than 9 ⁇ g/ml, less than 8 ⁇ g/ml, less than 7 ⁇ g/ml, less than 6 ⁇ g/ml, less than 5 ⁇ g/ml, less than 4 ⁇ g /ml, less than 3 ⁇ g/ml, less than 2 ⁇ g/ml, less than 1 ⁇ g/ml, less than 0.5 ⁇ g/ml, less than 0.25 ⁇ g/ml, less than 0.2 ⁇ g/ml, less than 0.1 ⁇ g/ml, less than 0.05 ⁇ g/ml, or less than The IC50 of 0.001 ⁇ g/ml neutralizes the new coronavirus (SARS-CoV-2).
- SARS-CoV-2 new coronavirus
- the antigen binding unit further comprises a heavy chain constant region (CH).
- the CH of the antigen binding unit includes the sequence of SEQ ID NO: 1457 or a sequence of one or more amino acid additions, deletions, or substitutions compared with SEQ ID NO: 1457.
- the CH of the antigen binding unit comprises a sequence selected from SEQ ID NO: 1457.
- the CH of the antigen binding unit includes 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid addition, deletion, Or substituted sequence.
- the CH of the antigen binding unit includes a sequence selected from SEQ ID NO: 1457 that has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% %, 96%, 97%, 98%, 99%, or 99% identity sequence.
- the antigen binding unit further comprises a light chain constant region (CL).
- the CL of the antigen binding unit includes the sequence of SEQ ID NO: 1458 or a sequence of one or more amino acid additions, deletions, or substitutions compared with SEQ ID NO: 1458.
- the CL of the antigen binding unit comprises a sequence selected from SEQ ID NO: 1458.
- the CL of the antigen binding unit includes 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid addition, deletion, Or substituted sequence.
- the CL of the antigen binding unit comprises a sequence selected from SEQ ID NO: 1458 that has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% %, 96%, 97%, 98%, 99%, or 99% identity sequence.
- nucleic acid molecule that encodes an antigen binding unit as described herein as defined above.
- a vector comprising an isolated nucleic acid molecule as defined above.
- the vector described herein can be a cloning vector or an expression vector.
- the vectors described herein are, for example, plasmids, cosmids, or bacteriophages and the like.
- a host cell comprising the isolated nucleic acid molecule or vector described herein.
- host cells include, but are not limited to, prokaryotic cells such as E. coli cells, and eukaryotic cells such as yeast cells, insect cells, plant cells, and animal cells (such as mammalian cells, such as mouse cells, human cells, etc.).
- the cells described herein can also be cell lines, such as HEK293 cells.
- a method for preparing the antigen-binding unit described herein which comprises culturing the host cell described herein under suitable conditions, and recovering the antigen-binding unit described herein from the cell culture.
- composition comprising the antigen binding unit, isolated nucleic acid molecule, vector or host cell as described above.
- kits comprising the antigen binding unit described herein.
- the antigen binding unit described herein further includes a detectable label.
- the kit further includes a second antibody, which specifically recognizes the antigen binding unit described herein.
- the second antibody further includes a detectable label.
- detectable labels are well known to those skilled in the art, and include, but are not limited to, radioisotopes, fluorescent substances, luminescent substances, colored substances and enzymes (such as horseradish peroxidase).
- this document provides a method for detecting the presence or level of a novel coronavirus or its S protein or S protein RBD in a sample, which includes using the antigen binding unit described herein.
- the antigen binding unit described herein further includes a detectable label.
- the method further comprises using a second antibody carrying a detectable label to detect the antigen binding unit described herein.
- the method can be used for diagnostic purposes (for example, the sample is a sample from a patient), or for non-diagnostic purposes (for example, the sample is a cell sample, not a sample from a patient).
- this article provides a method for diagnosing whether a subject is infected with a novel coronavirus, which comprises: using the antigen binding unit described herein to detect whether the novel coronavirus or its S protein or RBD of the S protein is derived from the subject. Existence in the subject’s sample.
- the antigen binding unit described herein further includes a detectable label.
- the method further comprises using a second antibody carrying a detectable label to detect the antigen binding unit described herein.
- the antigen binding unit described herein in the preparation of a kit for detecting the presence or level of a novel coronavirus or its S protein or RBD in a sample, Or used to diagnose whether the subject is infected with the new coronavirus.
- composition comprising the antigen binding unit described herein, and a pharmaceutically acceptable carrier and/or excipient.
- this document provides a method for neutralizing the virulence of a novel coronavirus in a sample, which includes contacting a sample containing the novel coronavirus with the antigen binding unit described herein.
- Such methods can be used for therapeutic purposes, or non-therapeutic purposes (e.g., the sample is a cell sample, not a patient or a sample from a patient).
- an antigen binding unit as described above which is used to neutralize the virulence of a novel coronavirus in a sample.
- the use of the antigen-binding unit described herein in the preparation of a pharmaceutical composition for the prevention or treatment of a novel coronavirus infection or a disease related to a novel coronavirus infection in a subject E.g. new coronavirus pneumonia.
- an antigen binding unit as described above which is used to prevent or treat a novel coronavirus infection in a subject or a disease related to a novel coronavirus infection (such as novel coronavirus pneumonia).
- this article provides a method for preventing or treating a novel coronavirus infection or a novel coronavirus infection-related disease (such as novel coronavirus pneumonia) in a subject, which includes giving a subject in need A prophylactic or therapeutically effective amount of the antigen binding unit described herein or the pharmaceutical composition described herein is administered.
- the subject is a mammal, such as a human.
- the antigen binding unit described herein or the pharmaceutical composition described herein can be administered to a subject by any appropriate route of administration.
- administration routes include, but are not limited to, oral, buccal, sublingual, topical, parenteral, rectal, intrathecal, or nasal routes.
- the drugs and pharmaceutical compositions provided herein can be used alone or in combination, and can also be used in combination with other pharmaceutically active agents (for example, antiviral drugs, such as fapilavir, remdesivir, interferon, etc.).
- the pharmaceutical composition further contains a pharmaceutically acceptable carrier and/or excipient.
- a conjugate comprising an antigen binding unit as described above, wherein the antigen binding unit is conjugated to a chemically functional moiety.
- the chemically functional moiety is selected from radioisotopes, enzymes, fluorescent compounds, chemiluminescent compounds, bioluminescent compound substrate cofactors, and inhibitors.
- Figures 1A-1C exemplarily show the SDS-PAGE detection results of the antigen binding units ABU-174, ABU-175 and ABU190.
- Figures 2A-2E exemplarily show the use of SPR technology to detect the affinity of antigen-binding units ABU-174 (A), ABU-175 (B), ABU190 (C), ABU297 (D) and ABU367 (E) with S protein The measurement results.
- Figures 3A-3C exemplarily show the assay results of the neutralization inhibitory activity of the antigen binding units ABU-174 (A), ABU-175 (B), and ABU190 (C) against SARS-CoV-2 pseudovirus.
- Figure 4 exemplarily shows the CPE assay result of the neutralization inhibitory activity of the ABU-175 antibody against SARS-CoV-2 true virus.
- Figure 5 exemplarily shows the PRNT assay results of the neutralization inhibitory activity of the antigen binding units ABU-174, ABU-175, and ABU190 against SARS-CoV-2 true virus.
- Figure 6 shows a schematic diagram of an exemplary method for providing antigen binding units as described herein.
- Figure 7 shows a summary of B cell sequencing results after antigen enrichment.
- Figure 8 shows the 25 clonotypes with the highest enrichment from the same patient (A) and the Ig class distribution of the patient's clonotypes (B).
- Figure 9 shows a cell typing diagram determined based on gene expression for the production B cells matching the light chain and heavy chain in the fifth batch.
- Figure 10 shows the clonotype analysis of the fifth batch of B cells that passed the above-mentioned standard screening.
- Figure 11A shows the number of antibodies that meet the above criteria produced after S protein enrichment and RBD enrichment as described in Example 1, respectively, as well as the binding ELISA results and Kd values and neutralization of RBD determined as described herein.
- the IC50 value of the pseudovirus Figure 11B shows the binding ELISA result and Kd value of the clonotype that does not contain IgG2, the variable region mutation rate> 2%, or contains memory B cells, and the Kd value and the IC50 of the neutralization pseudovirus. value.
- Figure 12 shows the crystal structure of the complex of antibody m396 Fab and SARS-CoV-RBD (PDB ID: 2DD8).
- polypeptide As used herein, the terms “polypeptide”, “peptide” and “protein” are used interchangeably herein to refer to polymers of amino acids of any length.
- the polymer can be linear, cyclic or branched, it can contain modified amino acids, and can be interrupted by non-amino acids.
- amino acid polymers that have been modified, such as by sulfation, glycosylation, lipidation, acetylation, phosphorylation, iodination, methylation, oxidation, proteolytic treatment, phosphorylation, iso Pennylation, racemization, selenization, transfer RNA-mediated addition of amino acids to proteins (such as arginination), ubiquitination, or any other manipulations, such as conjugation with labeled components.
- amino acid refers to natural and/or unnatural or synthetic amino acids, including glycine and D or L optical isomers, as well as amino acid analogs and peptidomimetics.
- polypeptide or amino acid sequence "derived" from a given protein refers to the origin of the polypeptide.
- the polypeptide has an amino acid sequence that is substantially the same as the amino acid sequence of the polypeptide encoded in the sequence, or a part thereof, wherein the part consists of at least 10-20 amino acids or at least 20-30 amino acids or at least 30-50 amino acids, or It can be identified immunologically with the polypeptide encoded in the sequence.
- the term also includes polypeptides expressed from a designated nucleic acid sequence.
- domain refers to a part of a protein that is physically or functionally distinguished from other parts of the protein or peptide.
- Physically defined domains include amino acid sequences that are extremely hydrophobic or hydrophilic, such as those that are membrane-bound or cytoplasmic-bound.
- the domain can also be defined by internal homology caused by gene duplication, for example.
- Functionally defined domains have different biological functions.
- the antigen-binding domain refers to the part of the antigen-binding unit or antibody that binds to the antigen.
- the functionally defined domain does not need to be encoded by a continuous amino acid sequence, and the functionally defined domain may contain one or more physically defined domains.
- amino acid refers to natural and/or unnatural or synthetic amino acids, including but not limited to D or L optical isomers, as well as amino acid analogs and peptidomimetics. Standard one-letter or three-letter codes are used to designate amino acids. In this context, amino acids are usually represented by one-letter and three-letter abbreviations well known in the art. For example, alanine can be represented by A or Ala.
- B lymphocytes and “B cells” are used interchangeably and are a type of lymphocytes in the body. Unlike T cells and natural killer cells, B cells express B cell receptors (BCR) on their cell membranes. BCR allows B cells to bind to a specific antigen, thereby initiating an antibody response against the antigen. B cells play an important role in the pathogenesis of autoimmune diseases. B cells mature in the bone marrow, then leave the bone marrow and express antigen-binding antibodies on the surface of their cells. When a naive B cell first encounters an antigen specifically targeted by its membrane-bound antibody, the cell begins to divide rapidly, and its offspring differentiate into memory B cells, and finally into effector cells called "plasmablasts". Plasma cells can produce large amounts of antibodies in secreted form. Secreted antibodies are the main effector molecules of humoral immunity.
- BCR B cell receptors
- V(D)J rearrangement and “V(D)J recombination” are used interchangeably and refer to the process by which T cells and B cells randomly assemble different gene fragments, with the purpose of generating unique Receptors (called antigen receptors).
- antigen receptors unique Receptors
- a specific VDJ recombination event occurs that causes the cell to produce a specific B cell receptor, namely BCR.
- VDJ rearrangement contributes to the diversity of BCR antigen recognition regions or sites.
- antibody refers to an immunoglobulin molecule generally composed of two pairs of polypeptide chains, each pair having a "light” (L) chain and a “heavy” (H) chain).
- Antibody light chains can be classified into kappa and lambda light chains.
- Heavy chains can be classified as mu, delta, gamma, alpha, or epsilon, and the isotype of the antibody is defined as IgM, IgD, IgG, IgA, and IgE, respectively.
- the variable and constant regions are connected by a "J" region of about 12 or more amino acids, and the heavy chain also includes a "D" region of about 3 or more amino acids.
- Each heavy chain is composed of a heavy chain variable region (VH) and a heavy chain constant region (CH).
- the heavy chain constant region is composed of 3 domains (CH1, CH2, and CH3).
- Each light chain is composed of a light chain variable region (VL) and a light chain constant region (CL).
- the constant region of the light chain consists of a domain CL.
- the constant region of an antibody can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (for example, effector cells) and the first component (C1q) of the classical complement system.
- the VH and VL regions can also be subdivided into regions with hyperdenaturation (called complementarity determining regions (CDR)), interspersed with more conservative regions called framework regions (FR).
- CDR complementarity determining regions
- Each VH and VL consists of 3 CDRs and 4 FRs arranged in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 from the amino terminus to the carboxy terminus.
- the variable regions (VH and VL) of each heavy chain/light chain pair respectively form the antibody binding site.
- the assignment of amino acids to each region or domain follows Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk (1987) J. Mol. Biol. 196: 901-917; Chothia et al.
- the CDR amino acid residue numbers in VH are 31-35 (CDR1), 50-65 (CDR2) and 95-102 (CDR3); the CDR amino acid residue numbers in VL are 24-34 (CDR1) ), 50-56 (CDR2) and 89-97 (CDR3).
- the CDR amino acid numbers in VH are 26-32 (CDR1), 52-56 (CDR2) and 95-102 (CDR3); the amino acid residue numbers in VL are 24-34 (CDR1), 50-56 (CDR2) and 89-97 (CDR3).
- the numbering of CDR amino acid residues in VH is about 26-33 (CDR1), 51-56 (CDR2) and 93-102 (CDR3); and the numbering of CDR amino acid residues in VL is about 27-32 (CDR1), 50-51 (CDR2) and 89-97 (CDR3) (as disclosed in https://www.novoprolabs.com/tools/cdr).
- the term "antibody” is not limited by any specific method of producing antibodies. For example, it includes recombinant antibodies, monoclonal antibodies, and polyclonal antibodies.
- the antibodies may be antibodies of different isotypes, for example, IgG (eg, IgG1, IgG2, IgG3 or IgG4 subtype), IgA1, IgA2, IgD, IgE or IgM antibodies.
- the term "antigen-binding fragment" of an antibody refers to a polypeptide comprising a fragment of a full-length antibody that retains the ability to specifically bind to the same antigen to which the full-length antibody binds, and/or competes with the full-length antibody It is also called “antigen binding part” for specific binding to antigen. See generally, Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nd edition, Raven Press, NY (1989), which is incorporated herein by reference in its entirety for all purposes. Recombinant DNA technology can be used. Or through the enzymatic or chemical cleavage of intact antibodies to produce antigen-binding fragments of antibodies.
- antigen-binding fragments include Fab, Fab′, F(ab′) 2 , Fd, Fv, dAb and complementarity determining regions (CDR) Fragments, single-chain antibodies (e.g., scFv), chimeric antibodies, diabodies, and polypeptides that contain at least a portion of an antibody sufficient to confer specific antigen-binding ability to the polypeptide.
- CDR complementarity determining regions
- the antigen binding of the antibody Fragments are single-chain antibodies (e.g., scFv) in which the VL and VH domains pair to form a monovalent molecule by allowing them to be produced as a linker of a single polypeptide chain (see, e.g., Bird et al., Science 242: 423 426 (1988) And Huston et al., Proc. Natl. Acad. Sci. USA 85: 5879 5883 (1988)).
- scFv molecules can have the general structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL- COOH.
- a suitable prior art linker consists of a repetitive GGGGS amino acid sequence or a variant thereof.
- a linker having the amino acid sequence (GGGGS) 4 can be used, but variants thereof can also be used (Holliger et al. (1993), Proc . Natl. Acad. Sci. USA 90: 6444-6448).
- Other linkers that can be used as described herein are described by Alfthan et al. (1995), Protein Eng. 8: 725-731, Choi et al. (2001), Eur. J. Immunol. 31: 94-106, Hu et al. (1996), Cancer Res. 56: 3055-3061, Kipriyanov et al. (1999), J. Mol. Biol. 293: 41-56 and Roovers et al. (2001), Cancer Immunol. Description.
- the antigen-binding fragments of antibodies are diabodies, ie, diabodies, in which the VH and VL domains are expressed on a single polypeptide chain, but a linker that is too short is used to allow two structures in the same chain Pairing between the domains, thereby forcing the domain to pair with the complementary domain of the other chain and creating two antigen binding sites (see, for example, Holliger P. et al., Proc. Natl. Acad. Sci. USA 90: 6444 6448 ( 1993), and Poljak RJ et al., Structure 2: 1121 1123 (1994)).
- antibody includes not only intact antibodies but also antigen-binding fragments of antibodies.
- the term “antigen-binding unit” includes the above-defined antibody and antigen-binding fragments thereof.
- the term "monoclonal antibody” refers to an antibody or a fragment of an antibody from a group of highly homologous antibody molecules, that is, a group of identical antibodies, except for natural mutations that may occur spontaneously. Antibody molecule.
- the monoclonal antibody has high specificity for a single epitope on the antigen.
- Polyclonal antibodies are relative to monoclonal antibodies, which usually include at least two or more different antibodies, and these different antibodies usually recognize different epitopes on the antigen.
- Monoclonal antibodies can usually be obtained using hybridoma technology first reported by Kohler et al. (Nature, 256: 495, 1975), but can also be obtained using recombinant DNA technology (for example, see Journal of virological methods, 2009, 158(1-2): 171-179).
- neutralizing antibody refers to an antibody or antibody fragment that can eliminate or significantly reduce the virulence (for example, the ability to infect cells) of the target virus.
- sequence is the sequence of amino acids in the polypeptide in the direction from the amino terminal to the carboxy terminal, wherein the residues adjacent to each other in the sequence are in the primary structure of the polypeptide.
- the middle is continuous.
- sequence can also be a linear sequence of a part of a polypeptide known to contain additional residues in one or two directions.
- identity refers to the difference between two or more polynucleotide sequences or between two or more polypeptide sequences Sequence similarity or interchangeability.
- sequence identity refers to the difference between two or more polynucleotide sequences or between two or more polypeptide sequences Sequence similarity or interchangeability.
- programs such as Emboss Needle or BestFit to determine the sequence identity, similarity or homology between two different amino acid sequences, you can use the default settings, or you can select an appropriate scoring matrix, such as blosum45 or blosum80, to optimize Identity, similarity, or homology score.
- homologous polynucleotides are those that hybridize under stringent conditions as defined herein and have at least 70%, preferably at least 80%, more preferably at least 90%, more preferably 95%, more preferably compared to these sequences A polynucleotide having a sequence identity of 97%, more preferably 98%, and even more preferably 99%.
- homologous polypeptides preferably have at least 80%, or at least 90%, or at least 95%, or at least 97%, or at least 98% sequence identity, or at least 99% sequence identity.
- percent sequence identity is defined as after aligning the sequences and introducing gaps if necessary to obtain the maximum sequence identity percentage, and not considering any conservative substitutions.
- sequence identity the percentage of amino acid residues in the query sequence that are identical to the amino acid residues of the second, reference polypeptide sequence or part thereof.
- Various methods within the skill in the art for example, using publicly available computer software, such as BLAST, BLAST-2, ALIGN, NEEDLE, or Megalign (DNASTAR) software, can be used to achieve alignments aimed at determining the percentage of amino acid sequence identity. .
- the percent identity can be measured over the length of the entire defined polypeptide sequence, or can be measured over a shorter length, for example, the length of a fragment taken from a larger, defined polypeptide sequence, such as Fragments of at least 5, at least 10, at least 15, at least 20, at least 50, at least 100, or at least 200 consecutive residues.
- Fragments of at least 5, at least 10, at least 15, at least 20, at least 50, at least 100, or at least 200 consecutive residues.
- the antigen binding unit described herein may have one or more modifications relative to the reference sequence.
- the modification may be deletion, insertion or addition, or substitution or substitution of amino acid residues.
- “Deletion” refers to a change in amino acid sequence due to the lack of one or more amino acid residues.
- Insertion or “addition” refers to an amino acid sequence change that results in the addition of one or more amino acid residues compared to a reference sequence.
- substitution or “substitution” refers to the replacement of one or more amino acids with different amino acids.
- the mutation of the antigen-binding unit relative to the reference sequence can be determined by comparing the antigen-binding unit with the reference sequence. The optimal alignment of sequences for comparison can be performed according to any known method in the art.
- antigen refers to a substance that is recognized and specifically bound by an antigen binding unit.
- Antigens can include peptides, proteins, glycoproteins, polysaccharides and lipids; parts thereof, and combinations thereof.
- Non-limiting exemplary antigens include proteins from coronaviruses such as SARS-CoV-2, and their other homologs.
- isolated refers to separation from cellular and other components, wherein in nature, polynucleotides, peptides, polypeptides, proteins, antibodies, or fragments thereof are normally associated with them. Associated. Those skilled in the art know that non-naturally occurring polynucleotides, peptides, polypeptides, proteins, antibodies, or fragments thereof do not need to be “isolated” to distinguish them from their naturally occurring counterparts.
- concentrate in addition, “concentrated”, “isolated” or “diluted” polynucleotides, peptides, polypeptides, proteins, antibodies, or fragments thereof are distinguishable from their naturally occurring counterparts because of the concentration or number of molecules per unit volume Greater than (“concentrated”) or less than from its naturally occurring counterpart ("isolated”). Enrichment can be measured based on absolute amounts, such as the weight of solution per unit volume, or it can be measured relative to the second, potentially interfering species present in the source mixture.
- polynucleotide refers to polymeric forms of nucleotides of any length (whether deoxyribonucleotides or ribonucleotides) or their analogs.
- a polynucleotide can have any three-dimensional structure, and can perform any known or unknown function.
- polynucleotides coding or non-coding regions of genes or gene fragments, loci determined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomes RNA, ribozyme, cDNA, recombinant polynucleotide, branched chain polynucleotide, plasmid, vector, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probe, primer, oligonucleotide or synthetic DNA .
- Polynucleotides may contain modified nucleotides, such as methylated nucleotides and nucleotide analogs.
- modifications to the nucleotide structure can be imparted before or after assembly of the polymer.
- the sequence of nucleotides can be interrupted by non-nucleotide components.
- the polynucleotide can be further modified after polymerization, for example by conjugation with a labeling component.
- polynucleotide When applied to polynucleotides, "recombinant" means that the polynucleotide is a variety of other procedures for cloning, restriction digestion, and/or ligation steps, and other procedures that produce constructs different from those found in nature. The product of the combination.
- gene or “gene fragment” are used interchangeably herein. They refer to polynucleotides containing at least one open reading frame that can encode a specific protein after transcription and translation.
- the gene or gene fragment can be genomic, cDNA or synthetic, as long as the polynucleotide contains at least one open reading frame, which can cover the entire coding region or a segment thereof.
- operably connected or “effectively connected” refer to juxtaposition in which the components so described are in a relationship that allows them to function in their intended manner. For example, if a promoter sequence promotes transcription of a coding sequence, the promoter sequence is operably linked to the coding sequence.
- expression refers to the process by which polynucleotides are transcribed into mRNA, and/or the process by which transcribed mRNA (also referred to as “transcripts") is subsequently translated into peptides, polypeptides, or proteins.
- the transcript and the encoded polypeptide are collectively referred to as gene products. If the polynucleotide is derived from genomic DNA, expression may include splicing of mRNA in eukaryotic cells.
- the term "vector” refers to a nucleic acid delivery vehicle into which polynucleotides can be inserted.
- the vector can express the protein encoded by the inserted polynucleotide, the vector is called an expression vector.
- the vector can be introduced into the host cell through transformation, transduction or transfection, so that the genetic material elements it carries can be expressed in the host cell.
- Vectors are well known to those skilled in the art, including but not limited to: plasmids; phagemids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or artificial chromosomes (PAC) derived from P1; bacteriophages such as lambda Bacteriophage or M13 phage and animal virus etc.
- Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papillary viruses.
- Polyoma vacuole virus (such as SV40).
- a vector can contain a variety of elements that control expression, including but not limited to promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes.
- the vector may also contain an origin of replication site.
- the term "host cell” refers to a cell that can be used to introduce a vector, which includes, but is not limited to, prokaryotic cells such as Escherichia coli or Bacillus subtilis, and fungal cells such as yeast cells or Aspergillus , Such as insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK293 cells or human cells.
- prokaryotic cells such as Escherichia coli or Bacillus subtilis
- fungal cells such as yeast cells or Aspergillus
- insect cells such as S2 Drosophila cells or Sf9
- animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK293 cells or human cells.
- biological sample includes a variety of sample types obtained from living organisms, and can be used in diagnostic or monitoring tests.
- the term includes blood and other liquid samples of biological origin, solid tissue samples, such as biopsy specimens or tissue cultures, or cells derived therefrom and their progeny.
- the term includes samples that have been processed in any way after they have been obtained, for example by treatment with reagents, solubilization, or enrichment for certain components.
- the term includes clinical samples, and also includes cells in cell cultures, cell supernatants, cell lysates, serum, plasma, biological fluids, and tissue samples.
- the terms "recipient”, “individual”, “subject”, “host”, and “patient” are used interchangeably herein and refer to a person who wishes to diagnose, treat, or treat Any mammalian subject, especially humans.
- treatment As used herein, the terms “treatment”, “treatment”, etc. are used herein to generally refer to obtaining a desired pharmacological and/or physiological effect.
- the effect may be prophylactic in terms of completely or partially preventing the disease or its symptoms, and/or may be therapeutic in terms of partially or completely stabilizing or curing the disease and/or adverse reactions attributed to the disease.
- Treatment encompasses any treatment of a disease in a mammal, such as mice, rats, rabbits, pigs, primates, including humans and other apes, especially humans, and The term includes: (a) preventing a disease or symptom from occurring in subjects who may be susceptible to the disease or symptom but not yet diagnosed; (b) inhibiting the symptoms of the disease; (C) preventing the development of the disease; (d) alleviating the disease Symptoms; (e) cause the disease or symptoms to subside; or any combination thereof.
- specific binding refers to a non-random binding reaction between two molecules, such as the reaction between an antibody and the antigen to which it is directed.
- an antibody that specifically binds to a certain antigen means that the antibody has a concentration of less than about 10 -5 M, for example, less than about 10 -6 M, 10 -7 M, The affinity (KD) of 10 -8 M, 10 -9 M, or 10 -10 M or less binds to the antigen.
- KD refers to the dissociation equilibrium constant of a specific antibody-antigen interaction, which is used to describe the binding affinity between the antibody and the antigen.
- KD is defined as the ratio of two kinetic rate constants Ka/Kd, where "Ka” refers to the rate constant of antibody binding to antigen, and “Kd” refers to the rate constant of antibody dissociation from the antibody/antigen complex .
- Ka refers to the rate constant of antibody binding to antigen
- Kd refers to the rate constant of antibody dissociation from the antibody/antigen complex .
- KD dissociation equilibrium constant
- the specific binding properties between two molecules can be measured using methods known in the art, for example, using surface plasmon resonance (SPR) in a BIACORE instrument.
- SPR surface plasmon resonance
- neutralizing activity refers to the ability of an antibody or antibody fragment to bind to the antigen protein on the virus, thereby preventing the virus from infecting cells and/or the maturation of the virus progeny and/or the release of the virus progeny Antibodies or antibody fragments with neutralizing activity can prevent the amplification of the virus, thereby inhibiting or eliminating the infection of the virus.
- the neutralizing activity of the antibody or antibody fragment by viruses in IC 50 inhibition “Half maximal inhibitory concentration” (IC 50) is a measure of antibody drugs in inhibiting biological or biochemical function (e.g., viral potency) of. IC 50 is calculated herein on the virus (e.g.
- the antigen binding unit described herein is particularly suitable for diagnosing, preventing and treating novel coronavirus infection or diseases related to novel coronavirus infection (for example, novel coronavirus pneumonia).
- the term "antigen" refers to a substance that contains an epitope against which an immune response is generated.
- the antigen is a protein or peptide, which is capable of inducing an immune response specific to the antigen in vivo.
- the antigen may be an antigen derived from a microorganism such as a virus, such as a protein derived from a virus or a fragment thereof.
- the term "epitope” refers to an antigenic determinant in a molecule (such as an antigen), that is, refers to a part or fragment of a molecule recognized by the immune system (such as by the B cell receptor BCR).
- the epitope of the protein eg, viral antigen
- the epitope of the protein comprises a continuous or discontinuous portion of the protein, and preferably has a length of 5 to 100, preferably 5 to 50, more preferably 8 to 30, most preferably 10 to 25 Amino acids, for example, the length of the epitope may preferably be 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids .
- the term "clonotype” refers to a recombinant nucleic acid of lymphocytes encoding immune receptors or a portion thereof.
- the "clonotype” is a recombinant nucleic acid derived from a T cell or B cell, which encodes a T cell receptor (TCR) or a B cell receptor (BCR) or a part thereof.
- TCR T cell receptor
- BCR B cell receptor
- the clonotype can encode all or part of the following: VDJ rearrangement of IgH, DJ rearrangement of IgH, VJ rearrangement of IgK, VJ rearrangement of IgL, VDJ rearrangement of TCR ⁇ , DJ of TCR ⁇ Rearrangement, VJ rearrangement of TCR ⁇ , VJ rearrangement of TCR ⁇ , VDJ rearrangement of TCR ⁇ , VD rearrangement of TCR ⁇ , ⁇ deletion element (KDE) rearrangement, etc.
- clonotypes have a sufficiently long sequence to represent or reflect the diversity of immune molecules from which they are derived. Therefore, in some embodiments, the length of the clonotype is in the range of 25 to 400 nucleotides. In some embodiments, the length of the clonotype is in the range of 25 to 200 nucleotides.
- a method of providing an antigen-binding unit for a predetermined antigen comprising (a) obtaining a blood sample from an individual, wherein the individual is confirmed to carry the antigen at the first time, and the The second time after the first time is confirmed not to carry the antigen or the amount of the antigen carried is reduced; (b) enriching the B cells in the blood sample; (c) for including multiple individuals VDJ sequencing of the single-cell transcriptome of a sample of enriched B cells is performed to provide clonotype information of the antigen-binding unit; and (d) confirming the antigen-binding unit for the antigen based on the clonotype information.
- the antigen is derived from a pathogen.
- the pathogens include, but are not limited to, allergens, viruses, bacteria, fungi, parasites, and other infectious substances and pathogens.
- the individual may be an individual who has been diagnosed with the virus.
- the virus includes, but is not limited to, adenovirus, herpes simplex type I, herpes simplex type 2, varicella-zoster virus, Epstein-Barr virus (EBV), human cytomegalovirus, human Herpes virus type 8, human papilloma virus, BK virus, JC virus, smallpox virus, hepatitis B virus, human Boca virus, parvovirus B19, human astrovirus, Norwalk virus, Coxsackie virus, Hepatitis A virus, polio virus, rhinovirus, severe acute respiratory syndrome virus, hepatitis C virus, yellow fever virus, dengue virus, West Nile virus, rubella virus, hepatitis E virus, human immunodeficiency virus ( HIV), influenza virus, Ebola virus, measles virus, mumps virus, parainfluenza virus, respiratory syncytial virus, Nipah virus, rabies virus, hepatitis D virus, rotavirus, circovirus, aden
- the antigen is a viral antigen. In some embodiments, the antigen is SARS-COV-2 antigen. In some embodiments, the antigen is the S protein of SARS-COV-2 antigen. In some embodiments, the antigen is the receptor binding domain (RBD) of the S protein of the novel coronavirus (SARS-CoV-2).
- RBD receptor binding domain
- the individual may be an individual infected with a pathogen containing the antigen. In some embodiments, the individual may be an individual who is infected with a pathogen containing the antigen but does not show clinical symptoms. In some embodiments, the individual may be an individual who has been infected with a pathogen containing the antigen and has exhibited clinical symptoms. In some embodiments, the individual is an individual who is infected with a pathogen containing the antigen and is in the incubation period. In some embodiments, the individual is an individual who is infected with a pathogen containing the antigen and is in the infectious phase. In some embodiments, the individual is an individual who has been infected with a pathogen containing the antigen and is in the recovery phase. In some embodiments, the individual is an individual who has been infected with a pathogen containing the antigen and has recovered.
- the individual is confirmed to carry the antigen at the first time.
- the first time may be a time period during which the individual is infected with a pathogen containing the antigen but does not show clinical symptoms. In some embodiments, the first time may be a period of time during which the individual has been infected with a pathogen containing the antigen and has shown clinical symptoms. In some embodiments, the first time may be a time period during which the individual is infected with the pathogen containing the antigen and is in the incubation period. In some embodiments, the first time may be a time period during which the individual is infected with the pathogen containing the antigen and is in the infectious period. In some embodiments, the first time may be a period of time during which the individual is infected with a pathogen containing the antigen and is in the recovery phase.
- the individual is confirmed not to carry the antigen or the amount of the antigen carried is reduced at a second time after the first time.
- the second time may be a time period during which the individual is infected with a pathogen containing the antigen but does not show clinical symptoms.
- the second time may be a time period during which the individual has been infected with a pathogen containing the antigen and has shown clinical symptoms.
- the second time may be a time period during which the individual is infected with the pathogen containing the antigen and is in the incubation period.
- the second time may be a time period during which the individual is infected with the pathogen containing the antigen and is in the infectious period.
- the second time may be a period of time during which the individual is infected with a pathogen containing the antigen and is in the recovery phase. In some embodiments, the second time may be a period of time during which the individual has been infected with the pathogen containing the antigen and has recovered.
- the second time is about 12 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 20 days, 25 days, 30 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months Or 1 year.
- the individual is confirmed not to carry the antigen at the second time.
- the pathogen is a virus, and the individual is confirmed not to carry the antigen of the virus at a second time.
- the amount of the antigen confirmed to be carried by the individual at the second time is reduced.
- the pathogen is a virus, and the amount of the viral antigen confirmed to be carried by the individual at the second time decreases.
- the load of the virus confirmed to be carried by the individual at the second time is reduced.
- the antigen is SARS-CoV-2, and the individual is confirmed to have a reduced SARS-CoV-2 load at the second time.
- the load of the SARS-CoV-2 confirmed to be carried by the individual at the second time is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, At least 60%, at least 70%, at least 80%, at least 90% or 100%.
- the individual is confirmed not to carry the antigen or the amount of the antigen carried is reduced at a plurality of different second times after the first time. In some embodiments, the individual is confirmed not to carry the antigen at a plurality of different second times.
- the pathogen is a virus, and the individual is confirmed not to carry the antigen of the virus at a plurality of different second times. In some embodiments, the amount of the antigen confirmed to be carried by the individual at a plurality of different second times is reduced. In some embodiments, the amount of the antigen confirmed to be carried by the individual gradually decreases at a plurality of different second times.
- the pathogen is a virus, and the amount of the viral antigen confirmed to be carried by the individual at a plurality of different second times decreases. In some embodiments, the pathogen is a virus, and the amount of the viral antigen confirmed to be carried by the individual at a plurality of different second times gradually decreases. In some embodiments, the individual has a reduced load of the virus confirmed to carry at a plurality of different second times. In some embodiments, the load of the virus confirmed to be carried by the individual gradually decreases at a plurality of different second times. In some embodiments, the antigen is SARS-CoV-2, and the individual has been confirmed to carry a reduced load of SARS-CoV-2 at multiple different second times.
- the antigen is SARS-CoV-2
- the load of SARS-CoV-2 confirmed to be carried by the individual at a plurality of different second times gradually decreases.
- the load of SARS-CoV-2 confirmed to be carried by said individual at a plurality of different second times is reduced by at least 10%, at least 20%, at least 30%, at least 40%, At least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100%.
- the load of SARS-CoV-2 confirmed to be carried by said individual at a plurality of different second times is gradually reduced by at least 10%, at least 20%, at least 30%, at least 40% , At least 50%, at least 60%, at least 70%, at least 80%, at least 90% or 100%.
- the plurality of second time intervals are about 12 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days , 12 days, 13 days, 14 days, 15 days, 20 days, 25 days, 30 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months or 1 year.
- the presence or amount of the antigen can be determined by any method known in the art.
- the presence or amount of the antigen can be determined by a nucleic acid amplification reaction.
- nucleic acid amplification reactions include, but are not limited to, reverse transcription PCR (RT-PCR), polymerase chain reaction (PCR), variants of PCR (e.g., real-time PCR, allele-specific PCR, assembly PCR, asymmetric PCR, Digital PCR, emulsion PCR, dial-out PCR (dial-out PCR), helicase-dependent PCR, nested PCR, hot-start PCR, inverse PCR, methylation-specific PCR, miniprimer PCR, Multiplex PCR, nested PCR, overlap-extension PCR, thermal asymmetric interlaced PCR (thermal asymmetric interlaced PCR), step-down PCR) and ligase chain reaction (LCR).
- RT-PCR reverse transcription PCR
- PCR polymerase chain reaction
- the presence or amount of the antigen is determined by detecting the DNA of the antigen. In some embodiments, the presence or amount of the antigen is determined by detecting the RNA of the antigen. In the case of detecting RNA, DNA can be obtained by reverse transcription of RNA and subsequent DNA amplification can be used to determine the amplified DNA product.
- the antigen is a virus, and the presence or amount of the virus is determined by detecting the DNA or RNA of the virus. In some embodiments, the presence or amount of the virus is determined by detecting the DNA or RNA of the virus in a sample obtained from the individual. The sample may be cells, skin, tissue and/or tissue fluid obtained from any anatomical location of the individual.
- the sample may be blood, body cavity fluid, sputum, pus, feces, breast milk, serum, saliva, urine, gastric and digestive juice, tears, eye fluid, sweat, derived from the individual Mucus, glandular secretions, spinal fluid, hair, nails, skin cells, plasma, nasal swabs, throat swabs, nasopharyngeal washes, and/or other excreta or body tissues.
- step (b) in the method includes enriching B cells from sorted peripheral blood mononuclear cells (PBMC). In some embodiments, step (b) in the method further comprises enriching memory B cells in the blood sample. In some embodiments, the memory B cells are enriched by CD27 antibodies. In some embodiments, the memory B cells are enriched by CD27 antibody-carrying substrates, CD27 antibody-carrying microparticles, CD27 antibody-carrying magnetic beads, and/or CD27 antibody-carrying columns.
- PBMC peripheral blood mononuclear cells
- the method further includes one or more steps selected from the following to exclude a part of the enriched B cells before step (c): selecting CD27+ B cells; excluding naive B cells; excluding naive B cells; Depleted B cells; exclude non-B cells; and select cells in which the antigen can be bound.
- the B cells in the blood sample of the individual exclude a portion of the enriched B cells by the CD27 antibody.
- the B cells exclude a portion of the enriched B cells through a substrate carrying CD27 antibody, microparticles carrying CD27 antibody, magnetic beads carrying CD27 antibody, and/or a column carrying CD27 antibody.
- the B cells in the individual's blood sample exclude a portion of the enriched B cells by excluding naive B cells. In some embodiments, the B cells in the individual's blood sample exclude a portion of the enriched B cells by excluding depleted B cells. In some embodiments, the B cells in the individual's blood sample exclude a portion of the enriched B cells by excluding non-B cells.
- peripheral blood mononuclear cells are first sorted and B cells are enriched, and then a CD27 antibody is used to exclude a part of the enriched B cells.
- peripheral blood mononuclear cells are first sorted and enriched for B cells, and then naive B cells are excluded to exclude a portion of the enriched B cells.
- peripheral blood mononuclear cells are first sorted and enriched for B cells, and then depleted B cells are excluded to exclude a portion of the enriched B cells.
- peripheral blood mononuclear cells are first sorted and B cells are enriched, and then non-B cells are excluded to exclude a part of the enriched B cells.
- peripheral blood mononuclear cells are first sorted and enriched for B cells, followed by CD27 antibody, and then by excluding naive B cells, excluding depleted B cells, and/or excluding non-B cells To exclude part of the enriched B cells.
- the portion of excluded B cells is at least 10% of the enriched B cells. In some embodiments, a portion of the excluded B cells is at least 20% of the enriched B cells. In some embodiments, the portion of the excluded B cells is at least 30% of the enriched B cells. In some embodiments, the portion of excluded B cells is at least 40% of the enriched B cells. In some embodiments, the portion of excluded B cells is at least 50% of the enriched B cells. In some embodiments, a portion of the excluded B cells is at least 60% of the enriched B cells. In some embodiments, a portion of the excluded B cells is at least 70% of the enriched B cells. In some embodiments, the portion of excluded B cells is at least 80% of the enriched B cells.
- a portion of the excluded B cells is at least 90% of the enriched B cells. In some embodiments, the portion of excluded B cells is at least 95% of the enriched B cells. In some embodiments, the portion of excluded B cells is at least 96% of the enriched B cells. In some embodiments, a portion of the excluded B cells is at least 97% of the enriched B cells. In some embodiments, a portion of the excluded B cells is at least 98% of the enriched B cells. In some embodiments, the portion of excluded B cells is at least 99% of the enriched B cells.
- the method further includes performing one, two, three, four, five or more of the following steps after step (c) to exclude part of the antigen-binding unit clonotype: selection Enrich clonotypes with a frequency higher than 1; select or exclude clonotypes from B cells expressing IgA1, IgA2, IgD, IgM, IgG1, IgG2, IgG3 and/or IgG4; exclude non-B cell clonotypes by cell typing ; Exclude naive B cell clonotypes by cell typing; exclude untransformed B cells by cell typing; exclude exhausted B cell clonotypes by cell typing; exclude monocytes by cell typing; use cell typing Exclude dendritic cells; exclude T cells through cell typing; exclude natural killer cells through cell typing; and exclude clonotypes with variable region mutation rates less than 1%, 1.5%, or 2%.
- the method further includes selecting a clonotype with an enrichment frequency higher than 1 after step (c) to exclude a part of the antigen-binding unit clonotype. In some embodiments, the method further includes selecting or excluding clonotypes from B cells expressing IgA1, IgA2, IgD, IgM, IgG1, IgG2, IgG3, and/or IgG4 after step (c) to exclude antigen binding Part of the clonotype of the unit.
- the method further comprises selecting clonotypes from B cells expressing IgA1, IgA2, IgD, IgM, IgG1, IgG2, IgG3, and/or IgG4 after step (c) to exclude antigen-binding unit clones Part of the type. In some embodiments, the method further includes excluding clonotypes from B cells expressing IgA1, IgA2, IgD, IgM, IgG1, IgG2, IgG3, and/or IgG4 after step (c) to exclude antigen binding unit clones Part of the type.
- the method further includes excluding non-B cell clonotypes by cell typing after step (c) to exclude part of the antigen-binding unit clonotypes. In some embodiments, the method further includes excluding naive B cell clonotypes by cell typing after step (c) to exclude part of the antigen-binding unit clonotypes. In some embodiments, the method further includes excluding non-transformed B cells by cell typing after step (c) to exclude part of the antigen-binding unit clonotype. In some embodiments, the method further includes excluding depleted B cell clonotypes by cell typing after step (c) to exclude part of the antigen-binding unit clonotypes.
- the method further includes excluding monocytes by cell typing after step (c) to exclude part of the antigen-binding unit clonotype. In some embodiments, the method further includes excluding dendritic cells by cell typing after step (c) to exclude part of the antigen-binding unit clonotype. In some embodiments, the method further includes excluding T cells by cell typing after step (c) to exclude part of the antigen-binding unit clonotype. In some embodiments, the method further includes excluding natural killer cells by cell typing after step (c) to exclude part of the antigen-binding unit clonotype. In some embodiments, the method further includes excluding clonotypes with a variable region mutation rate of less than 1%, 1.5%, or 2% after step (c) to exclude part of the antigen-binding unit clonotype.
- clonotypes derived from B cells expressing IgA1, IgA2, IgD, IgM, IgG1, IgG2, IgG3, and/or IgG4 can be selected or excluded.
- the method includes selecting a clonotype of B cells from one of IgAl, IgA2, IgD, IgM, IgG1, IgG2, IgG3, and IgG4.
- the method includes selecting clonotypes of B cells from two of IgA1, IgA2, IgD, IgM, IgG1, IgG2, IgG3, and IgG4.
- the method includes selecting clonotypes of B cells from three of IgA1, IgA2, IgD, IgM, IgG1, IgG2, IgG3, and IgG4. In some embodiments, the method includes selecting clonotypes of B cells from four of IgA1, IgA2, IgD, IgM, IgG1, IgG2, IgG3, and IgG4. In some embodiments, the method includes selecting clonotypes of B cells from five of IgA1, IgA2, IgD, IgM, IgG1, IgG2, IgG3, and IgG4.
- the method includes selecting clonotypes of B cells from six of IgA1, IgA2, IgD, IgM, IgG1, IgG2, IgG3, and IgG4. In some embodiments, the method includes selecting clonotypes of B cells from seven of IgA1, IgA2, IgD, IgM, IgG1, IgG2, IgG3, and IgG4. In some embodiments, the method includes excluding clonotypes of B cells from one of IgAl, IgA2, IgD, IgM, IgG1, IgG2, IgG3, and IgG4.
- the method includes excluding clonotypes of B cells from two of IgA1, IgA2, IgD, IgM, IgG1, IgG2, IgG3, and IgG4. In some embodiments, the method includes excluding clonotypes of B cells from three of IgA1, IgA2, IgD, IgM, IgG1, IgG2, IgG3, and IgG4. In some embodiments, the method includes excluding clonotypes of B cells from four of IgA1, IgA2, IgD, IgM, IgG1, IgG2, IgG3, and IgG4.
- the method includes excluding clonotypes of B cells from five of IgA1, IgA2, IgD, IgM, IgG1, IgG2, IgG3, and IgG4. In some embodiments, the method includes excluding clonotypes of B cells from six of IgA1, IgA2, IgD, IgM, IgG1, IgG2, IgG3, and IgG4. In some embodiments, the method includes excluding clonotypes of B cells from seven of IgA1, IgA2, IgD, IgM, IgG1, IgG2, IgG3, and IgG4.
- the excluded unit clonotypes are at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96% of all the unit clonotypes. %, 97%, 98%, 99%. In some embodiments, the eliminated unit clonotypes are at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% of all the unit clonotypes.
- the method further comprises one, two, three, four, five or more of the following selections after step (c), so that the selected clonotype is One part is confirmed as the antigen-binding unit in step (d): select clonotypes with an enrichment frequency higher than 1; select or exclude expressions from IgA1, IgA2, IgD, IgM, IgG1, IgG2, IgG3 and/or IgG4 Clonotypes of B cells; exclude non-B cell clonotypes through cell typing; exclude naive B cell clonotypes through cell typing; exclude exhausted B cell clonotypes through cell typing; exclude monocytes through cell typing Exclude dendritic cells through cell typing; exclude T cells through cell typing; exclude natural killer cells through cell typing; and exclude clonotypes with variable region mutation rates less than 1%, 1.5%, or 2%.
- the method further includes selecting a clonotype with a frequency of enrichment higher than 1 after step (c), so that a part of the selected clonotype is confirmed as the antigen in step (d) Combination unit.
- the method further includes selecting or excluding clonotypes from B cells expressing IgA1, IgA2, IgD, IgM, IgG1, IgG2, IgG3, and/or IgG4 after step (c), so that A part of the selected clonotype is confirmed as the antigen binding unit in step (d).
- the method further includes performing cell typing to exclude non-B cell clonotypes after step (c), so that a part of the selected clonotype is confirmed as the antigen in step (d) Combination unit. In some embodiments, the method further includes performing cell typing to exclude naive B cell clonotypes after step (c), so that a part of the selected clonotype is confirmed as the antigen in step (d) Combination unit. In some embodiments, the method further includes performing cell typing to exclude depleted B cell clonotypes after step (c), so that a part of the selected clonotype is confirmed as the selected clonotype in step (d). The antigen binding unit.
- the method further includes performing cell typing to exclude monocytes after step (c), so that a part of the selected clonotype is confirmed as the antigen binding unit in step (d) .
- the method further includes performing cell typing to exclude dendritic cells after step (c), so that a part of the selected clonotype is confirmed as the antigen binding in step (d) unit.
- the method further includes excluding T cells by cell typing after step (c), so that a part of the selected clonotype is confirmed as the antigen binding unit in step (d).
- the method further includes performing cell typing to exclude natural killer cells after step (c), so that a part of the selected clonotype is confirmed as the antigen binding unit in step (d) .
- the method further includes performing after step (c) to exclude clonotypes with a variable region mutation rate of less than 1%, 1.5%, or 2%, so that a part of the selected clonotypes are in step (d). ) Was confirmed as the antigen-binding unit.
- a part of the selected clonotypes confirmed as the antigen binding unit in step (d) is at least 10%, 20%, 30%, 40%, 50%, 60% of all clonotypes , 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%. In some embodiments, a part of the selected clonotypes confirmed as the antigen binding unit in step (d) is at least 50%, 60%, 70%, 80%, 90%, 95% of all clonotypes. %, 96%, 97%, 98%, 99%.
- the method further includes performing light and heavy chain matching based on the obtained sequence information. In some embodiments, the light and heavy chain matching is performed by a computer algorithm. In some embodiments, the method further includes performing pedigree analysis based on the obtained sequence information. In some embodiments, the pedigree analysis is performed by a computer algorithm. In some embodiments, the method further includes comparing the clonotype information with one or more reference sequences. In some embodiments, the method further includes visualizing cell clusters. In some embodiments, the visualization of cell clusters is implemented by a computer algorithm. In some embodiments, the method includes assembly, annotation, and clonotype analysis of the contig.
- the assembly, annotation, and clonotype analysis of contigs are performed by computer algorithms.
- the method includes annotating the structure of the CDR regions of the light chain and the heavy chain.
- the annotation of the structure of the CDR regions of the light chain and the heavy chain is implemented by a computer algorithm.
- the method includes predicting the structure of CDR3.
- the prediction of the CDR3 structure is implemented by a computer algorithm.
- the method includes mapping V(D)J sequence reads.
- the mapping of the V(D)J sequence reading is implemented by a computer algorithm.
- the method includes calculating the high frequency mutation rate by the following formula:
- the gap is the number of base pairs in the insertion or deletion region.
- the method includes comparing the predicted CDR3H structure with the CDR3H structure of the reference sequence. In some embodiments, the comparison is performed by a computer algorithm.
- the reference sequence is an antibody or fragment thereof that specifically binds to the antigen. In some embodiments, the reference sequence specifically binds to an antigen of SARS-CoV. In some embodiments, the reference sequence specifically binds to the antigen of SARS-CoV-2. In some embodiments, the reference sequence specifically binds to the S protein of SARS-CoV-2. In some embodiments, the reference sequence specifically binds to the receptor binding domain (RBD) of the SARS-CoV-2 S protein. Any antibody or fragment thereof known in the art can be used as a reference sequence in this application. In some embodiments, the reference sequence is an antibody or fragment thereof against SARS-CoV known in the art.
- the reference sequence is an antibody or fragment thereof against SARS-CoV-2 known in the art. In some embodiments, the reference sequence is an antibody or fragment thereof against the S protein of SARS-CoV-2 known in the art. In some embodiments, the reference sequence is an antibody or fragment thereof against the S protein binding domain (RBD) of SARS-CoV-2 known in the art. In some embodiments, the reference sequence is from the PDB (Protein Data Bank) database.
- PDB Protein Data Bank
- the reference sequence is an antibody or a fragment thereof, and the comparison includes predicting the CDR3H structure of the clonotype based on the transcriptome sequence information, and comparing the predicted CDR3H structure of the clonotype with the The CDR3H structure of the antibody or its fragment was compared.
- the reference sequence is an antibody or a fragment thereof, and the comparison includes predicting the CDR1H structure of the clonotype based on the transcriptome sequence information, and comparing the predicted CDR3H structure of the clonotype with the The CDR1H structure of the antibody or its fragment was compared.
- the reference sequence is an antibody or a fragment thereof
- the comparison includes predicting the CDR2H structure of the clonotype according to the transcriptome sequence information, and comparing the predicted CDR3H structure of the clonotype with the The CDR2H structures of antibodies or fragments thereof were compared.
- the reference sequence is a known antibody against the S protein of SARS-CoV-2 or a fragment thereof, and the comparison includes predicting a clonal CDR3H structure based on the transcriptome sequence information, and The predicted CDR3H structure of the clonotype is compared with the CDR3H structure of the antibody or fragment thereof.
- the reference sequence is a known antibody or fragment thereof against the S protein binding domain (RBD) of SARS-CoV-2, and the comparison includes predicting a clone based on the transcriptome sequence information And compare the predicted CDR3H structure of the clonotype with the CDR3H structure of the antibody or its fragment.
- the method further comprises expressing the antigen binding unit in the host cell.
- Any host cell known in the art can be used to express the antigen binding unit in this application.
- the host cell includes eukaryotic cells and prokaryotic cells.
- the host cell includes, but is not limited to, bacterial cells, fungal cells, animal cells, insect cells, plant cells, and the like.
- bacterial host cells examples include those belonging to the genus Escherichia, Serratia, Bacillus, Brevibacterium, Corynebacterium, Microorganisms such as Microbacterium and Pseudomonas.
- bacterial host cells may include, but are not limited to, Escherichia coli XL1-Blue, XL2-Blue, DH1, MC1000, KY3276, W1485, JM109, HB101, No. 49, iW3110, NY49, G1698, BL21, or TB1.
- Other bacterial host cells can include, but are not limited to, Serratia ficaria, Serratia fonticola, Serratia liquefaciens, and Serratia marcescens. , Bacillus subtilis, Bacillus amyloliquefaciens, Brevibacterium ammoniagenes, Brevibacterium immariophilum ATCC 14068, Brevibacterium saccharolyticum ATCC14066, Brevibacterium flavum 14067, Brevibacterium flavum Brevibacterium lactofermentum ATCC 13869, Corynebacterium glutamicum ATCC 13032, Corynebacterium glutamicum ATCC 13869, Corynebacterium acetoacidophilum ATCC 13870, Ammonium microbacterium ( Microbacterium ammoniaphilum ATCC15354; Pseudomonas putida, Pseudomonas sp. D-0110, etc.
- Yeast host cells that can be used in this application may include those belonging to Kluyveromyces, Trichosporon, Saccharomyces, Schizosaccharomyces, Schwanniomyces, Pichia, Candida and other microorganisms, such as Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces lactis, and sprouts Microorganisms such as Trichosporon pullulans, Schwanniomyces alluvius, and Candida utilis.
- eukaryotic cells examples include animal cells, such as mammalian cells.
- host cells include but are not limited to Chinese hamster ovary cells (CHO) or monkey cells, such as COS cells, HepG2 cells, A549 cells, and any cells available through ATCC or other depository institutions.
- CHO Chinese hamster ovary cells
- COS cells such as COS cells, HepG2 cells, A549 cells, and any cells available through ATCC or other depository institutions.
- the method further includes purifying the antigen binding unit. Any purification method known in the art can be used to purify the antigen binding unit described in this application. In some embodiments, the purification includes, but is not limited to, ion exchange chromatography, hydrophobic chromatography, and affinity chromatography.
- it further includes evaluating the ability of the antigen binding unit to bind the antigen.
- the ability of the antigen binding unit to bind to the antigen is evaluated by the KD equilibrium dissociation constant (KD).
- At least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the antigen binding unit binds to the antigen at a rate higher than that of The rate at which the antigen dissociates.
- At least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the antigen binding unit is less than 100 nM, less than 50 nM, less than 20 nM, An equilibrium dissociation constant (KD) of less than 15 nM, less than 10 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.1 nM, less than 0.05 nM, or less than 0.01 nM binds the antigen.
- KD equilibrium dissociation constant
- At least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the antigen binding unit is verified by ELISA to have the ability to bind to the antigen . In some embodiments, at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the antigen binding unit is capable of neutralizing the antigen. In some embodiments, at least about 10% of the antigen binding unit is less than 20 ⁇ g/ml, less than 10 ⁇ g/ml, less than 9 ⁇ g/ml, less than 8 ⁇ g/ml, less than 7 ⁇ g/ml, less than 6 ⁇ g/ml, less than 5 ⁇ g/ml.
- ml less than 4 ⁇ g/ml, less than 3 ⁇ g/ml, less than 2 ⁇ g/ml, less than 1 ⁇ g/ml, less than 0.5 ⁇ g/ml, less than 0.25 ⁇ g/ml, less than 0.2 ⁇ g/ml, less than 0.1 ⁇ g/ml, less than 0.05 ⁇ g/ ml, or less than 0.001 ⁇ g / ml in the IC 50 and the antigen.
- At least about 20% of the antigen binding unit is less than 20 ⁇ g/ml, less than 10 ⁇ g/ml, less than 9 ⁇ g/ml, less than 8 ⁇ g/ml, less than 7 ⁇ g/ml, less than 6 ⁇ g/ml, less than 5 ⁇ g/ml.
- ml less than 4 ⁇ g/ml, less than 3 ⁇ g/ml, less than 2 ⁇ g/ml, less than 1 ⁇ g/ml, less than 0.5 ⁇ g/ml, less than 0.25 ⁇ g/ml, less than 0.2 ⁇ g/ml, less than 0.1 ⁇ g/ml, less than 0.05 ⁇ g/ ml, or less than 0.001 ⁇ g / ml in the IC 50 and the antigen.
- At least about 30% of the antigen binding unit is less than 20 ⁇ g/ml, less than 10 ⁇ g/ml, less than 9 ⁇ g/ml, less than 8 ⁇ g/ml, less than 7 ⁇ g/ml, less than 6 ⁇ g/ml, less than 5 ⁇ g/ml.
- ml less than 4 ⁇ g/ml, less than 3 ⁇ g/ml, less than 2 ⁇ g/ml, less than 1 ⁇ g/ml, less than 0.5 ⁇ g/ml, less than 0.25 ⁇ g/ml, less than 0.2 ⁇ g/ml, less than 0.1 ⁇ g/ml, less than 0.05 ⁇ g/ ml, or less than 0.001 ⁇ g / ml in the IC 50 and the antigen.
- At least about 40% of the antigen binding unit is less than 20 ⁇ g/ml, less than 10 ⁇ g/ml, less than 9 ⁇ g/ml, less than 8 ⁇ g/ml, less than 7 ⁇ g/ml, less than 6 ⁇ g/ml, less than 5 ⁇ g/ml.
- ml less than 4 ⁇ g/ml, less than 3 ⁇ g/ml, less than 2 ⁇ g/ml, less than 1 ⁇ g/ml, less than 0.5 ⁇ g/ml, less than 0.25 ⁇ g/ml, less than 0.2 ⁇ g/ml, less than 0.1 ⁇ g/ml, less than 0.05 ⁇ g/ ml, or less than 0.001 ⁇ g / ml in the IC 50 and the antigen.
- At least about 50% of the antigen binding unit is less than 20 ⁇ g/ml, less than 10 ⁇ g/ml, less than 9 ⁇ g/ml, less than 8 ⁇ g/ml, less than 7 ⁇ g/ml, less than 6 ⁇ g/ml, less than 5 ⁇ g/ml.
- ml less than 4 ⁇ g/ml, less than 3 ⁇ g/ml, less than 2 ⁇ g/ml, less than 1 ⁇ g/ml, less than 0.5 ⁇ g/ml, less than 0.25 ⁇ g/ml, less than 0.2 ⁇ g/ml, less than 0.1 ⁇ g/ml, less than 0.05 ⁇ g/ ml, or less than 0.001 ⁇ g / ml in the IC 50 and the antigen.
- At least about 60% of the antigen binding unit is less than 20 ⁇ g/ml, less than 10 ⁇ g/ml, less than 9 ⁇ g/ml, less than 8 ⁇ g/ml, less than 7 ⁇ g/ml, less than 6 ⁇ g/ml, less than 5 ⁇ g/ml.
- ml less than 4 ⁇ g/ml, less than 3 ⁇ g/ml, less than 2 ⁇ g/ml, less than 1 ⁇ g/ml, less than 0.5 ⁇ g/ml, less than 0.25 ⁇ g/ml, less than 0.2 ⁇ g/ml, less than 0.1 ⁇ g/ml, less than 0.05 ⁇ g/ ml, or less than 0.001 ⁇ g / ml in the IC 50 and the antigen.
- At least about 70% of the antigen binding unit is less than 20 ⁇ g/ml, less than 10 ⁇ g/ml, less than 9 ⁇ g/ml, less than 8 ⁇ g/ml, less than 7 ⁇ g/ml, less than 6 ⁇ g/ml, less than 5 ⁇ g/ml.
- ml less than 4 ⁇ g/ml, less than 3 ⁇ g/ml, less than 2 ⁇ g/ml, less than 1 ⁇ g/ml, less than 0.5 ⁇ g/ml, less than 0.25 ⁇ g/ml, less than 0.2 ⁇ g/ml, less than 0.1 ⁇ g/ml, less than 0.05 ⁇ g/ ml, or less than 0.001 ⁇ g / ml in the IC 50 and the antigen.
- At least about 80% of the antigen binding unit is less than 20 ⁇ g/ml, less than 10 ⁇ g/ml, less than 9 ⁇ g/ml, less than 8 ⁇ g/ml, less than 7 ⁇ g/ml, less than 6 ⁇ g/ml, less than 5 ⁇ g/ml.
- ml less than 4 ⁇ g/ml, less than 3 ⁇ g/ml, less than 2 ⁇ g/ml, less than 1 ⁇ g/ml, less than 0.5 ⁇ g/ml, less than 0.25 ⁇ g/ml, less than 0.2 ⁇ g/ml, less than 0.1 ⁇ g/ml, less than 0.05 ⁇ g/ ml, or less than 0.001 ⁇ g / ml in the IC 50 and the antigen.
- At least about 90% of the antigen binding unit is less than 20 ⁇ g/ml, less than 10 ⁇ g/ml, less than 9 ⁇ g/ml, less than 8 ⁇ g/ml, less than 7 ⁇ g/ml, less than 6 ⁇ g/ml, less than 5 ⁇ g/ml.
- ml less than 4 ⁇ g/ml, less than 3 ⁇ g/ml, less than 2 ⁇ g/ml, less than 1 ⁇ g/ml, less than 0.5 ⁇ g/ml, less than 0.25 ⁇ g/ml, less than 0.2 ⁇ g/ml, less than 0.1 ⁇ g/ml, less than 0.05 ⁇ g/ ml, or less than 0.001 ⁇ g / ml in the IC 50 and the antigen.
- the antigen binding unit can be obtained by the methods described herein within several days. In some embodiments, it can be passed as described herein within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, two weeks, three weeks, and four weeks. Method to obtain the antigen binding unit.
- a method for preparing an antigen-binding unit against a predetermined antigen comprising identifying the antigen-binding unit against the antigen according to the method of any preceding claim, and expressing the antigen-binding unit against the antigen in a host cell Antigen-binding unit, and harvesting and purifying the antigen-binding unit.
- the antigen binding unit described herein includes a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region includes VH CDR1, VH CDR2, and VH CDR3, and the light
- the chain variable region includes VL CDR1, VL CDR2 and VL CDR3.
- the VH of the antigen-binding unit described herein may include a sequence selected from SEQ ID NO.: 721-1080 and 3111-3145, which includes one or more sequences selected from SEQ ID NO: 721-1080 and 3111-3145 A sequence of amino acid additions, deletions, or substitutions, or a sequence selected from SEQ ID NO: 721-1080 and 3111-3145 with at least 80%, 85%, 90%, 91%, 92%, 93%, 94% , 95%, 96%, 97%, 98%, 99%, or 99% identity sequence.
- the VH of the antigen-binding unit described herein may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 Add, delete or replace.
- the VH of the antigen-binding unit described herein may have more than 1, 2, 3, and 3 compared with the reference polypeptide. 1, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 additions, deletions or replacements.
- the VH of the antigen-binding unit described herein may have fewer than 2, 3, 4 compared to the reference polypeptide. 1, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 add , Delete or replace.
- the VH CDR1 of the antigen-binding unit described herein may comprise a sequence selected from SEQ ID NO.: 1461-1820 and 2901-2935, which includes one or A sequence of multiple amino acid additions, deletions, or substitutions, or a sequence selected from SEQ ID NO: 1461-1820 and 2901-2935 that has at least 80%, 85%, 90%, 91%, 92%, 93%, 94 %, 95%, 96%, 97%, 98%, 99%, or 99% identity sequence.
- the VH CDR1 of the antigen-binding unit described herein may have 1, 2, or 3 compared with the reference polypeptide. One, four, or five additions, deletions or substitutions.
- there are amino acid additions, deletions or substitutions in the VH CDR1 of the antigen-binding unit described herein compared with the reference polypeptide sequence there may be more than one or two VH CDR1s of the antigen-binding unit described herein compared with the reference polypeptide. , 3, 4, or 5 additions, deletions or substitutions.
- VH CDR1 of the antigen binding unit described herein compared with the reference polypeptide sequence there may be less than 2, 3 VH CDR1s of the antigen binding unit described herein compared with the reference polypeptide. , 4, or 5 additions, deletions or substitutions.
- the VH CDR2 of the antigen-binding unit described herein may include a sequence selected from SEQ ID NO.: 1821-2180 and 2936-2970, which includes one or more sequences compared with a sequence selected from SEQ ID NO: 1821-2180 and 2936-2970.
- the VH CDR2 of the antigen-binding unit described herein may have 1, 2, 3, and 3 compared with the reference polypeptide. One, four, or five additions, deletions or substitutions.
- there are amino acid additions, deletions or substitutions in the VH CDR2 of the antigen-binding unit described herein compared with the reference polypeptide sequence there may be more than one or two VH CDR2s of the antigen-binding unit described herein compared with the reference polypeptide. , 3, 4, or 5 additions, deletions or substitutions.
- the VH CDR2 of the antigen-binding unit described herein may have fewer than 2, 3 compared to the reference polypeptide. , 4, or 5 additions, deletions or substitutions.
- the VH CDR3 of the antigen-binding unit described herein may include a sequence selected from SEQ ID NO.: 1-360 and 2971-3005, which includes one or A sequence of multiple amino acid additions, deletions, or substitutions, or a sequence selected from SEQ ID NO: 1-360 and 2971-3005 with at least 80%, 85%, 90%, 91%, 92%, 93%, 94 %, 95%, 96%, 97%, 98%, 99%, or 99% identity sequence.
- the VH CDR3 of the antigen-binding unit described herein may have 1, 2, 3, and 3 compared with the reference polypeptide. One, four, or five additions, deletions or substitutions.
- there are amino acid additions, deletions or substitutions in the VH CDR3 of the antigen-binding unit described herein compared with the reference polypeptide sequence there may be more than one or two VH CDR3s of the antigen-binding unit described herein compared with the reference polypeptide. , 3, 4, or 5 additions, deletions or substitutions.
- the VH CDR3 of the antigen-binding unit described herein may have fewer than 2, 3 compared with the reference polypeptide. , 4, or 5 additions, deletions or substitutions.
- the VL of the antigen-binding unit described herein may include a sequence selected from SEQ ID NO.: 1081-1440 and 3146-3180, which includes one or more sequences selected from SEQ ID NO: 1081-1440 and 3146-3180.
- the VL of the antigen-binding unit described herein compared with the reference polypeptide sequence there may be 1, 2, 3, or 3 VLs in the VL of the antigen-binding unit described herein compared with the reference polypeptide. 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 Add, delete or replace.
- the VL of the antigen-binding unit described herein may have more than one, two, or three compared with the reference polypeptide.
- the VL of the antigen-binding unit described herein may have fewer than 2, 3, 4 compared to the reference polypeptide. 1, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 add , Delete or replace.
- the VL CDR1 of the antigen-binding unit described herein may comprise a sequence selected from SEQ ID NO.: 2181-2540 and 3006-3040, compared with a sequence selected from SEQ ID NO: 2181-2540 and 3006-3040 A sequence of one or more amino acid additions, deletions, or substitutions, or at least 80%, 85%, 90%, 91%, 92%, 93% with a sequence selected from SEQ ID NO: 2181-2540 and 3006-3040 , 94%, 95%, 96%, 97%, 98%, 99%, or 99% identity sequence.
- the VL CDR1 of the antigen-binding unit described herein may have 1, 2, 3, and 3 compared with the reference polypeptide. One, four, or five additions, deletions or substitutions.
- there are amino acid additions, deletions or substitutions in the VL CDR1 of the antigen-binding unit described herein compared with the reference polypeptide sequence there may be more than one or two VL CDR1s of the antigen-binding unit described herein compared with the reference polypeptide. , 3, 4, or 5 additions, deletions or substitutions.
- VL CDR1 of the antigen-binding unit described herein compared with the reference polypeptide sequence there may be less than 2, 3 VL CDR1s of the antigen-binding unit described herein compared with the reference polypeptide. , 4, or 5 additions, deletions or substitutions.
- the VL CDR2 of the antigen-binding unit described herein may include a sequence selected from SEQ ID NO.: 2541-2900 and 3041-3075, which includes one or more sequences than the sequence selected from SEQ ID NO: 2541-2900 and 3041-3075.
- VL CDR2 of the antigen-binding unit described herein compared with the reference polypeptide sequence there may be one, two, or three VL CDR2s of the antigen-binding unit described herein compared with the reference polypeptide. One, four, or five additions, deletions or substitutions.
- the VLCDR2 of the antigen-binding unit described herein may have more than 1, 2, 3, 4, or 5 additions, deletions or substitutions.
- VL CDR2 of the antigen-binding unit described herein compared with the reference polypeptide sequence there may be less than 2, 3 or fewer VL CDR2s of the antigen-binding unit described herein compared with the reference polypeptide. , 4, or 5 additions, deletions or substitutions.
- the VL CDR3 of the antigen-binding unit described herein may include a sequence selected from SEQ ID NO.: 361-720 and 3076-3110, which includes one or more sequences compared with a sequence selected from SEQ ID NO: 361-720 and 3076-3110.
- VL CDR3 of the antigen-binding unit described herein compared with the reference polypeptide sequence there may be one, two, or three VL CDR3s of the antigen-binding unit described herein compared with the reference polypeptide. One, four, or five additions, deletions or substitutions.
- the VLCDR3 of the antigen-binding unit described herein may have more than 1, 2, 3, 4, or 5 additions, deletions or substitutions.
- VL CDR3 of the antigen-binding unit described herein compared with the reference polypeptide sequence there may be fewer than 2, 3 VL CDR3s of the antigen-binding unit described herein compared with the reference polypeptide. , 4, or 5 additions, deletions or substitutions.
- the VH CDR1 of the antigen-binding unit described herein may comprise a sequence selected from SEQ ID NO.: 1461-1820 and 2901-2935, which includes one or A sequence of multiple amino acid additions, deletions, or substitutions, or a sequence selected from SEQ ID NO: 1461-1820 and 2901-2935 that has at least 80%, 85%, 90%, 91%, 92%, 93%, 94 %, 95%, 96%, 97%, 98%, 99%, or 99% identity sequence; and the VL CDR1 of the antigen binding unit described herein may comprise a sequence selected from SEQ ID NO.: 2181-2540 and 3006
- the sequence of -3040, compared with a sequence selected from SEQ ID NO: 2181-2540 and 3006-3040 contains one or more amino acid additions, deletions, or substitutions, or a sequence selected from SEQ ID NO: 2181-2540 and
- the sequence of 3006-3040 has at least 80%, 85%, 90%, 91%, 92%, 9
- the VH CDR2 of the antigen-binding unit described herein may include a sequence selected from SEQ ID NO.: 1821-2180 and 2936-2970. Compared with the sequence selected from SEQ ID NO: 1821-2180 and 2936-2970, the VH CDR2 includes one or A sequence of multiple amino acid additions, deletions, or substitutions, or a sequence selected from SEQ ID NO: 1821-2180 and 2936-2970 with at least 80%, 85%, 90%, 91%, 92%, 93%, 94 %, 95%, 96%, 97%, 98%, 99%, or 99% identity sequence; and the VL CDR2 of the antigen binding unit described herein may comprise a sequence selected from SEQ ID NO.: 2541-2900 and 3041 The sequence of -3075, compared with a sequence selected from SEQ ID NO: 2541-2900 and 3041-3075, contains one or more amino acid additions, deletions, or substitutions, or a sequence selected from SEQ ID NO: 2541-2900 and
- the VH CDR3 of the antigen-binding unit described herein may include a sequence selected from SEQ ID NO.: 1-360 and 2971-3005, which includes one or A sequence of multiple amino acid additions, deletions, or substitutions, or a sequence selected from SEQ ID NO: 1-360 and 2971-3005 with at least 80%, 85%, 90%, 91%, 92%, 93%, 94 %, 95%, 96%, 97%, 98%, 99%, or 99% identity sequence; and the VL CDR3 of the antigen binding unit described herein may comprise SEQ ID NO.: 361-720 and 3076
- the sequence of -3110, compared with the sequence selected from SEQ ID NO: 361-720 and 3076-3110, contains one or more amino acid additions, deletions, or substitutions, or a sequence selected from SEQ ID NO: 361-720 and
- the sequence of 3076-3110 has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,
- the VH of the antigen binding unit described herein may include VH CDR1, VH CDR2, and VH CDR3, wherein the VH CDR1 is selected from the sequence of SEQ ID NO.: 1461-1820 and 2901-2935, and is selected from the sequence of SEQ ID NO: 1461.
- the sequence contains one or more amino acid additions, deletions, or substitutions, or is at least 80%, 85%, and the sequence selected from SEQ ID NO: 1461-1820 and 2901-2935 Sequences with 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99% identity; wherein the VH CDR2 is selected from SEQ ID NO.:
- the sequence of 1821-2180 and 2936-2970 compared with the sequence selected from SEQ ID NO: 1821-2180 and 2936-2970, contains one or more amino acid addition, deletion, or substitution sequence, or the sequence selected from SEQ ID NO :
- the sequence of 1821-2180 and 2936-2970 has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99%
- the VH CDR3 is selected from the sequence of SEQ ID NO.: 1-
- the VL of the antigen binding unit described herein may include VL CDR1, VL CDR2, and VL CDR3, wherein the VL CDR1 is selected from the sequence of SEQ ID NO.: 2181-2540 and 3006-3040, and is selected from the sequence of SEQ ID NO: 2181 Compared with the sequence of -2540 and 3006-3040, the sequence contains one or more amino acid additions, deletions, or substitutions, or has at least 80%, 85%, and the sequence selected from SEQ ID NO: 2181-2540 and 3006-3040.
- VL CDR2 is selected from SEQ ID NO.:
- the sequence of 2541-2900 and 3041-3075 compared with a sequence selected from SEQ ID NO: 2541-2900 and 3041-3075, contains one or more amino acid additions, deletions, or substitutions, or a sequence selected from SEQ ID NO :
- the sequence of 2541-2900 and 3041-3075 has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99%
- the VL CDR3 is selected from the sequence of SEQ ID NO.: 361-720 and 3076-3110, compared with the sequence selected from SEQ ID NO: 361-720 and 3076-3110, it contains one or A sequence of multiple amino acid additions, deletions, or substitutions, or at least 80%, 85%, 90%, 9
- the VH of the antigen binding unit described herein may comprise a sequence selected from a combination of the following CDR1, CDR2, and CDR3:
- the VH may comprise a sequence selected from a combination of the following CDR1, CDR2, and CDR3:
- the VH CDR1 of the antigen binding unit described herein may include the same sequence as the CDR1 contained in SEQ ID NOs: 721-1080 and 3111-3145; the VH CDR2 of the antigen binding unit described herein may Contains the same sequence as the CDR2 contained in SEQ ID NO: 721-1080 and 3111-3145; the VH CDR3 of the antigen binding unit described herein may be contained in SEQ ID NO: 721-1080 and 3111-3145
- the CDR3 contained in the same sequence; the VL CDR1 of the antigen binding unit may include the same sequence as the CDR1 contained in SEQ ID NOs: 1081-1440 and 3146-3180; the VLCDR2 of the antigen binding unit May include the same sequence as the CDR2 contained in SEQ ID NO: 1081-1440 and 3146-3180; and/or the VL CDR3 of the antigen binding unit may include the same sequence as SEQ ID NO: 1081-1440 and 3146-3180 CDR3 contained in the same sequence.
- the antibodies provided herein comprise one, two, three, four, five, or six amino acid sequences, wherein each amino acid sequence is independently selected from the amino acid sequences listed below:
- Heavy chain variable region CDR1 amino acid sequence SEQ ID NO: 1634, SEQ ID NO: 1635, SEQ ID NO: 1650, SEQ ID NO: 1757, and SEQ ID NO: 2907;
- Heavy chain variable region CDR2 amino acid sequence SEQ ID NO: 1994, SEQ ID NO: 1995, SEQ ID NO: 2010, SEQ ID NO: 2117, and SEQ ID NO: 2942;
- the heavy chain variable region CDR3 amino acid sequence SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 190, SEQ ID NO: 297, and SEQ ID NO: 2977.
- the antibodies provided herein comprise one, two, three, four, five, or six amino acid sequences, wherein each amino acid sequence is independently selected from the amino acid sequences listed below:
- the antibodies provided herein comprise one, two, three, four, five, or six amino acid sequences, wherein each amino acid sequence is independently selected from the amino acid sequences listed below:
- CDR1 amino acid sequence of light chain variable region SEQ ID NO: 2355;
- the antibodies provided herein comprise one, two, three, four, five, or six amino acid sequences, wherein each amino acid sequence is independently selected from the amino acid sequences listed below:
- CDR3 amino acid sequence of light chain variable region SEQ ID NO: 550;
- CDR2 amino acid sequence of heavy chain variable region SEQ ID NO: 2010;
- the antibodies provided herein comprise one, two, three, four, five, or six amino acid sequences, wherein each amino acid sequence is independently selected from the amino acid sequences listed below:
- CDR1 amino acid sequence of light chain variable region SEQ ID NO: 2477;
- CDR2 amino acid sequence of heavy chain variable region SEQ ID NO: 2117;
- the antibodies provided herein comprise one, two, three, four, five, or six amino acid sequences, wherein each amino acid sequence is independently selected from the amino acid sequences listed below:
- CDR2 amino acid sequence of heavy chain variable region SEQ ID NO: 2942;
- the antibodies provided herein comprise one or two amino acid sequences, wherein each amino acid sequence is independently selected from the amino acid sequences listed below:
- the antibodies provided herein comprise one or two amino acid sequences, wherein each amino acid sequence is independently selected from the amino acid sequences listed below:
- the antibodies provided herein comprise one or two amino acid sequences, wherein each amino acid sequence is independently selected from the amino acid sequences listed below:
- the antibodies provided herein comprise one or two amino acid sequences, wherein each amino acid sequence is independently selected from the amino acid sequences listed below:
- the antibodies provided herein comprise one or two amino acid sequences, wherein each amino acid sequence is independently selected from the amino acid sequences listed below:
- the antibodies provided herein comprise one or two amino acid sequences, wherein each amino acid sequence is independently selected from the amino acid sequences listed below:
- the antigen binding unit described herein can bind to the new coronavirus (SARS-CoV-2) S protein.
- the antigen binding unit described herein can be combined with the receptor binding domain (RBD) of the new coronavirus (SARS-CoV-2) S protein.
- RBD receptor binding domain
- the binding ability of the antigen binding unit to the RBD can be characterized or represented by any method known in the art.
- binding can be characterized by binding affinity, which can be the strength of the interaction between the antigen binding unit and the antigen.
- the binding affinity can be determined by any method known in the art, such as an in vitro binding test.
- the binding affinity of an antigen-binding unit herein can be expressed in terms of KD.
- KD is defined as the ratio of two kinetic rate constants Ka/Kd, where "Ka” refers to the rate constant of antibody binding to antigen, and “Kd” refers to the ratio of antibody from antibody/Kd The rate constant for dissociation in the antigen complex.
- the antigen binding unit as disclosed herein specifically binds to the receptor binding domain (RBD) of the new coronavirus (SARS-CoV-2) S protein with a KD in the range of about 10 ⁇ M to about 1 fM.
- the antigen binding unit may be less than about 10 ⁇ M, 1 ⁇ M, 0.1 ⁇ M, 50 nM, 20 nM, 15 nM, 10 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 50 pM, 10 pM, 1 pM, 0.1 pM, 10 fM. , 1fM, 0.1fM or less than 0.1fM KD specifically binds to the receptor binding domain (RBD) of the new coronavirus (SARS-CoV-2) S protein.
- RBD receptor binding domain
- SARS-CoV-2 new coronavirus
- the antigen binding unit disclosed herein can be less than 100 nM, less than 50 nM, less than 20 nM, less than 15 nM, less than 10 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.1 nM, less than 0.05 nM, Or the equilibrium dissociation constant (KD) of less than 0.01 nM binds to the receptor binding domain (RBD) of the S protein of the new coronavirus (SARS-CoV-2).
- KD equilibrium dissociation constant
- the antigen binding unit described herein has neutralizing activity against the new coronavirus (SARS-CoV-2).
- the neutralizing activity of the antigen binding unit described herein against the novel coronavirus (SARS-CoV-2) can be analyzed by pseudovirus.
- Pseudovirus has cell infection characteristics similar to herpes virus, can simulate the early process of true virus infection of cells, and can be detected and analyzed safely and quickly.
- the neutralizing activity of the antigen-binding unit described herein against the novel coronavirus (SARS-CoV-2) can be detected by methods known in the art, such as a microporous cell neutralization test, refer to Temperton N J et al., Emerge Infect Dis, 2005, 11(3), 411-416.
- the neutralizing activity of the antigen-binding unit described herein against the novel coronavirus (SARS-CoV-2) can be tested using experimental cells such as Huh-7 cells and the pseudovirus SARS-CoV-2 virus.
- the antigen-binding unit described herein can be, for example, less than 100 ⁇ g/ml, less than 50 ⁇ g/ml, less than 20 ⁇ g/ml, less than 10 ⁇ g/ml, less than 9 ⁇ g/ml, less than 8 ⁇ g/ml, less than 7 ⁇ g/ml, less than 6 ⁇ g/ml, Less than 5 ⁇ g/ml, less than 4 ⁇ g/ml, less than 3 ⁇ g/ml, less than 2 ⁇ g/ml, less than 1 ⁇ g/ml, less than 0.5 ⁇ g/ml, less than 0.25 ⁇ g/ml, less than 0.2 ⁇ g/ml, less than 0.1 ⁇ g/ml, less than 0.05 ⁇ g/
- the neutralizing activity of the antigen-binding unit described herein against the novel coronavirus (SARS-CoV-2) can be detected by the SARS-CoV-2 true virus through Plaque Reduction Neutralization Test (PRNT), and passed The reduction of plaque after incubation was calculated to calculate the IC50 of the antigen binding unit described herein to neutralize the SARS-CoV-2 true virus.
- SARS-CoV-2 novel coronavirus
- the antigen-binding unit described herein can be, for example, less than 100 ⁇ g/ml, less than 50 ⁇ g/ml, less than 20 ⁇ g/ml, less than 10 ⁇ g/ml, less than 9 ⁇ g/ml, less than 8 ⁇ g/ml, less than 7 ⁇ g/ml, less than 6 ⁇ g/ml, Less than 5 ⁇ g/ml, less than 4 ⁇ g/ml, less than 3 ⁇ g/ml, less than 2 ⁇ g/ml, less than 1 ⁇ g/ml, less than 0.5 ⁇ g/ml, less than 0.25 ⁇ g/ml, less than 0.2 ⁇ g/ml, less than 0.1 ⁇ g/ml, less than 0.05 ⁇ g/ml, less than 1ng/ml, less than 0.5ng/ml, less than 0.25ng/ml, less than 0.2ng/ml, less than 0.1ng/ml, less than 50pg/ml,
- the method comprises culturing a host cell expressing the antigen-binding unit under conditions suitable for expression of the antigen-binding unit, and isolating the antigen-binding unit expressed by the host cell.
- the expressed antigen binding unit can be isolated using a variety of protein purification techniques known in the art. Generally, antigen binding units are isolated from the culture medium as secreted polypeptides, although they can also be recovered from host cell lysates or bacterial periplasm when they are directly produced without signal peptides. If the antigen-binding units are membrane-bound, they can be dissolved by an appropriate detergent solution commonly used by those skilled in the art.
- the recovered antigen-binding unit can be subjected to salt precipitation (for example, with ammonium sulfate), ion exchange chromatography (for example, running on a cation or anion exchange column at neutral pH and eluting with a step gradient of increasing ionic strength), gel filtration Chromatography (including gel filtration HPLC) and tag affinity column chromatography, or affinity resins such as protein A, protein G, hydroxyapatite and anti-immunoglobulin for further purification.
- salt precipitation for example, with ammonium sulfate
- ion exchange chromatography for example, running on a cation or anion exchange column at neutral pH and eluting with a step gradient of increasing ionic strength
- gel filtration Chromatography including gel filtration HPLC
- tag affinity column chromatography or affinity resins such as protein A, protein G, hydroxyapatite and anti-immunoglobulin for further purification.
- derivatized immunoglobulins added with the following moieties can be used: chemical linkers, detectable moieties such as fluorescent dyes, enzymes, substrates, chemiluminescent moieties, specific binding moieties such as streptavidin Harmonin, avidin or biotin, or drug conjugate.
- an antigen binding unit conjugated to a chemically functional moiety is also provided herein.
- this part is a label capable of generating a detectable signal.
- conjugated antigen binding units can be used in, for example, detection systems, such as the severity of viral infections, imaging of infected foci, and the like.
- labels are known in the art and include, but are not limited to, radioisotopes, enzymes, fluorescent compounds, chemiluminescent compounds, bioluminescent compound substrate cofactors, and inhibitors.
- This part can be covalently linked to the antigen binding unit, recombinantly linked or conjugated to the antigen binding unit by a second reagent such as a second antibody, protein A or biotin-avidin complex.
- a signal peptide is a short amino acid sequence that directs newly synthesized proteins through the cell membrane (usually the endoplasmic reticulum in eukaryotic cells) and the inner or both inner and outer membranes of bacteria.
- the signal peptide can be located in the N-terminal part of the polypeptide or the C-terminal part of the polypeptide, and the signal peptide can be enzymatically removed from the cell between the biosynthesis and secretion of the polypeptide.
- Such peptides can be introduced into the antigen binding unit to allow the secretion of synthetic molecules.
- Reagents that enhance immune reactivity include, but are not limited to, bacterial superantigens.
- Reagents that facilitate coupling to the solid support include, but are not limited to, biotin or avidin.
- the immunogenic carrier includes, but is not limited to, any physiologically acceptable buffer.
- Biological response modifiers include cytokines, particularly tumor necrosis factor (TNF), interleukin-2, interleukin-4, granulocyte macrophage colony stimulating factor and gamma-interferon.
- the chemically functional part can be prepared recombinantly, for example, by generating a fusion gene encoding the antigen binding unit and the functional part.
- the antigen binding unit can be chemically bonded to the moiety by any of a variety of well-known chemical procedures.
- the moiety is a protein
- the connection can be through a heterobifunctional crosslinking agent, for example, SPDP, carbodiimide glutaraldehyde, and the like.
- This part can be covalently linked or conjugated via a second reagent, such as a second antibody, protein A or biotin-avidin complex.
- Paramagnetic moieties and their conjugation to antibodies are well known in the art. See, for example, Miltenyi et al. (1990) Cytometry 11:231-238.
- an isolated polynucleotide encoding the antigen binding unit described herein.
- the nucleotide sequence corresponding to each region of the L or H chain of an existing antibody can be easily obtained and sequenced using conventional techniques (including but not limited to hybridization, PCR, and DNA sequencing).
- Hybridoma cells that produce monoclonal antibodies are used as a preferred source of antibody nucleotide sequences.
- a large number of hybridoma cells that produce a series of monoclonal antibodies can be obtained from public or private repositories. The largest storage institution is the American Type Culture Collection, which provides a variety of well-characterized hybridoma cell lines.
- antibody nucleotides can be obtained from immunized or unimmunized rodents or humans, and from organs such as the spleen and peripheral blood lymphocytes. Specific techniques suitable for the extraction and synthesis of antibody nucleotides are described in Orlandi et al. (1989) Proc. Natl. Acad. Sci. USA 86: 3833-3837; Larrick et al. 1989) biochem. Biophys. Res. Commun. 160: 1250-1255; Sastry et al. (1989) Proc. Natl. Acad. Sci., USA 86: 5728-5732; and U.S. Patent No. 5,969,108.
- the antibody nucleotide sequence can also be modified, for example, by substituting coding sequences for the constant regions of human heavy and light chains to replace homologous non-human sequences. In this way, chimeric antibodies are prepared that retain the binding specificity of the original antibody.
- the polynucleotides encoding the heavy chain and/or light chain of the antigen-binding unit can be codon-optimized to achieve optimized expression of the subject's antigen-binding unit in the desired host cell.
- codon optimization method natural codons are replaced by the most common codons from a reference genome, where the codon translation rate of each amino acid is designed to be higher.
- Additional exemplary methods for generating codon-optimized polynucleotides for expression of the desired protein are described in Kanaya et al., Gene, 238:143-155 (1999), Wang et al., Mol. Biol. Evol. , 18(5): 792-800 (2001), US Patent No. 5,795,737, US Publication No. 2008/0076161 and WO 2008/000632, the method can be applied to the heavy chain and/or light chain of the antigen binding unit.
- polynucleotides herein include polynucleotides encoding functional equivalents of exemplary polypeptides and fragments thereof.
- nucleotides of the L and H sequences and the heterodimerization sequences suitable for constructing the polynucleotides and vectors described herein can have considerable variation. These variations are included in the content of this article.
- SARS-CoV-2 novel coronavirus
- telaprevir boceprevir
- semiprevir sofosbuvir
- daclastavir analpine Asunaprevir
- lamivudine lamivudine
- adefovir adefovir
- entecavir tenofovir
- telbivudine interferon alpha and pegylated interferon ⁇ .
- the second agent may be selected from hydroxychloroquine, chloroquine, favilavir, Gimsilumab, AdCOVID (University of Alabama at Birmingham), AT-100 (Airway Therapeutics), TZLS-501 (Tiziana Life Science) , OYA1 (OyaGen), BPI-002 (BeyondSpring), INO-4800 (Inovio Pharmaceutical), NP-120 (ifenprodil), Remdesivir (GS-5734), Actemra (Roche), Galidevir (BCX4430) , SNG001 (Synairgen Research), or a combination thereof.
- the second agent may be an agent for alleviating the symptoms of an inflammatory condition complicated by the subject.
- the anti-inflammatory agents include non-steroidal anti-inflammatory drugs (NSAID) and corticosteroids.
- NSAID includes, but is not limited to, salicylate, such as acetylsalicylic acid; diflunisal, salicylic acid, and salicylate; propionic acid derivatives, such as ibuprofen; naproxen; Ketoprofen, flurbiprofen, oxaprazine, fenoprofen, loxoprofen, and ketoprofen; acetic acid derivatives, such as indomethacin, diclofenac, tolmetin, aceclofenac, sulphur Linic acid, nabumetone, etodolac and ketorolac; enolic acid derivatives, such as piroxicam, lornoxicam, meloxicam, isoxicam, tenoxicam,
- the second agent may be an immunosuppressive agent.
- Immunosuppressants that can be used in combination with the antigen binding unit include, but are not limited to, hydroxychloroquine, sulfasalazine, leflunomide, etanercept, infliximab, adalimumab, D-penicillamine, Oral gold compounds, injectable gold compounds (intramuscular injection), minocycline, gold sodium thiomalate, auranofin, D-penicillamine, clobenzari, bucillamine, and acotaril , Cyclophosphamide, azathioprine, methotrexate, mizoribine, cyclosporine and tacrolimus.
- the specific dosage will vary according to the specific antigen-binding unit selected, the dosing schedule to be followed, whether to be administered in combination with other agents, the time of administration, the tissue to be administered, and the physical delivery system carrying the specific antigen-binding unit.
- the specific antigen-binding unit selected, the dosing schedule to be followed, whether to be administered in combination with other agents, the time of administration, the tissue to be administered, and the physical delivery system carrying the specific antigen-binding unit.
- An antigen binding unit in the range of 66, 67, 68, 69 or 70 mg.
- Antigen binding unit in the range of 55mg.
- antigen binding in the range of about 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54 or 55 mg is administered to the subject weekly unit.
- the antigen binding unit is administered to the subject in an amount.
- the antigen binding unit is administered to the subject in an amount of about 6 to 10 mg, about 6.5 to 9.5 mg, about 6.5 to 8.5 mg, about 6.5 to 8 mg, or about 7 to 9 mg per day on average.
- the dosage of the antigen binding unit can be about, at least about, or at most about 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000mg or mg/kg, Or any range within which it can be derived.
- the expected dose of mg/kg refers to the mg amount of antigen binding unit per kilogram of the subject's total body weight. It is expected that when multiple doses are given to a patient, the doses may vary in amount or they may be the same.
- composition comprising a subject antibody or functional fragment thereof and a pharmaceutically acceptable carrier, excipient or stabilizer, which includes but is not limited to inert solid diluents and fillers, diluents, sterile Aqueous solution and various organic solvents, penetration enhancers, solubilizers and adjuvants.
- a pharmaceutically acceptable carrier excipient or stabilizer
- inert solid diluents and fillers include but is not limited to inert solid diluents and fillers, diluents, sterile Aqueous solution and various organic solvents, penetration enhancers, solubilizers and adjuvants.
- the pharmaceutical composition may be in unit dosage form suitable for single administration of precise dosages.
- the pharmaceutical composition may further include an antigen binding unit as an active ingredient, and may include conventional pharmaceutical carriers or excipients. In addition, it may include other drugs or medicaments, carriers, adjuvants, and the like.
- Exemplary parenteral administration forms include solutions or suspensions of active polypeptides and/or PEG-modified polypeptides in sterile aqueous solutions, such as aqueous propylene glycol solutions or dextrose solutions. If necessary, such dosage forms may be suitably buffered with salts such as histidine and/or phosphate.
- the composition may further include one or more pharmaceutically acceptable additives and excipients.
- additives and excipients include, but are not limited to, anti-sticking agents, defoamers, buffers, polymers, antioxidants, preservatives, chelating agents, viscosity modifiers (viscomodulator), tonicity modifiers, flavoring agents, coloring agents, Flavoring agents, sunscreens, suspending agents, binders, fillers, plasticizers, lubricants and mixtures thereof.
- the kit described herein comprises the antigen binding unit described herein or a conjugate thereof as described herein. Also provided is the use of the antigen binding unit described herein in the preparation of a kit for detecting the presence or level of the novel coronavirus or its S protein or RBD in a sample, or for diagnosis Whether the subject is infected with the new coronavirus.
- the sample includes, but is not limited to, excrement, oral or nasal secretions, alveolar lavage fluid, etc. from a subject (such as a mammal, preferably a human).
- the detection method may use enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay, chemiluminescence immunoassay, radioimmunoassay, fluorescence immunoassay, immunochromatography, competition method, and similar detection methods.
- ELISA enzyme-linked immunosorbent assay
- enzyme immunoassay enzyme immunoassay
- chemiluminescence immunoassay chemiluminescence immunoassay
- radioimmunoassay radioimmunoassay
- fluorescence immunoassay immunochromatography
- competition method and similar detection methods.
- the molecular biology experimental methods and immunoassays used in this article basically refer to J. Sambrook et al., Molecular Cloning: Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989, and FM Ausubel et al., Compiled Molecular Biology Experiment Guide, 3rd Edition, John Wiley & Sons, Inc., 1995; the restriction enzymes were used in accordance with the conditions recommended by the product manufacturer. If specific conditions are not indicated in the examples, it shall be carried out in accordance with the conventional conditions or the conditions recommended by the manufacturer.
- the reagents or instruments used without the manufacturer's indication are all conventional products that can be purchased commercially.
- PBMC cell collection and B cell enrichment In the P2+ biosafety laboratory, STEMCELL SepMate TM -15 (Stemcell Technologies, catalog number: 86415) was used to extract PBMC. Subsequently, according to the manufacturer's instructions, the extracted PBMCs were enriched for memory B cells using STEMCELL EasySep Human Memory B Cell Isolation Kit (Stemcell Technologies, catalog number: 17864).
- CD27+ memory B cell enrichment According to the manufacturer’s instructions, use STEMCELL EasySep Human Memory B Cell Isolation Kit (Stemcell Technologies), use EasySep TM magnet to separate CD27+ B cells that bind to CD27 antibody, and count (Countess Automated Cell Counter ).
- Antigen-binding B cell enrichment Biotinylated Spike/RBD recombinant protein purchased from Sino Biology is used. Prepare fresh antigen/streptavidin M-280 Dynabeads (Thermofisher) complex before each B cell enrichment. Vortex 100 ⁇ l of M-280 beads containing 6.5 x 107 beads for 30 seconds, and let stand to room temperature. Then wash the beads twice with 1ml 1x PBS on the magnetic stand, and eluted in 100 ⁇ l 1x PBS. Mix 100 ⁇ l magnetic beads with 20 ⁇ g biotinylated Spike/RBD protein, and incubate at room temperature for 30 minutes.
- the complex was washed 3 times with 500 ⁇ l of 1x PBS on a magnetic stand.
- the washed complex was eluted in 100 ⁇ l of 1x PBS, and placed on ice to be used.
- the complex is equilibrated to room temperature. Add the Spike/RBD magnetic bead complex directly to the B cell mixture, mix and incubate on a thermomixer at 4°C for 30 minutes. Place the mixture on a magnetic stand and remove the supernatant.
- Chromium Single Cell V(D)J Reagent Kits purchased from 10X genomics, catalog number: 100006 were used to perform single-cell transcriptome VDJ sequencing on the enriched memory B cells.
- the enriched B cells from 10 patients were treated as one batch, and a total of six batches of sequencing analysis were performed.
- FIG. 8 shows the 25 clonotypes with the highest enrichment from the same patient (A) and the Ig class distribution of the patient's clonotypes (B). According to this method, more than 8,400 antigen-binding IgG+ clonotypes were identified from the enriched B cells of the above 60 patients.
- Cutadapt (Martin, 2011) was used to remove bases with a quality score of less than 30 at the 3'end.
- Use "cellranger vdj" for contig assembly, annotation and clonotype analysis.
- the SAAB+ pipeline (Kovaltsuk et al., 2020) was used to annotate the structure of the CDR regions of the light and heavy chains, and the embedded FREAD (Choi and Deane, 2009) was used to predict the structure of CDR3.
- Use IgBlast-1.15.0 (Ye et al., 2013) to map V(D)J sequence reading.
- the lineage of each clonotype is determined by DNA mutation pattern and Ig category. Graph the pedigree by igraph (Csardi and Nepusz, 2006).
- the clonotype was selected by establishing the following criteria: (1) Enrichment frequency> 1; (2) Contains B cells expressing IgG1; (3) Does not contain B cells expressing IgG2; (4) Variable region mutation rate> 2% ; And (5) contains memory B cells. According to this standard, 169 antibodies that meet the criteria and 47 antibodies that do not meet the above criteria were selected.
- Figure 9 shows a cell typing map determined based on gene expression for the production B cells matching the light chain and heavy chain in the fifth batch.
- Figure 10 shows the clonotype analysis of the fifth batch of B cells that passed the above-mentioned standard screening. The clonotypes that meet the above criteria are located on the right side of the dotted line in the figure.
- Figure 11A shows the number of antibodies that meet the above criteria produced after S protein enrichment and RBD enrichment as described in Example 1, respectively, as well as the binding ELISA results and Kd values and neutralization of RBD determined as described herein.
- the IC50 value of the pseudovirus 46% of the antibodies that meet the criteria have a Kd value of less than 20nM for binding to RBD, and the IC50 for 25% neutralization of the pseudovirus is less than 3 ⁇ g/ml.
- Figure 11B shows the binding ELISA results and Kd values of clonotypes that do not meet the criteria of not containing IgG2, variable region mutation rate> 2%, or containing memory B cells with RBD, and the IC50 value of neutralizing pseudovirus .
- FIG. 12 shows the crystal structure of the complex of antibody m396Fab and SARS-CoV-RBD (PDB ID: 2DD8). The lower part is the RBD, the upper left is the m396-H domain, and the upper right is the m396-L domain.
- the sequencing results were analyzed, and 395 strains of antigen binding units were obtained, which were named ABU1-395.
- the sequence information of the obtained antigen-binding unit is shown in Table 1 below.
- ABU-270 990 1350 ABU-271 991 1351 ABU-272 992 1352 ABU-273 993 1353 ABU-274 994 1354 ABU-275 995 1355 ABU-276 996 1356 ABU-277 997 1357 ABU-278 998 1358 ABU-279 999 1359 ABU-280 1000 1360 ABU-281 1001 1361 ABU-282 1002 1362 ABU-283 1003 1363 ABU-284 1004 1364 ABU-285 1005 1365 ABU-286 1006 1366 ABU-287 1007 1367 ABU-288 1008 1368 ABU-289 1009 1369 ABU-290 1010 1370 ABU-291 1011 1371 ABU-292 1012 1372 ABU-293 1013 1373 ABU-294 1014 1374 ABU-295 1015 1375 ABU-296 1016 1376 ABU-297 1017 1377 ABU-298 1018 1378 ABU-299 1019 1379 ABU-300 1020 1380 ABU-301 1021 13
- nucleic acid molecules encoding antibody heavy and light chains are synthesized in vitro, and then cloned into expression vectors, respectively, to obtain recombinant expression vectors encoding antibody heavy and light chains, respectively.
- the recombinant expression vectors encoding the heavy chain and light chain of the antibody obtained above were co-transfected into HEK293 cells. After 4-6 hours of transfection, the cell culture medium was changed to a serum-free medium, and the culture was continued at 37°C for 6 days. After the culture is completed, the antibody protein expressed by the cells is purified from the culture through an affinity purification column. Subsequently, the purified target protein was detected by reducing and non-reducing SDS-PAGE.
- the recombinantly expressed S protein RBD was used as the coating antigen, and the horseradish peroxidase (HRP) labeled Goat anti-human IgG Fc was used as the secondary antibody, and the antigen reaction of the purified antibody to be tested was detected by ELISA experiment sex.
- HRP horseradish peroxidase
- a 96-well plate was coated with recombinantly expressed S protein RBD (its amino acid sequence is shown in SEQ ID NO: 1459, and the concentration is 0.01 ⁇ g/ml or 1 ⁇ g/ml), and then the 96-well plate is treated with blocking solution Closed.
- the monoclonal antibodies to be tested (control antibody, ABU-174, ABU-175 and ABU190; concentrations of 0.1 ⁇ g/ml respectively) were added and incubated. After washing with ELISA washing solution, horseradish peroxidase (HRP) labeled Goat anti-human IgG Fc was added as a secondary antibody (diluted at 1:500), and the incubation continued. Then, the ELISA plate was washed with PBST, and a color developer was added to develop the color. Then read the absorbance value of OD450nm on the microplate reader. The results are shown in Table 2. It can be seen from Table 2 that ABU-174, ABU-175 and ABU190 can specifically recognize and bind to S protein RBD.
- HRP horseradish peroxidase
- Table 2 The reactivity of ABU-174, ABU-175 and ABU190 antigen binding units with S protein RBD (OD450 reading) detected by ELISA
- SPR surface plasmon resonance technology
- Biacore T200 for measurement, first couple the biotin-labeled SARS-COV-2 RBD domain to the SA chip (GE Company), and the signal resonance unit RU value increased by 100 units.
- the running buffer is PBS with pH 7.4 plus 0.005% P20 to ensure that the buffer in the analyte (such as antibody) is consistent with the running buffer.
- the purified antibody was diluted in a 3-fold gradient to make the concentration between 50-0.78125nM.
- Table 3 lists the binding affinity of exemplary antigen-binding units herein to the RBD region of Spike protein, wherein the KD value of each antigen-binding unit is less than 20 nM.
- Figure 2A-2 further exemplarily shows the binding affinity of ABU-174, ABU-175, ABU190, ABU297 and ABU367 to the RBD region of Spike protein.
- the KD value of ABU-174 is 0.29nM
- the KD value of ABU-175 is 0.039nM
- the KD value of ABU190 is 2.8nM
- the KD value of ABU297 is 0.824nM
- the KD value of ABU is 0.18. nM.
- Figures 2A-2E show that ABU-174, ABU-175, ABU190, ABU297 and ABU367 all have good affinity with the new coronavirus S protein.
- Example 5 Evaluation of the ability of the antigen binding unit herein to neutralize the SARS-CoV-2 pseudovirus
- the microporous cell neutralization method was used to detect the effect of the antigen binding unit in this article on SARS- Neutralizing activity of CoV-2 pseudovirus.
- the SARS-CoV-2 pseudovirus used in this example is provided by the China Institute for Food and Drug Control. It has cell infection characteristics similar to true viruses, can simulate the early process of true viruses infecting cells, and carries the reporter gene luciferase. Quick and easy detection and analysis. The operation of pseudovirus is safe, and the neutralization experiment can be completed in the P2 laboratory to detect the neutralization titer of the antibody.
- the specific steps of the experimental method are as follows.
- A2-H2 are set as cell control wells (CC), which contain only experimental cells
- the wells of A3-H3 are set as Virus control wells (VV), which contain experimental cells and pseudoviruses
- VV Virus control wells
- A4-A11, B4-B11, C4-C11, D4-D11, E4-E11, F4-F11, G4-G11, H4-H11 are set to Experimental wells, which contain experimental cells, pseudoviruses, and different concentrations of antibodies to be tested; the remaining wells are set as blanks.
- the experimental cells and pseudoviruses used in this example are Huh-7 cells and SARS-CoV-2 virus (both provided by China Food and Drug Control Research Institute).
- DMEM complete medium containing 1% antibiotics, 25mM HEPES, 10% FBS
- DMEM complete medium containing 1% antibiotics, 25mM HEPES, 10% FBS
- 50 ⁇ l/well of the test antibody diluted in DMEM complete medium at a specified concentration of 50 ⁇ l/well are 1/30 ⁇ g/ ⁇ l, 1/90 ⁇ g/ ⁇ l, 1/270 ⁇ g/ ⁇ l, 1/810 ⁇ g/ ⁇ l, 1/2430 ⁇ g/ ⁇ l, 1/7290 ⁇ g/ ⁇ l, 1/21870 ⁇ g/ ⁇ l, 1/65610 ⁇ g/ ⁇ l.
- Inhibition rate [1-(average value of luminous intensity of experimental hole-average value of luminous intensity of CC hole)/(average value of luminous intensity of VV hole-average value of luminous intensity of CC hole)] ⁇ 100%.
- the IC50 of the antibody to be tested is calculated by the Reed-Muench method.
- Table 5 lists the IC 50 of the exemplary antigen-binding units herein and SARS-CoV-2 pseudovirus, wherein the IC50 value of each antigen-binding unit is less than 1 ⁇ g/ml.
- ABU-308 ⁇ 0.5 ABU-322 ⁇ 0.1 ABU-340 ⁇ 0.5 ABU-341 ⁇ 0.1 ABU-344 ⁇ 1 ABU-349 ⁇ 0.1 ABU-351 ⁇ 0.1 ABU-352 ⁇ 0.1 ABU-354 ⁇ 0.1 ABU-355 ⁇ 0.1 ABU-356 ⁇ 0.1 ABU-357 ⁇ 1 ABU-358 ⁇ 0.1 ABU-359 ⁇ 0.1 ABU-360 ⁇ 0.1 ABU-361 ⁇ 0.5 ABU-362 ⁇ 0.5 ABU-365 ⁇ 0.1 ABU-367 ⁇ 0.1 ABU-368 ⁇ 0.5 ABU-369 ⁇ 0.1 ABU-371 ⁇ 1 ABU-372 ⁇ 0.5 ABU-373 ⁇ 0.5 ABU-375 ⁇ 0.1 ABU-376 ⁇ 0.1 ABU-377 ⁇ 0.5 ABU-379 ⁇ 0.5 ABU-380 ⁇ 0.1 ABU-381 ⁇ 0.1 ABU-382 ⁇ 0.1 ABU-386 ⁇ 0.1 ABU-391 ⁇ 1 ABU-392 ⁇ 0.1 ABU-395 ⁇ 0.1
- Figures 3A-3C further exemplarily show the neutralizing activity of ABU-174, ABU-175 and ABU190 against SARS-CoV-2 pseudovirus. It can be seen from Figure 3A-3C that ABU-174, ABU-175 and ABU190 all have good neutralizing activity, with IC50 of 0.026 ⁇ g/ml (ABU-174), 0.0086 ⁇ g/ml (ABU-175), 0.039 ⁇ g, respectively /ml(ABU190).
- Example 6 Evaluation of the ability of the antigen binding unit herein to neutralize SARS-CoV-2 true virus
- the neutralizing activity of the antibody to be tested was evaluated by the cytopathic (CPE) assay and the plaque reduction neutralization test (PRNT), respectively.
- CPE cytopathic
- PRNT plaque reduction neutralization test
- SARS-CoV-2 virus provided by the Military Medical Academy
- the titer the TCID50 of 10 5 / ml, and all experimental procedures were completed in BSL-3 laboratories.
- CPE cytopathic
- step (3) After the completion of the culture in step (1), discard the cell culture medium in the 96-well culture plate, and add the mixed solution (200 ⁇ l) containing the test antibody and the true virus prepared in step (2) as the experimental group. After incubating for 1 hour, aspirate the supernatant from the wells and add 200 ⁇ l DMEM medium (containing 2% antibiotics and 16 ⁇ g/ml trypsin) to each well.
- DMEM medium containing 2% antibiotics and 16 ⁇ g/ml trypsin
- a cell control group and a virus control group were set up in parallel.
- the cell control group (4 multiple wells)
- 200 ⁇ l DMEM medium containing 2% antibiotics and 16 ⁇ g/ml trypsin
- the virus control group after discarding the cell culture medium in the wells, add 100 TCID50 true virus (100 ⁇ l) to each well, and incubate at 37°C for 1 hour; after the incubation, aspirate the supernatant from the wells , Add 200 ⁇ l DMEM medium (containing 2% antibiotics and 16 ⁇ g/ml trypsin) to each well.
- CPE cytopathic
- the test results of the antigen-binding unit ABU-174 are shown in Table 6 below. The results show that the antigen-binding unit ABU-174 has an inhibitory effect on the virus on cells, and the neutralizing antibody titer is 1.6 ng/ ⁇ l.
- the detection results of the antigen-binding unit ABU-175 are shown in Table 7 and Figure 4 below. The results show that the antigen-binding unit ABU-175 has an inhibitory effect on the virus on cells, and the neutralizing antibody titer is 0.7 ng/ ⁇ l.
- step (3) After the completion of the culture in step (1), discard the cell culture medium in the 96-well culture plate, and add the mixed solution (200 ⁇ l) containing the test antibody and the true virus prepared in step (2) as the experimental group. After incubating for 1 hour, aspirate the supernatant from the wells and add 200 ⁇ l DMEM medium (containing 2% antibiotics and 16 ⁇ g/ml trypsin) to each well.
- DMEM medium containing 2% antibiotics and 16 ⁇ g/ml trypsin
- a cell control group and a virus control group were set up in parallel.
- the cell control group after discarding the cell culture medium in the wells, add 200 ⁇ l DMEM medium (containing 2% antibiotics and 16 ⁇ g/ml trypsin) to each well.
- the virus control group (4 multiple wells), after discarding the cell culture medium in the wells, add 100 TCID50 true virus (100 ⁇ l) to each well, and incubate at 37°C for 1 hour; after the incubation, aspirate the supernatant from the wells , Add 200 ⁇ l DMEM medium (containing 2% antibiotics and 16 ⁇ g/ml trypsin) to each well.
- Figure 5 shows the dose-response curves of the exemplary antigen binding units ABU-174, ABU-175 and ABU190 herein. It can be seen from Figure 5 that the antigen binding units ABU-174, ABU-175 and ABU190 all have good neutralizing activity against SARS-CoV-2 true virus, and can effectively inhibit virus infection and cell invasion, with IC50 of 0.5 ⁇ g/ml ( ABU-174), 0.3 ⁇ g/ml (ABU-175) and 0.8 ⁇ g/ml (ABU-190).
- SARS-CoV-2 infects cells through interaction with hACE2 receptor.
- the neutralizing effect of the antigen-binding unit in the article on SARS-CoV-2 in vivo was evaluated in two different animal models.
- hACE2 transgenic mice were used as an animal model, and treatment was performed in two different modes: pre-exposure prevention or post-exposure prevention. Specifically, hACE2 transgenic mice were intranasally infected with SARS-CoV-2 viruses (2019-nCoV Beta CoV/Wuhan/AMMS01/2020) at a dose of 105TCID50.
- SARS-CoV-2 viruses 2019-nCoV Beta CoV/Wuhan/AMMS01/2020
- the antigen-binding unit herein was injected intraperitoneally into hACE2 transgenic mice at a dose of 20 mg/kg, and the antigen-binding unit was tested as a pre-exposure preventive intervention The effect of.
- the antigen binding unit at a dose of 20 mg/kg was injected into mice.
- HG1K IgG1 antibody against H7N9 virus
- the body weight that can reflect the health of the infected mice was recorded every day for 5 consecutive days.
- hamster In the second model, hamster (Mesocricetus auratus) was used as an animal model, and treatment was performed in two different modes: pre-exposure prevention or post-exposure prevention. Specifically, similar to hACE2 transgenic mice, hamsters were infected intranasally with SARS-CoV-2 provirus (SARS-COV-2/WH-09/human/020/CHN) at a dose of 105 TCID50.
- SARS-CoV-2 provirus SARS-CoV-2 provirus
- the antigen binding unit herein at a dose of 20 mg/kg is injected into the hamster.
- animals were injected with PBS 2 hours after infection.
- the antigen binding unit herein is injected intraperitoneally into the hamster at different doses (including 20, 10, 5, and 2 mg/kg) according to body weight.
- hamsters injected with phosphate buffered saline (PBS) were used as controls.
- the weight of the infected hamster was recorded daily for 7 consecutive days.
- the hamsters were sacrificed 7 days after infection, and the lungs were collected for viral load analysis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
一种制备抗体的方法,涉及免疫学领域和分子病毒学领域,特别是新型冠状病毒的诊断、预防和治疗领域。具体而言,涉及抗新型冠状病毒的单克隆抗体,以及包含所述抗体的组合物(例如,诊断剂和治疗剂)。此外还涉及所述抗体的制备和筛选以及用途。
Description
本文涉及免疫学领域和分子病毒学领域,特别是新型冠状病毒的诊断、预防和治疗领域。具体而言,本文涉及抗新型冠状病毒的抗体,以及包含所述抗体的组合物(例如,诊断剂和治疗剂)。此外,本文还涉及所述抗体的筛选、制备和用途。本文所述的抗体可用于诊断、预防和/或治疗新型冠状病毒的感染和/或由所述感染引起的疾病(例如,新型冠状病毒肺炎)。
新型冠状病毒SARS-CoV-2是导致新型冠状病毒肺炎(COVID-19)的病原体,是一种单链RNA病毒,它与2002-2003年引发疫情的重症急性呼吸综合征冠状病毒(SARS-CoV)以及2012年引发疫情的中东呼吸综合征冠状病毒(MERS-CoV)同属冠状病毒科(Coronaviridae)。冠状病毒颗粒呈圆形或椭圆形,亦为多形性,直径50-200nm,属于尺寸较大的病毒。冠状病毒是包膜病毒,病毒衣壳外面包裹着脂质包膜,其上排列较宽的刺突蛋白(Spike,S蛋白,SEQ ID No:1460),形状如太阳光环。已有研究证实,新型冠状病毒SARS-CoV-2的病毒表面具有S蛋白,其能够在病毒感染宿主的过程中通过其包含的受体结合结构域(RBD)结合宿主细胞受体血管紧张素转换酶2(ACE2)分子,从而启动病毒膜与宿主细胞膜发生融合,导致宿主细胞感染病毒。
迄今为止,中和抗体已被证明是治疗病毒性疾病的有效方法。一般来说,患者体内的B淋巴细胞受到抗原的刺激后,会被活化,进而转变和分化成多种不同的细胞,并产生抗体。据现有的研究报道,新型冠状病毒肺炎康复者的外周血内抗新型冠状病毒的抗体,它们由经活化的B细胞产生和分泌。然而,康复者血浆内存在着多种B细胞,并且不同的B细 胞所产生的抗体的结合活性和中和效价也有所不同。到目前为止,尚无研究报道具有高结合活性和/或高中和活性的抗新型冠状病毒的抗体。
因此,需要开发能够抗新型冠状病毒SARS-CoV-2的具有高结合活性和/或高中和活性的抗体,以提供有效的诊断、预防和/或治疗新型冠状病毒感染的手段。
发明内容
本文所提供的下述技术方案满足了上述需求,并且提供了相关的优点。
一方面,本文提供一种提供针对预先确定的抗原的抗原结合单元的方法,包括(a)获得来自个体的血液样品,其中所述个体在第一时间经确认携带所述抗原,并在所述第一时间之后的第二时间经确认不携带所述抗原或者所携带的所述抗原的量减少;(b)富集所述血液样品中的B细胞;(c)对包含多个所述个体的富集的B细胞的样品进行单细胞转录组的VDJ测序,以提供抗原结合单元的克隆型信息;以及(d)基于所述克隆型信息确认所述针对所述抗原的抗原结合单元。
在一些实施方案中,所述方法中的所述步骤(b)还包括选择所述血液样品中的记忆B细胞。
在一些实施方案中,所述方法在所述步骤(c)之前还包括通过以下步骤中的一个、两个、三个或四个来排除至少30%、40%、50%、60%、70%、80%、90%、95%的所述富集的B细胞:选择CD27+B细胞;排除幼稚B细胞;排除耗尽的B细胞;排除非B细胞;以及选择其中能够结合所述抗原的细胞。
在一些实施方案中,所述方法还包括在步骤(c)之后进行以下步骤中的一个、两个、三个、四个、五个或更多个以排除至少30%、40%、50%、60%、70%、80%、90%、95%的抗原结合单元克隆型:选择富集频率高于1的克隆型;选择或排除来自于表达IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和/或IgG4的B细胞的克隆型;通过细胞分型排除非B细胞克隆型;通过细胞分型排除幼稚B细胞克隆型;通过细胞分型排除未经转换 的B细胞;通过细胞分型排除耗尽的B细胞克隆型;通过细胞分型排除单核细胞;通过细胞分型排除树突状细胞;通过细胞分型排除T细胞;通过细胞分型排除自然杀伤细胞;以及排除可变区突变率小于1%、1.5%或2%的克隆型。
在一些实施方案中,所述方法还包括在步骤(c)之后进行以下步骤中的一个、两个、三个、四个、五个或更多个的选择,从而使得至少大约10%、20%、30%、40%、50%、60%、70%、80%或90%的所选择的克隆型在步骤(d)中被确认为所述抗原结合单元:选择富集频率高于1的克隆型;选择或排除来自于表达IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和/或IgG4的B细胞的克隆型;通过细胞分型排除非B细胞克隆型;通过细胞分型排除幼稚B细胞克隆型;通过细胞分型排除耗尽的B细胞克隆型;通过细胞分型排除单核细胞;通过细胞分型排除树突状细胞;通过细胞分型排除T细胞;通过细胞分型排除自然杀伤细胞;以及排除可变区突变率小于1%、1.5%或2%的克隆型。
在一些实施方案中,所述方法还包括还包括根据所获得的序列信息进行轻重链匹配。
在一些实施方案中,所述方法还包括还包括根据所获得的序列信息进行谱系分析。
在一些实施方案中,所述第二时间是在所述第一时间之后大约1天、2天、3天、4天、5天、6天、7天、8天、9天、10天、11天、12天、13天、14天、15天、20天、25天、30天。
在一些实施方案中,所述个体在所述第二时间经确认不携带所述抗原。在一些实施方案中,所述个体在所述第二时间经确认不携带所述抗原或者所携带的所述抗原的量减少。在一些实施方案中,所述个体在多个不同的第二时间经确认不携带所述抗原或者所携带的所述抗原的量减少。
在一些实施方案中,所述多个第二时间间隔大约1天、2天、3天、4天、5天、6天、7天、8天、9天、10天、11天、12天、13天、14天、15天、20天、25天、30天。
在一些实施方案中,所述个体在多个不同的第二时间经确认所携带的所述抗原的量逐渐减少。
在一些实施方案中,所述抗原为病毒抗原。在一些实施方案中,所述抗原为新型冠状病毒(SARS-CoV-2)。在一些实施方案中,所述抗原为新型冠状病毒(SARS-CoV-2)S蛋白的受体结合结构域(RBD)。在一些实施方案中,所述方法还包括将所述克隆型信息与一个或多个参比序列进行对比。在一些实施方案中,所述参比序列为特异性结合所述抗原的抗体或其片段。在一些实施方案中,所述参比序列特异性结合SARS-CoV。在一些实施方案中,所述参比序列特异性结合SARS-CoV S蛋白的受体结合结构域(RBD)。在一些实施方案中,所述参比序列为抗体或其片段,并且所述对比包括根据所述转录组序列信息预测克隆型的CDR3H结构,并将所述克隆型的预测的CDR3H结构与所述抗体或其片段的CDR3H结构进行对比。
在一些实施方案中,所述方法还包括在宿主细胞中表达所述抗原结合单元。在一些实施方案中,所述方法还包括纯化所述抗原结合单元。在一些实施方案中,还包括评价所述抗原结合单元结合所述抗原的能力。
在一些实施方案中,至少大约10%、20%、30%、40%、50%、60%、70%、80%或90%的所述抗原结合单元的结合所述抗原的速率高于与所述抗原解离的速率。
在一些实施方案中,至少大约10%、20%、30%、40%、50%、60%、70%、80%或90%的所述抗原结合单元以小于100nM、小于50nM、小于20nM、小于15nM、小于10nM、小于5nM、小于4nM、小于3nM、小于2nM、小于1nM、小于0.5nM、小于0.1nM、小于0.05nM、或小于0.01nM的平衡解离常数(KD)结合所述抗原。
在另一个方面,本文提供一种制备针对预先确定的抗原的抗原结合单元的方法,包括根据任一前述权利要求所述的方法鉴定针对所述抗原的抗原结合单元,在宿主细胞中表达所述抗原结合单元,以及收获并纯化所述抗原结合单元。
一方面,本文提供一种抗原结合单元,其包含重链可变区(VH)和轻链可变区(VL),所述重链可变区包含VH CDR1、VH CDR2和VH CDR3,所述轻链可变区包含VL CDR1、VL CDR2和VL CDR3;其中所述VH CDR3包含选自SEQ ID NO:1-360和2971-3005的序列或者与SEQ ID NO:1-360和2971-3005相比包含一个或多个氨基酸添加、删除、或取代的序列,和/或其中所述VL CDR3包含选自SEQ ID NO:361-720和3076-3110的序列或者与SEQ ID NO:361-720和3076-3110相比包含一个或多个氨基酸添加、删除、或取代的序列。
在一些实施方案中,所述抗原结合单元以小于100nM、小于50nM、小于20nM、小于15nM、小于10nM、小于5nM、小于4nM、小于3nM、小于2nM、小于1nM、小于0.5nM、小于0.1nM、小于0.05nM、或小于0.01nM的平衡解离常数(KD)结合新型冠状病毒(SARS-CoV-2)S蛋白的受体结合结构域(RBD)。
在一些实施方案中,所述的抗原结合单元以小于20μg/ml、小于10μg/ml、小于9μg/ml、小于8μg/ml、小于7μg/ml、小于6μg/ml、小于5μg/ml、小于4μg/ml、小于3μg/ml、小于2μg/ml、小于1μg/ml、小于0.5μg/ml、小于0.25μg/ml、小于0.2μg/ml、小于0.1μg/ml、小于0.05μg/ml、或小于0.001g/ml的IC
50中和新型冠状病毒(SARS-CoV-2)。
在一些实施方案中,所述抗原结合单元的所述VH CDR1包含选自SEQ ID NO:1461-1820和2901-2935的序列或者与SEQ ID NO:1461-1820和2901-2935相比包含一个或多个氨基酸添加、删除、或取代的序列。在一些实施方案中,所述抗原结合单元的所述VH CDR1包含选自SEQ ID NO:1461-1820和2901-2935的序列。在一些实施方案中,所述抗原结合单元的所述VH CDR1包含与SEQ ID NO:1461-1820和2901-2935相比包含5、4、3、2或1个氨基酸添加、删除、或取代的序列。在一些实施方案中,所述抗原结合单元的所述VH CDR1包含与SEQ ID NO:721-1080和3111-3145中所包含的CDR1相同的序列。
在一些实施方案中,所述抗原结合单元的所述VH CDR2包含选自SEQ ID NO:1821-2180和2936-2970的序列或者与SEQ ID NO:1821-2180 和2936-2970相比包含一个或多个氨基酸添加、删除、或取代的序列。在一些实施方案中,所述抗原结合单元的所述VH CDR2包含选自SEQ ID NO:1821-2180和2936-2970的序列。在一些实施方案中,所述抗原结合单元的所述VH CDR2包含与SEQ ID NO:1821-2180和2936-2970相比包含5、4、3、2或1个氨基酸添加、删除、或取代的序列。在一些实施方案中,所述抗原结合单元的所述VH CDR2包含与SEQ ID NO:721-1080和3111-3145中所包含的CDR2相同的序列。
在一些实施方案中,所述抗原结合单元的所述VL CDR1包含选自SEQ ID NO:2181-2540和3006-3040的序列或者与SEQ ID NO:2181-2540和3006-3040相比包含一个或多个氨基酸添加、删除、或取代的序列。在一些实施方案中,所述抗原结合单元的所述VL CDR1包含选自SEQ ID NO:2181-2540和3006-3040的序列。在一些实施方案中,所述抗原结合单元的所述VLCDR1包含与SEQ ID NO:2181-2540和3006-3040相比包含5、4、3、2或1个氨基酸添加、删除、或取代的序列。在一些实施方案中,所述抗原结合单元的所述VL CDR1包含与SEQ ID NO:1081-1440和3146-3180中所包含的CDR1相同的序列。
在一些实施方案中,所述抗原结合单元的所述VL CDR2包含选自SEQ ID NO:2541-2900和3041-3075的序列或者与SEQ ID NO:2541-2900和3041-3075相比包含一个或多个氨基酸添加、删除、或取代的序列。在一些实施方案中,所述抗原结合单元的所述VL CDR2包含选自SEQ ID NO:2541-2900和3041-3075的序列。在一些实施方案中,所述抗原结合单元的所述VLCDR2包含与SEQ ID NO:2541-2900和3041-3075相比包含5、4、3、2或1个氨基酸添加、删除、或取代的序列。在一些实施方案中,所述抗原结合单元的所述VL CDR2包含与SEQ ID NO:1081-1440和3146-3180中所包含的CDR2相同的序列。
在一些实施方案中,所述抗原结合单元的所述VH包含选自SEQ ID NO:721-1080和3111-3145的序列或者与SEQ ID NO:721-1080和3111-3145相比包含一个或多个氨基酸添加、删除、或取代的序列。在一些实施方案中,所述抗原结合单元的所述VH包含选自SEQ ID NO:721-1080 和3111-3145的序列。在一些实施方案中,所述抗原结合单元的所述VH包含与SEQ ID NO:721-1080和3111-3145相比包含10、9、8、7、6、5、4、3、2或1个氨基酸添加、删除、或取代的序列。在一些实施方案中,所述抗原结合单元的所述VH包含与选自SEQ ID NO:721-1080和3111-3145的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列。
在一些实施方案中,所述抗原结合单元的所述VL包含选自SEQ ID NO:1081-1440和3146-3180的序列或者与SEQ ID NO:1081-1440和3146-3180相比包含一个或多个氨基酸添加、删除、或取代的序列。在一些实施方案中,所述抗原结合单元的所述VL包含选自SEQ ID NO:1081-1440和3146-3180的序列。在一些实施方案中,所述抗原结合单元的所述VL包含与SEQ ID NO:1081-1440和3146-3180相比包含10、9、8、7、6、5、4、3、2或1个氨基酸添加、删除、或取代的序列。在一些实施方案中,所述抗原结合单元的所述VL包含与选自SEQ ID NO:1081-1440和3146-3180的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列。
另一方面,本文提供一种抗原结合单元,其包含重链可变区(VH)和轻链可变区(VL),所述重链可变区包含VH CDR1、VH CDR2和VH CDR3,所述轻链可变区包含VL CDR1、VL CDR2和VL CDR3;其中所述VH CDR1包含选自SEQ ID NO:1461-1820和2901-2935的序列、与SEQ ID NO:1461-1820和2901-2935相比包含一个或多个氨基酸添加、删除、或取代的序列、或者与SEQ ID NO:721-1080和3111-3145中所包含的CDR1相同的序列,其中所述VH CDR2包含选自SEQ ID NO:1821-2180和2936-2970的序列、与SEQ ID NO:1821-2180和2936-2970相比包含一个或多个氨基酸添加、删除、或取代的序列、或者与SEQ ID NO:721-1080和3111-3145中所包含的CDR2相同的序列,其中所述VH CDR3包含选自SEQ ID NO:1-360和2971-3005的序列、与SEQ ID NO:1-360和2971-3005相比包含一个或多个氨基酸添加、删除、或取代的序列、或者与SEQ ID NO:721-1080和3111-3145中所包含的CDR3相同的序列; 和/或其中所述VL CDR1包含选自SEQ ID NO:2181-2540和3006-3040的序列、与SEQ ID NO:2181-2540和3006-3040相比包含一个或多个氨基酸添加、删除、或取代的序列、或者与SEQ ID NO:1081-1440和3146-3180中所包含的CDR1相同的序列,所述VL CDR2包含选自SEQ ID NO:2541-2900和3041-3075的序列、与SEQ ID NO:2541-2900和3041-3075相比包含一个或多个氨基酸添加、删除、或取代的序列、或者与SEQ ID NO:1081-1440和3146-3180中所包含的CDR2相同的序列,所述VL CDR3包含选自SEQ ID NO:361-720和3076-3110的序列、与SEQ ID NO:361-720和3076-3110相比包含一个或多个氨基酸添加、删除、或取代的序列、或者与SEQ ID NO:1081-1440和3146-3180中所包含的CDR3相同的序列。
另一方面,本文提供一种抗原结合单元,其包含重链可变区(VH)和轻链可变区(VL),所述重链可变区包含VH CDR1、VH CDR2和VH CDR3,所述轻链可变区包含VL CDR1、VL CDR2和VL CDR3;其中所述VH CDR1包含选自SEQ ID NO:1461-1820和2901-2935的序列或者与SEQ ID NO:1461-1820和2901-2935相比包含一个或多个氨基酸添加、删除、或取代的序列,其中所述VH CDR2包含选自SEQ ID NO:1821-2180和2936-2970的序列或者与SEQ ID NO:1821-2180和2936-2970相比包含一个或多个氨基酸添加、删除、或取代的序列,其中所述VH CDR3包含选自SEQ ID NO:1-360和2971-3005的序列或者与SEQ ID NO:1-360和2971-3005相比包含一个或多个氨基酸添加、删除、或取代的序列;和/或其中所述VL CDR1包含选自SEQ ID NO:2181-2540和3006-3040的序列或者与SEQ ID NO:2181-2540和3006-3040相比包含一个或多个氨基酸添加、删除、或取代的序列,所述VLCDR2包含选自SEQ ID NO:2541-2900和3041-3075的序列或者与SEQ ID NO:2541-2900和3041-3075相比包含一个或多个氨基酸添加、删除、或取代的序列,所述VL CDR3包含选自SEQ ID NO:361-720和3076-3110的序列或者与SEQ ID NO:361-720和3076-3110相比包含一个或多个氨基酸添加、删除、或取代的序列。
在一些实施方案中,所述抗原结合单元的所述VH包含选自SEQ ID NO:721-1080和3111-3145的序列或者与SEQ ID NO:721-1080和3111-3145相比包含一个或多个氨基酸添加、删除、或取代的序列。在一些实施方案中,所述抗原结合单元的所述VH包含选自SEQ ID NO:721-1080和3111-3145的序列。在一些实施方案中,所述抗原结合单元的所述VH包含与SEQ ID NO:721-1080和3111-3145相比包含10、9、8、7、6、5、4、3、2或1个氨基酸添加、删除、或取代的序列。在一些实施方案中,所述抗原结合单元的所述VH包含与选自SEQ ID NO:721-1080和3111-3145的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列。
在一些实施方案中,所述抗原结合单元的所述VL包含选自SEQ ID NO:1081-1440和3146-3180的序列或者与SEQ ID NO:1081-1440和3146-3180相比包含一个或多个氨基酸添加、删除、或取代的序列。在一些实施方案中,所述抗原结合单元的所述VL包含选自SEQ ID NO:1081-1440和3146-3180的序列。在一些实施方案中,所述抗原结合单元的所述VL包含与SEQ ID NO:1081-1440和3146-3180相比包含10、9、8、7、6、5、4、3、2或1个氨基酸添加、删除、或取代的序列。在一些实施方案中,所述抗原结合单元的所述VL包含与选自SEQ ID NO:1081-1440和3146-3180的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列。
在一些实施方案中,所述的抗原结合单元以小于100nM、小于50nM、小于20nM、小于15nM、小于10nM、小于5nM、小于4nM、小于3nM、小于2nM、小于1nM、小于0.5nM、小于0.1nM、小于0.05nM、或小于0.01nM的平衡解离常数(KD)结合新型冠状病毒(SARS-CoV-2)S蛋白的受体结合结构域(RBD)。
在一些实施方案中,所述的抗原结合单元以小于20μg/ml、小于10μg/ml、小于9μg/ml、小于8μg/ml、小于7μg/ml、小于6μg/ml、小于5μg/ml、小于4μg/ml、小于3μg/ml、小于2μg/ml、小于1μg/ml、小于 0.5μg/ml、小于0.25μg/ml、小于0.2μg/ml、小于0.1μg/ml、小于0.05μg/ml、或小于0.001μg/ml的IC50中和新型冠状病毒(SARS-CoV-2)。
另一方面,本文提供一种抗原结合单元,其包含重链可变区(VH)和轻链可变区(VL),其中所述VH包含与选自SEQ ID NO:721-1080和3111-3145的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列,和/或其中所述VL包含与选自SEQ ID NO:1081-1440和3146-3180的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列。
在一些实施方案中,所述的抗原结合单元以小于100nM、小于50nM、小于20nM、小于15nM、小于10nM、小于5nM、小于4nM、小于3nM、小于2nM、小于1nM、小于0.5nM、小于0.1nM、小于0.05nM、或小于0.01nM的平衡解离常数(KD)结合新型冠状病毒(SARS-CoV-2)S蛋白的受体结合结构域(RBD)。
在一些实施方案中,所述的抗原结合单元以小于20μg/ml、小于10μg/ml、小于9μg/ml、小于8μg/ml、小于7μg/ml、小于6μg/ml、小于5μg/ml、小于4μg/ml、小于3μg/ml、小于2μg/ml、小于1μg/ml、小于0.5μg/ml、小于0.25μg/ml、小于0.2μg/ml、小于0.1μg/ml、小于0.05μg/ml、或小于0.001μg/ml的IC50中和新型冠状病毒(SARS-CoV-2)。
在一些实施方案中,所述抗原结合单元进一步包含重链恒定区(CH)。在一些实施方案中,所述抗原结合单元的所述CH包含SEQ ID NO:1457的序列或者与SEQ ID NO:1457相比包含一个或多个氨基酸添加、删除、或取代的序列。在一些实施方案中,所述抗原结合单元的所述CH包含选自SEQ ID NO:1457的序列。在一些实施方案中,所述抗原结合单元的所述CH包含与SEQ ID NO:1457相比包含10、9、8、7、6、5、4、3、2或1个氨基酸添加、删除、或取代的序列。在一些实施方案中,所述抗原结合单元的所述CH包含与选自SEQ ID NO:1457的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列。
在一些实施方案中,所述抗原结合单元进一步包含轻链恒定区(CL)。在一些实施方案中,所述抗原结合单元的所述CL包含SEQ ID NO:1458的序列或者与SEQ ID NO:1458相比包含一个或多个氨基酸添加、删除、或取代的序列。在一些实施方案中,所述抗原结合单元的所述CL包含选自SEQ ID NO:1458的序列。在一些实施方案中,所述抗原结合单元的所述CL包含与SEQ ID NO:1458相比包含10、9、8、7、6、5、4、3、2或1个氨基酸添加、删除、或取代的序列。在一些实施方案中,所述抗原结合单元的所述CL包含与选自SEQ ID NO:1458的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列。
在另一个方面,本文提供了分离的核酸分子,其编码如上文所定义的本文所述的抗原结合单元。
在另一个方面,本文提供了一种载体,其包含如上文所定义的分离的核酸分子。本文所述的载体可以是克隆载体,也可以是表达载体。在一些实施方案中,本文所述的载体是例如质粒、粘粒、或噬菌体等等。
在另一个方面,还提供了包含本文所述的分离的核酸分子或载体的宿主细胞。此类宿主细胞包括但不限于,原核细胞例如大肠杆菌细胞,以及真核细胞例如酵母细胞、昆虫细胞、植物细胞和动物细胞(如哺乳动物细胞,例如小鼠细胞、人细胞等)。本文所述的细胞还可以是细胞系,例如HEK293细胞。
在另一个方面,还提供了制备本文所述的抗原结合单元的方法,其包括,在合适的条件下培养本文所述的宿主细胞,和从细胞培养物中回收本文所述的抗原结合单元。
在另一个方面,本文提供了一种组合物,其包含如上文所描述的抗原结合单元、分离的核酸分子、载体或宿主细胞。
在另一个方面,本文提供了一种试剂盒,其包括本文所述的抗原结合单元。在一些实施方案中,本文所述的抗原结合单元还包括可检测的标记。在一些实施方案中,所述试剂盒还包括第二抗体,其特异性识别本文所述的抗原结合单元。优选地,所述第二抗体还包括可检测的标记。此类可检 测的标记是本领域技术人员熟知的,包括但不限于,放射性同位素,荧光物质,发光物质,有色物质和酶(例如辣根过氧化物酶)等。
在另一个方面,本文提供了检测新型冠状病毒或其S蛋白或S蛋白的RBD在样品中的存在或其水平的方法,其包括,使用本文所述的抗原结合单元。在一些实施方案中,本文所述的抗原结合单元还包括可检测的标记。在另一个优选的实施方案中,所述方法还包括,使用携带可检测的标记的第二抗体来检测本文所述的抗原结合单元。所述方法可以用于诊断目的(例如,所述样品是来自患者的样品),或者非诊断目的(例如,所述样品是细胞样品,而非来自患者的样品)。
在另一个方面,本文提供了诊断受试者是否感染了新型冠状病毒的方法,其包括:使用本文所述的抗原结合单元检测新型冠状病毒或其S蛋白或S蛋白的RBD在来自所述受试者的样品中的存在。在一些实施方案中,本文所述的抗原结合单元还包括可检测的标记。在另一个优选的实施方案中,所述方法还包括,使用携带可检测的标记的第二抗体来检测本文所述的抗原结合单元。
在另一个方面,提供了本文所述的抗原结合单元在制备试剂盒中的用途,所述试剂盒用于检测新型冠状病毒或其S蛋白或S蛋白的RBD在样品中的存在或其水平,或用于诊断受试者是否感染了新型冠状病毒。
在另一个方面,本文提供了一种药物组合物,其包含本文所述的抗原结合单元,以及药学上可接受的载体和/或赋形剂。
在另一个方面,本文提供了用于中和样品中新型冠状病毒的毒力的方法,其包括,将包含新型冠状病毒的样品与本文所述的抗原结合单元接触。此类方法可以用于治疗目的,或非治疗目的(例如所述样品是细胞样品,而不是患者或来自患者的样品)。
在另一个方面,提供了本文所述的抗原结合单元用于制备药物的用途,所述药物用于中和样品中新型冠状病毒的毒力。在另一个方面,本文提供了如上文所描述的抗原结合单元,其用于中和样品中新型冠状病毒的毒力。
在另一个方面,提供了本文所述的抗原结合单元在制备药物组合物中的用途,所述药物组合物用于预防或治疗受试者的新型冠状病毒感染或与新型冠状病毒感染相关的疾病(例如新型冠状病毒肺炎)。在另一个方面,本文提供了如上文所描述的抗原结合单元,其用于预防或治疗受试者的新型冠状病毒感染或与新型冠状病毒感染相关的疾病(例如新型冠状病毒肺炎)。
在另一个方面,本文提供了用于预防或治疗受试者的新型冠状病毒感染或新型冠状病毒感染相关的疾病(例如新型冠状病毒肺炎)的方法,其包括,给有此需要的受试者施用预防或治疗有效量的本文所述的抗原结合单元,或者本文所述的药物组合物。
在一些实施方案中,所述受试者是哺乳动物,例如人。
可通过任何适当的施用途径来将本文所述的抗原结合单元或者本文所述的药物组合物施用给受试者。此类施用途径包括但不限于,口服、口腔、舌下、局部、肠胃外、直肠、叶鞘内、或鼻腔途径。
本文所提供的药物和药物组合物可以单独使用或联合使用,也可以与其他药学活性剂(例如抗病毒药物,如法匹拉韦、瑞德西韦和干扰素等)联合使用。在一些实施方案中,所述药物组合物还含药学上可接受的载体和/或赋形剂。
在另一个方面,本文提供了缀合物,其其包含如上文所描述的抗原结合单元,其中所述抗原结合单元与化学功能部分缀合。在一些实施方案中,所述化学功能部分选自射性同位素、酶、荧光化合物、化学发光化合物、生物发光化合物底物辅因子和抑制剂。
图1A-1C示例性地显示了抗原结合单元ABU-174、ABU-175和ABU190的SDS-PAGE检测结果。
图2A-2E示例性地显示了使用SPR技术检测抗原结合单元ABU-174(A)、ABU-175(B)、ABU190(C)、ABU297(D)和ABU367(E)与S蛋白的亲和力的测定结果。
图3A-3C示例性地显示了抗原结合单元ABU-174(A)、ABU-175(B)、ABU190(C)对SARS-CoV-2假病毒的中和抑制活性的测定结果。
图4示例性地显示了ABU-175抗体对SARS-CoV-2真病毒的中和抑制活性的CPE测定结果。
图5示例性地显示了抗原结合单元ABU-174、ABU-175、和ABU190对SARS-CoV-2真病毒的中和抑制活性的PRNT测定结果。
图6所示为示例性的本文所述的提供抗原结合单元的方法示意图。
图7显示经抗原富集后的B细胞测序结果的总结。
图8显示来自同一位患者的富集程度最高的25个克隆型(A)以及该患者克隆型的Ig类别分布(B)。
图9显示为对第5批次中轻链重链相匹配的生产性B细胞基于基因表达所确定的细胞分型图。
图10显示为通过上述标准筛选的第5批次的B细胞的克隆型分析。
图11A显示分别通过如实施例1中所述的S蛋白富集和RBD富集后所产生的满足如上标准的抗体数量以及根据本文所述测定的与RBD的结合ELISA结果和Kd值以及中和假病毒的IC50值;图11B中显示不满足不包含IgG2、可变区突变率>2%或者包含记忆B细胞的标准的克隆型与RBD的结合ELISA结果和Kd值以及中和假病毒的IC50值。
图12显示为抗体m396 Fab与SARS-CoV-RBD复合物的晶体结构(PDB ID:2DD8)。
虽然本文已经示出并描述了本文所述的优选实施方案,但对于本领域技术人员显而易见的是,这样的实施方案只是通过示例的方式提供的。本领域技术人员在不脱离本文所述的情况下现将想到许多变化、改变和替代。应当理解,在实施本文所述的过程中可以采用本文所述的本文实施方案的各种替代方案。旨在用以下权利要求限定本文所述的范围,因此涵盖这些权利要求范围内的方法和结构及其等同物。
当提供数值范围时,应当理解,在此范围的上限与下限之间的每个中间值(精确到下限单位的十分之一,除非上下文另有明确规定)以及在所述范围内的其它任何所指出的或中间的值都包含在本发明内。这些较小范围的上限和下限可独立地包括在较小范围中,而且也包含在本发明内,除了所述范围内任何具体排除的限值。当所述范围包含一个或两个限值时,除去任一或两个包含在内的限值的范围也包含在本发明中。
如本文中所使用的,术语“多肽”、“肽”和“蛋白质”在本文中可互换使用,以指任何长度的氨基酸聚合物。聚合物可以是直链、环状或支链的,它可以包含修饰的氨基酸,并且可以被非氨基酸中断。该术语还包括已经被修饰的氨基酸聚合物,该修饰例如是通过硫酸化、糖基化、脂化、乙酰化、磷酸化、碘化、甲基化、氧化、蛋白水解处理、磷酸化、异戊烯化、外消旋化、硒化、转移RNA介导的氨基酸向蛋白质的添加(如精氨酸化)、遍在蛋白化,或其它任何操作,如与标记组分的缀合。如本文所用的,术语“氨基酸”是指天然和/或非天然或合成的氨基酸,包括甘氨酸和D或L光学异构体,以及氨基酸类似物和拟肽。由指定蛋白质“衍生”的多肽或氨基酸序列是指多肽的起源。优选地,多肽具有与序列中编码的多肽的氨基酸序列基本相同的氨基酸序列,或其部分,其中该部分由至少10-20个氨基酸或至少20-30氨基酸或至少30-50个氨基酸组成,或者其可用序列中编码的多肽免疫学地标识。该术语还包括从指定核酸序列表达的多肽。如本文中所使用的,术语“结构域”是指蛋白质的一部分,它在物理上或功能上与该蛋白质或肽的其它部分区分开。物理上定义的结构域包括极具疏水性或亲水性的氨基酸序列,如那些膜结合的或细胞质结合的序列。结构域还可以通过例如由基因复制引起的内部同源性来定义。功能上定义的结构域具有不同的生物学功能。例如,抗原结合域是指抗原结合单元或抗体中与抗原结合的部分。功能上定义的结构域不需要由连续的氨基酸序列编码,且功能上定义的结构域可以含有一个或多个物理上定义的结构域。
如本文中所使用的,术语“氨基酸”是指天然的和/或非天然的或合成的氨基酸,包括但不限于D或L旋光异构体,以及氨基酸类似物和拟肽。 标准的单字母或三字母代码用来指称氨基酸。在本文中,氨基酸通常用本领域公知的单字母和三字母缩写来表示。例如,丙氨酸可用A或Ala表示。
如本文中所使用的,术语“B淋巴细胞”和“B细胞”可互换使用,是机体内淋巴细胞的一种。与T细胞和自然杀伤细胞不同的是,B细胞在其细胞膜上表达B细胞受体(BCR),BCR允许B细胞与特定抗原结合,从而针对该抗原发起抗体反应。B细胞在自身免疫疾病的发病机理中起重要作用。B细胞在骨髓内成熟,随后离开骨髓并在其细胞表面上表达抗原结合抗体。当幼稚B细胞初次遭遇其膜结合抗体所特异针对的抗原时,该细胞开始快速分裂,其后代分化成记忆B细胞,并最终分化为称为“成浆细胞”的效应细胞。浆细胞能够大量生成分泌形式的抗体。分泌型抗体是体液免疫的主要效应分子。
如本文所使用的,术语“V(D)J重排”、“V(D)J重组”可互换使用,指T细胞和B细胞随机组装不同基因片段的过程,其目的在于生成独特的受体(称为抗原受体)。在B细胞生长过程中,发生特定的VDJ重组事件使得该细胞产生特定的B细胞受体,即BCR。VDJ重排促成了BCR抗原识别区或位点的多样性。
如本文中所使用的,术语“抗体”是指通常由两对多肽链(每对具有一条“轻”(L)链和一条“重”(H)链)组成的免疫球蛋白分子。抗体轻链可分类为κ和λ轻链。重链可分类为μ、δ、γ、α或ε,并且分别将抗体的同种型定义为IgM、IgD、IgG、IgA和IgE。在轻链和重链内,可变区和恒定区通过大约12或更多个氨基酸的“J”区连接,重链还包含大约3个或更多个氨基酸的“D”区。各重链由重链可变区(VH)和重链恒定区(CH)组成。重链恒定区由3个结构域(CH1、CH2和CH3)组成。各轻链由轻链可变区(VL)和轻链恒定区(CL)组成。轻链恒定区由一个结构域CL组成。抗体的恒定区可介导免疫球蛋白与宿主组织或因子,包括免疫系统的各种细胞(例如,效应细胞)和经典补体系统的第一组分(C1q)的结合。VH和VL区还可被细分为具有高变性的区域(称为互补决定区(CDR)),其间散布有较保守的称为构架区(FR)的区域。各VH和VL由按下列顺序:FR1、 CDR1、FR2、CDR2、FR3、CDR3、FR4从氨基末端至羧基末端排列的3个CDR和4个FR组成。各重链/轻链对的可变区(VH和VL)分别形成抗体结合部位。氨基酸至各区域或结构域的分配遵循Kabat Sequences of Proteins of Immunological Interest(National Institutes of Health,Bethesda,Md.(1987and 1991)),或Chothia&Lesk(1987)J.Mol.Biol.196:901-917;Chothia等人(1989)Nature 342:878-883,或IMGT(ImMunoGenTics)(Lefranc,M.-P.,The Immunologist,7,132-136(1999);Lefranc,M.-P.et al.,Dev.Comp.Immunol.,27,55-77(2003))的定义。除非另有指出,本申请中抗体的VH和VL中的CDR均基于IMGT编码系统的定义。在Kabat编号系统下,VH中的CDR氨基酸残基编号为31-35(CDR1),50-65(CDR2)和95-102(CDR3);VL中的CDR氨基酸残基编号为24-34(CDR1),50-56(CDR2)和89-97(CDR3)。在Chothia下,VH中的CDR氨基酸编号为26-32(CDR1),52-56(CDR2)和95-102(CDR3);VL中的氨基酸残基编号为24-34(CDR1),50-56(CDR2)和89-97(CDR3)。在IMGT编号系统下,VH中CDR的氨基酸残基编号大约26-33(CDR1),51-56(CDR2)和93-102(CDR3);并且VL中的CDR氨基酸残基编号大约为27-32(CDR1),50-51(CDR2)和89-97(CDR3)(如https://www.novoprolabs.com/tools/cdr所公开)。术语“抗体”不受任何特定的产生抗体的方法限制。例如,其包括,重组抗体、单克隆抗体和多克隆抗体。抗体可以是不同同种型的抗体,例如,IgG(例如,IgG1,IgG2,IgG3或IgG4亚型),IgA1,IgA2,IgD,IgE或IgM抗体。
如本文中所使用的,术语抗体的“抗原结合片段”是指包含全长抗体的片段的多肽,其保持特异性结合全长抗体所结合的相同抗原的能力,和/或与全长抗体竞争对抗原的特异性结合,其也被称为“抗原结合部分”。通常参见,Fundamental Immunology,Ch.7(Paul,W.,ed.,第2版,Raven Press,N.Y.(1989),其以其全文通过引用合并入本文,用于所有目的。可通过重组DNA技术或通过完整抗体的酶促或化学断裂产生抗体的抗原结合片段。在一些情况下,抗原结合片段包括Fab、Fab′、F(ab′)
2、Fd、Fv、dAb和互补决定区(CDR)片段、单链抗体(例如,scFv)、嵌合抗体、 双抗体(diabody)和这样的多肽,其包含足以赋予多肽特异性抗原结合能力的抗体的至少一部分。在一些情况下,抗体的抗原结合片段是单链抗体(例如,scFv),其中VL和VH结构域通过使其能够产生为单个多肽链的连接体配对形成单价分子(参见,例如,Bird等人,Science 242:423 426(1988)和Huston等人,Proc.Natl.Acad.Sci.USA 85:5879 5883(1988))。此类scFv分子可具有一般结构:NH2-VL-接头-VH-COOH或NH2-VH-接头-VL-COOH。合适的现有技术接头由重复的GGGGS氨基酸序列或其变体组成。例如,可使用具有氨基酸序列(GGGGS)
4的接头,但也可使用其变体(Holliger等人(1993),Proc.Natl.Acad.Sci.USA90:6444-6448)。可用于本文所述的其他接头由Alfthan等人(1995),Protein Eng.8:725-731,Choi等人(2001),Eur.J.Immunol.31:94-106,Hu等人(1996),Cancer Res.56:3055-3061,Kipriyanov等人(1999),J.Mol.Biol.293:41-56和Roovers等人(2001),Cancer Immunol.描述。
在一些情况下,抗体的抗原结合片段是双抗体,即,双价抗体,其中VH和VL结构域在单个多肽链上表达,但使用太短的连接体以致不允许在相同链的两个结构域之间配对,从而迫使结构域与另一条链的互补结构域配对并且产生两个抗原结合部位(参见,例如,Holliger P.等人,Proc.Natl.Acad.Sci.USA 90:6444 6448(1993),和Poljak R.J.等人,Structure 2:1121 1123(1994))。
可使用本领域技术人员已知的常规技术(例如,重组DNA技术或酶促或化学断裂法)可从给定的抗体(例如本文提供的抗体)获得抗体的抗原结合片段(例如,上述抗体片段),并且以与用于完整抗体的方式相同的方式就特异性筛选抗体的抗原结合片段。
在本文中,除非上下文明确指出,否则当提及术语“抗体”时,其不仅包括完整抗体,而且包括抗体的抗原结合片段。
在本文中,除非上下文明确指出,术语“抗原结合单元”包括上述定义的抗体及其抗原结合片段。
如本文中所使用的,术语“单克隆抗体”是指,来自一群高度同源的抗体分子中的一个抗体或抗体的一个片段,也即,除可能自发出现的自然 突变外,一群完全相同的抗体分子。单抗对抗原上的单一表位具有高特异性。多克隆抗体是相对于单克隆抗体而言的,其通常包含至少2种或更多种的不同抗体,这些不同的抗体通常识别抗原上的不同表位。单克隆抗体通常可采用Kohler等首次报道的杂交瘤技术获得(Nature,256:495,1975),但也可采用重组DNA技术获得(如参见Journal of virological methods,2009,158(1-2):171-179)。
如本文中所使用的,“中和抗体”是指,能清除或显著降低目标病毒的毒力(例如,感染细胞的能力)的抗体或抗体片段。
如本文中所使用的,在多肽的情况下,“序列”是多肽中的氨基酸在从氨基末端到羧基末端方向上的顺序,其中该序列中彼此相邻的残基在该多肽的一级结构中是连续的。序列也可以是已知在一个或两个方向上包含额外残基的多肽的一部分的线性序列。
如本文中所使用的,“同一性”、“同源性”或“序列同一性”是指在两个或更多个多核苷酸序列之间或在两个或更多个多肽序列之间的序列相似性或可互换性。当使用诸如Emboss Needle或BestFit等程序确定两个不同氨基酸序列之间的序列同一性、相似性或同源性时,可以使用默认设置,或者可以选择适当的打分矩阵,例如blosum45或blosum80,来优化同一性、相似性或同源性得分。优选地,同源的多核苷酸是那些在如本文所定义的严格条件下杂交并且与这些序列相比具有至少70%、优选至少80%、更优选至少90%、更优选95%、更优选97%、更优选98%并且甚至更优选99%的序列同一性的多核苷酸。当对可比长度的序列进行最佳比对时,同源的多肽优选具有至少80%,或至少90%,或至少95%,或至少97%,或至少98%的序列同一性,或具有至少99%的序列同一性。
就本文所确定的抗原结合单元而言,“序列同一性百分比(%)”被定义为在比对序列并在必要情况下引入缺口以获得最大序列同一性百分比后,并且不把任何保守置换视为序列同一性的一部分,查询序列中与第二、参考多肽序列或其部分的氨基酸残基相同的氨基酸残基的百分比。可以以本领域技术内的各种方式,例如使用可公开获得的计算机软件,如BLAST、BLAST-2、ALIGN、NEEDLE或Megalign(DNASTAR)软件, 来实现旨在确定氨基酸序列同一性百分比的比对。本领域技术人员可以确定用于测量比对的合适的参数,包括在所比较的序列的全长上获得最大比对所需的任何算法。同一性百分比可以在整个定义的多肽序列的长度上进行测量,或者可以在较短的长度上,例如,在从较大的、定义的多肽序列取得的片段的长度上进行测量,该片段例如是至少5、至少10、至少15、至少20、至少50、至少100或至少200个连续残基的片段。这些长度只是示例性的,并且应该理解,由本文的表格、附图或序列表中所示的序列支持的任何片段长度可以用来描述在其上可以测量同一性百分比的长度。
本文所述的抗原结合单元可具有相对于参考序列的一个或多个修饰。所述修饰可以是缺失、插入或添加,或氨基酸残基的取代或置换。“缺失”是指由于缺少一个或多个氨基酸残基而导致的氨基酸序列变化。“插入”或“添加”是指导致与参考序列相比添加一个或多个氨基酸残基的氨基酸序列变化。“取代”或“置换”是指一个或多个氨基酸被不同的氨基酸所取代。在本文中,可以通过将抗原结合单元与参考序列进行比较来确定抗原结合单元相对于参考序列的突变。用于比较的序列的最佳比对可以根据本领域的任何已知方法进行。
如本文中所使用的,术语“抗原”是指被抗原结合单元识别并特异性结合的物质。抗原可以包括肽、蛋白质、糖蛋白、多糖和脂质;其部分,及其组合。非限制性的示例性抗原包括来自冠状病毒如SARS-CoV-2的蛋白,以及它们的其它同源物。
如本文中所使用的,术语“分离的”是指与细胞的和其它方面的成分分离的,其中在自然界中,多核苷酸、肽、多肽、蛋白质、抗体或其片段在正常情况下与之相关联。本领域技术人员知晓,非天然存在的多核苷酸、肽、多肽、蛋白质、抗体或其片段不需要“分离”来与其天然存在的对应物区分开来。另外,“浓缩的”、“分离的”或“稀释的”多核苷酸、肽、多肽、蛋白质、抗体或其片段与其天然存在的对应物是可区分的,因为每单位体积的分子浓度或数目大于(“浓缩的”)或小于从其天然存在的对应物(“分 离的”)。富集可基于绝对量来测量,例如每单位体积的溶液的重量,或者其可相对于来源混合物中存在的第二、可能干扰性的物质来测量。
术语“多核苷酸”、“核酸”、“核苷酸”和“寡核苷酸”可互换使用。它们是指任何长度的核苷酸(无论是脱氧核糖核苷酸还是核糖核苷酸)或其类似物的聚合形式。多核苷酸可具有任何三维结构,并且可以执行任何已知或未知的功能。以下是多核苷酸的非限制性实例:基因或基因片段的编码区或非编码区、从连锁分析确定的基因座、外显子、内含子、信使RNA(mRNA)、转移RNA、核糖体RNA、核酶、cDNA、重组多核苷酸、支链多核苷酸、质粒、载体、任意序列的分离的DNA、任意序列的分离的RNA、核酸探针、引物、寡核苷酸或合成的DNA。多核苷酸可以包含修饰的核苷酸,如甲基化核苷酸和核苷酸类似物。如果存在的话,对核苷酸结构的修饰可以在聚合物装配之前或之后赋予。核苷酸的序列可以被非核苷酸组分中断。多核苷酸可以在聚合后进一步修饰,例如通过与标记组分缀合。
当应用于多核苷酸时,“重组的”意味着该多核苷酸是克隆、限制酶切消化和/或连接步骤以及产生与自然界中发现的多核苷酸不同的构建体的其它程序的各种组合的产物。
术语“基因”或“基因片段”在本文中可互换使用。它们是指含有至少一个开放阅读框的多核苷酸,该开放阅读框能够在转录和翻译后编码特定蛋白质。基因或基因片段可以是基因组的、cDNA或合成的,只要该多核苷酸含有至少一个开放阅读框,该开放阅读框可以覆盖整个编码区或其区段。
术语“可操作地连接”或“有效连接”是指并置,其中这样描述的组件所处的关系允许它们以其预期方式发挥作用。例如,如果启动子序列促进编码序列的转录,则该启动子序列与该编码序列可操作地连接。
如本文所用的,“表达”是指多核苷酸被转录为mRNA的过程,和/或转录的mRNA(也称为“转录物”)随后被翻译成肽、多肽或蛋白质的过程。转录物和被编码的多肽统称为基因产物。如果多核苷酸衍生自基因组DNA,则表达可以包括真核细胞中mRNA的剪接。
如本文中所使用的,术语“载体(vector)”是指,可将多聚核苷酸插入其中的一种核酸运载工具。当载体能使插入的多核苷酸编码的蛋白获得表达时,载体称为表达载体。载体可以通过转化,转导或者转染导入宿主细胞,使其携带的遗传物质元件在宿主细胞中获得表达。载体是本领域技术人员公知的,包括但不限于:质粒;噬菌粒;人工染色体,例如酵母人工染色体(YAC)、细菌人工染色体(BAC)或P1来源的人工染色体(PAC);噬菌体如λ噬菌体或M13噬菌体及动物病毒等。可用作载体的动物病毒包括但不限于,逆转录酶病毒(包括慢病毒)、腺病毒、腺相关病毒、疱疹病毒(如单纯疱疹病毒)、痘病毒、杆状病毒、乳头瘤病毒、乳头多瘤空泡病毒(如SV40)。一种载体可以含有多种控制表达的元件,包括但不限于,启动子序列、转录起始序列、增强子序列、选择元件及报告基因。另外,载体还可含有复制起始位点。
如本文中所使用的,术语“宿主细胞”是指,可用于导入载体的细胞,其包括但不限于,如大肠杆菌或枯草芽孢杆菌等的原核细胞,如酵母细胞或曲霉菌等的真菌细胞,如S2果蝇细胞或Sf9等的昆虫细胞,或者如纤维原细胞,CHO细胞,COS细胞,NSO细胞,HeLa细胞,BHK细胞,HEK293细胞或人细胞等的动物细胞。
如本文中所使用的,术语“生物样品”包括多种从生物体获得的样品类型,并且可以在诊断或监测试验中使用。该术语包括血液和生物起源的其它液体样品,固体组织样品,如活检标本或组织培养物,或由其衍生的细胞及其后代。该术语包括在获得后已经以任何方式进行处理的样品,例如通过用试剂处理、溶解或针对某些组分进行富集。该术语包括临床样品,并且还包括在细胞培养物、细胞上清液、细胞裂解物、血清、血浆、生物流体和组织样品中的细胞。
如本文中所使用的,术语“接受者”、“个体”、“受试者”、“宿主”和“患者”在本文中可互换使用,并且是指希望对其进行诊断、处理或治疗的任何哺乳动物受试者,特别是人类。
如本文中所使用的,术语“治疗”、“处理”等在本文中用来泛指获得所需的药理学和/或生理学效果。该效果就完全或部分防止疾病或其症状而 言可以是预防性的,和/或就部分或完全稳定或治愈疾病和/或归因于该疾病的不良反应而言可以是治疗性的。如本文所用的“治疗”涵盖在哺乳动物中对疾病的任何治疗,该哺乳动物例如是小鼠、大鼠、兔、猪、灵长类动物,包括人类和其它猿类,特别是人,并且该术语包括:(a)防止疾病或症状在可能易患该疾病或症状但尚未发生诊断的受试者中发生;(b)抑制疾病症状;(C)阻止疾病的发展;(d)缓解疾病症状;(e)引起疾病或症状消退;或其任意组合。如本文中使用的,术语“特异性结合”是指,两分子间的非随机的结合反应,如抗体和其所针对的抗原之间的反应。在某些实施方式中,特异性结合某抗原的抗体(或对某抗原具有特异性的抗体)是指,抗体以小于大约10
-5M,例如小于大约10
-6M、10
-7M、10
-8M、10
-9M或10
-10M或更小的亲和力(KD)结合该抗原。
如本文中所使用的,术语“KD”是指特定抗体-抗原相互作用的解离平衡常数,其用于描述抗体与抗原之间的结合亲和力。在本文中,KD被定义为两个动力学速率常数Ka/Kd的比率,其中“Ka”指抗体与抗原结合的速率常数,“Kd”指抗体从抗体/抗原复合物中解离的速率常数。平衡解离常数KD越小,抗体-抗原结合越紧密,抗体与抗原之间的亲和力越高。通常,抗体以小于大约10
-5M的解离平衡常数(KD)结合抗原。两分子间的特异性结合性质可使用本领域公知的方法进行测定,例如使用表面等离子体共振术(SPR)在BIACORE仪中测定。
如本文中所使用的,术语“中和活性”是指抗体或抗体片段具有与病毒上的抗原蛋白相结合,从而阻止病毒感染细胞和/或病毒子代的成熟和/或病毒子代的释放的功能活性,具有中和活性的抗体或抗体片段可以阻止病毒的扩增,从而抑制或消除病毒的感染。在一些实施方案中,所述中和活性通过抗体或抗体片段对病毒抑制的IC
50表示。“半数最大抑制浓度”(IC
50)是药物如抗体在抑制生物或生化功能等方面(如病毒效力)的量度。在本文中的IC
50根据抗原结合片段对病毒(例如假病毒或真病毒)感染细胞的中和抑制率,并利用Reed-Muench法计算。本文提供一种抗原结合单元,其能够特异性识别和靶向新型冠状病毒的S蛋白,特别是S蛋白的受体结合结构域(RBD),并且显示出了高效的中和病毒的能力。 因此,本文所述的抗原结合单元特别适合用于诊断、预防和治疗新型冠状病毒感染或与新型冠状病毒感染相关的疾病(例如新型冠状病毒肺炎)。
如本文中使用的,术语“抗原”指包含针对其产生免疫应答的表位的物质。在一些实施方案中,抗原是蛋白或肽,其能够在体内诱导对该抗原为特异性的免疫反应。在一些实施方案中,抗原可以是来自于微生物如病毒的抗原,如来自于病毒的蛋白或其片段。
如本文中使用的,术语“表位”指在分子(如抗原)中的抗原决定簇,即,是指免疫系统识别(例如由B细胞受体BCR识别)的分子的一部分或片段。在一些实施方案中,蛋白质(例如病毒抗原)的表位包含所述蛋白质的连续或不连续部分,且优选长度为5至100,优选5至50,更优选8至30,最优选10至25个氨基酸,例如,所述表位的长度可优选为9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、或25个氨基酸。
如本文中所使用的,术语“克隆型”指编码免疫受体或其一部分的淋巴细胞的重组核酸。在一些实施方案中,“克隆型”是T细胞或B细胞来源的重组核酸,其编码T细胞受体(TCR)或B细胞受体(BCR)或其一部分。在一些实施方案中,克隆型可以编码以下中的全部或部分:IgH的VDJ重排、IgH的DJ重排、IgK的VJ重排、IgL的VJ重排、TCRβ的VDJ重排、TCRβ的DJ重排、TCRα的VJ重排、TCRγ的VJ重排、TCRδ的VDJ重排、TCRδ的VD重排、κ缺失元件(KDE)重排等。在一些实施方案中,克隆型具有足够长的序列以代表或反映它们所来源的免疫分子的多样性。因此,在一些实施方案中,克隆型的长度在25至400个核苷酸的范围。在一些实施方案中,克隆型的长度在25至200个核苷酸的范围。
抗原结合单元的制备
一方面,本文提供一种提供针对预先确定的抗原的抗原结合单元的方法,包括(a)获得来自个体的血液样品,其中所述个体在第一时间经确认携带所述抗原,并在所述第一时间之后的第二时间经确认不携带所 述抗原或者所携带的所述抗原的量减少;(b)富集所述血液样品中的B细胞;(c)对包含多个所述个体的富集的B细胞的样品进行单细胞转录组的VDJ测序,以提供抗原结合单元的克隆型信息;以及(d)基于所述克隆型信息确认所述针对所述抗原的抗原结合单元。
在一些实施方案中,所述抗原源自病原体。所述病原体包括但不限于过敏原、病毒、细菌、真菌、寄生虫和其它感染性物质和病原体。在一些实施方案中,所述个体可以是经诊断已感染病毒的个体。在一些实施方案中,所述病毒包括但不限于如腺病毒、单纯疱疹I型、单纯疱疹2型、水痘-带状疱疹病毒、爱泼斯坦-巴尔病毒(EBV)、人类巨细胞病毒、人疱疹病毒8型、人乳头瘤病毒、BK病毒、JC病毒、天花病毒、乙肝病毒、人博卡病毒、细小病毒B19、人星状病毒、诺瓦克病毒(Norwalk virus)、柯萨奇病毒、甲型肝炎病毒、脊髓灰质炎病毒、鼻病毒、严重急性呼吸综合征病毒、丙型肝炎病毒、黄热病病毒、登革热病毒、西尼罗河病毒、风疹病毒、戊型肝炎病毒、人类免疫缺陷病毒(HIV)、流感病毒、埃博拉病毒、麻疹病毒、腮腺炎病毒、副流感病毒、呼吸道合胞病毒、尼帕病毒、狂犬病毒、丁型肝炎病毒、轮状病毒、环状病毒和冠状病毒。在一些实施方案中,所述病毒为冠状病毒。在一些实施方案中,所述冠状病毒包括SARS-CoV和SARS-CoV-2。
在一些实施方案中,所述抗原为病毒抗原。在一些实施方案中,所述抗原为SARS-COV-2抗原。在一些实施方案中,所述抗原为SARS-COV-2抗原的S蛋白。在一些实施方案中,所述抗原为新型冠状病毒(SARS-CoV-2)S蛋白的受体结合结构域(RBD)。
在一些实施方案中,所述个体可以是感染了包含所述抗原的病原体的个体。在一些实施方案中,所述个体可以是感染了包含所述抗原的病原体但未表现出临床症状的个体。在一些实施方案中,所述个体可以是感染了包含所述抗原的病原体且已表现出临床症状的个体。在一些实施方案中,所述个体是感染了包含所述抗原的病原体且处于潜伏期的个体。在一些实施方案中,所述个体是感染了包含所述抗原的病原体且处于传染期的个体。在一些实施方案中,所述个体是感染了包含所述抗原的病原体且 处于恢复期的个体。在一些实施方案中,所述个体是感染了包含所述抗原的病原体且已痊愈的个体。
在一些实施方案中,所述个体在第一时间经确认携带所述抗原。在一些实施方案中,所述第一时间可以是所述个体感染了包含所述抗原的病原体但未表现出临床症状的时间段。在一些实施方案中,所述第一时间可以是所述个体感染了包含所述抗原的病原体且已表现出临床症状的时间段。在一些实施方案中,所述第一时间可以是所述个体感染了包含所述抗原的病原体且处于潜伏期的时间段。在一些实施方案中,所述第一时间可以是所述个体感染了包含所述抗原的病原体且处于传染期的时间段。在一些实施方案中,所述第一时间可以是所述个体感染了包含所述抗原的病原体且处于恢复期的时间段。
在一些实施方案中,所述个体在所述第一时间之后的第二时间经确认不携带所述抗原或者所携带的所述抗原的量减少。在一些实施方案中,所述第二时间可以是所述个体感染了包含所述抗原的病原体但未表现出临床症状的时间段。在一些实施方案中,所述第二时间可以是所述个体感染了包含所述抗原的病原体且已表现出临床症状的时间段。在一些实施方案中,所述第二时间可以是所述个体感染了包含所述抗原的病原体且处于潜伏期的时间段。在一些实施方案中,所述第二时间可以是所述个体感染了包含所述抗原的病原体且处于传染期的时间段。在一些实施方案中,所述第二时间可以是所述个体感染了包含所述抗原的病原体且处于恢复期的时间段。在一些实施方案中,所述第二时间可以是所述个体感染了包含所述抗原的病原体且已痊愈的时间段。
在一些实施方案中,所述第二时间是在所述第一时间之后大约12小时、1天、2天、3天、4天、5天、6天、7天、8天、9天、10天、11天、12天、13天、14天、15天、20天、25天、30天、1个月、2个月、3个月、4个月、5个月、6个月或1年。
在一些实施方案中,所述所述个体在第二时间经确认不携带所述抗原。在一些实施方案中,所述病原体为病毒,所述所述个体在第二时间经确认不携带所述病毒的抗原。在一些实施方案中,所述个体在第二时间经 确认携带的所述抗原的量减少。在一些实施方案中,所述病原体为病毒,所述个体在第二时间经确认携带的所述病毒抗原的量变少。在一些实施方案中,所述个体在第二时间经确认携带的所述病毒的载量减少。在一些实施方案中,所述抗原为SARS-CoV-2,所述所述个体在第二时间经确认携带的SARS-CoV-2的载量减少。在一些实施方案中,所述所述所述个体在第二时间经确认携带的SARS-CoV-2的载量减少至少10%、至少20%、至少30%、至少40%、至少50%、至少60%、至少70%、至少80%、至少90%或100%。
在一些实施方案中,所述个体在所述第一时间之后的多个不同的第二时间经确认不携带所述抗原或者所携带的所述抗原的量减少。在一些实施方案中,所述所述个体在多个不同的第二时间经确认不携带所述抗原。在一些实施方案中,所述病原体为病毒,所述所述个体在多个不同的第二时间经确认不携带所述病毒的抗原。在一些实施方案中,所述个体在多个不同的第二时间经确认携带的所述抗原的量减少。在一些实施方案中,所述个体在多个不同的第二时间经确认所携带的所述抗原的量逐渐减少。在一些实施方案中,所述病原体为病毒,所述个体在多个不同的第二时间经确认携带的所述病毒抗原的量变少。在一些实施方案中,所述病原体为病毒,所述个体在多个不同的第二时间经确认携带的所述病毒抗原的量逐渐减少。在一些实施方案中,所述个体在多个不同的第二时间经确认携带的所述病毒的载量减少。在一些实施方案中,所述个体在多个不同的第二时间经确认携带的所述病毒的载量逐渐减少。在一些实施方案中,所述抗原为SARS-CoV-2,所述所述个体在多个不同的第二时间经确认携带的SARS-CoV-2的载量减少。在一些实施方案中,所述抗原为SARS-CoV-2,所述所述个体在多个不同的第二时间经确认携带的SARS-CoV-2的载量逐渐减少。在一些实施方案中,所述所述所述个体在多个不同的第二时间经确认携带的SARS-CoV-2的载量减少至少10%、至少20%、至少30%、至少40%、至少50%、至少60%、至少70%、至少80%、至少90%或100%。在一些实施方案中,所述所述所述个体在多个不同的第二时间经确认携带的SARS-CoV-2的载量逐渐减少至少10%、至少20%、 至少30%、至少40%、至少50%、至少60%、至少70%、至少80%、至少90%或100%。
在一些实施方案中,所述多个第二时间间隔大约12小时、1天、2天、3天、4天、5天、6天、7天、8天、9天、10天、11天、12天、13天、14天、15天、20天、25天、30天、1个月、2个月、3个月、4个月、5个月、6个月或1年。
所述抗原的存在或存在的量可通过任何本领域已知的方法测定。在一些实施方案中,所述抗原的存在或存在的量可通过核酸扩增反应测定。核酸扩增反应的实例包括但不限于逆转录PCR(RT-PCR)、聚合酶链反应(PCR)、PCR的变型(例如,实时PCR、等位基因特异性PCR、装配PCR、非对称PCR、数字PCR、乳液PCR、拨出PCR(dial-out PCR)、解旋酶依赖的PCR、巢式PCR、热启动PCR、反向PCR、甲基化特异性PCR、微引物PCR(miniprimer PCR)、多重PCR、巢式PCR、重叠-延伸PCR、热非对称交错PCR(thermal asymmetric interlaced PCR)、递降PCR)以及连接酶链反应(LCR)。在一些实施方案中,所述抗原的存在或存在的量通过检测所述抗原的DNA确定。在一些实施方案中,所述抗原的存在或存在的量通过检测所述抗原的RNA确定。在对RNA进行检测的情况下,可通过RNA的逆转录来获得DNA并且可利用随后的DNA扩增来测定扩增的DNA产物。在一些实施方案中,所述抗原为病毒,所述病毒与的存在或存在的量通过检测所述病毒的DNA或RNA确定。在一些实施方案中,所述病毒的存在或存在的量通过检测从所述个体获得的样品中的病毒的DNA或RNA确定。所述样品可以是来自所述个体任何解剖学位置获得的细胞、皮肤、组织和/或组织液。在一些实施方案中,所述样品可以是源自所述个体的血液、体腔液、痰、脓、粪便、乳汁、血清、唾液、尿液、胃液和消化液、泪液、眼部液体、汗液、粘液、腺体分泌物、脊髓液、毛发、指甲、皮肤细胞、血浆、鼻拭子、咽拭子、鼻咽洗液和/或其他排泄物或身体组织。
在一些实施方案中,所述方法中的步骤(b)包括从分选的外周血单核细胞(PBMC)富集B细胞。在一些实施方案中,所述方法中的步骤(b) 进一步包括富集所述血液样品中的记忆B细胞。在一些实施方案中,所述记忆B细胞通过CD27抗体富集。在一些实施方案中,所述记忆B细胞通过携带CD27抗体的基底、携带CD27抗体的微粒、携带CD27抗体的磁珠和/或携带CD27抗体的柱富集。
在一些实施方案中,所述方法进一步包括在步骤(c)之前通过选自以下的一个或多个步骤以排除所富集的B细胞的一部分:选择CD27+B细胞;排除幼稚B细胞;排除耗尽的B细胞;排除非B细胞;以及选择其中能够结合所述抗原的细胞。在一些实施方案中,所述个体血液样品中的B细胞通过CD27抗体排除所富集的B细胞的一部分。在一些实施方案中,所述B细胞通过携带CD27抗体的基底、携带CD27抗体的微粒、携带CD27抗体的磁珠和/或携带CD27抗体的柱排除所富集的B细胞的一部分。在一些实施方案中,所述个体血液样品中的B细胞通过排除幼稚B细胞以排除所富集的B细胞的一部分。在一些实施方案中,所述个体血液样品中的B细胞通过排除耗尽的B细胞以排除所富集的B细胞的一部分。在一些实施方案中,所述个体血液样品中的B细胞通过排除非B细胞以排除所富集的B细胞的一部分。
在一些实施方案中,首先分选外周血单核细胞(PBMC)并富集B细胞,再通过CD27抗体以排除所富集的B细胞的一部分。在一些实施方案中,首先分选外周血单核细胞(PBMC)并富集B细胞,再排除幼稚B细胞以排除所富集的B细胞的一部分。在一些实施方案中,首先分选外周血单核细胞(PBMC)并富集B细胞,再排除耗尽的B细胞以排除所富集的B细胞的一部分。在一些实施方案中,首先分选外周血单核细胞(PBMC)并富集B细胞,再排除非B细胞以排除所富集的B细胞的一部分。在一些实施方案中,首先分选外周血单核细胞(PBMC)并并富集B细胞,随后通过CD27抗体,再通过排除排除幼稚B细胞、排除耗尽的B细胞和/或排除非B细胞以排除所富集的B细胞一部分。
在一些实施方案中,排除的B细胞一部分为所富集的B细胞的至少10%。在一些实施方案中,排除的B细胞一部分为所富集的B细胞的至少20%。在一些实施方案中,排除的B细胞一部分为所富集的B细胞的 至少30%。在一些实施方案中,排除的B细胞一部分为所富集的B细胞的至少40%。在一些实施方案中,排除的B细胞一部分为所富集的B细胞的至少50%。在一些实施方案中,排除的B细胞一部分为所富集的B细胞的至少60%。在一些实施方案中,排除的B细胞一部分为所富集的B细胞的至少70%。在一些实施方案中,排除的B细胞一部分为所富集的B细胞的至少80%。在一些实施方案中,排除的B细胞一部分为所富集的B细胞的至少90%。在一些实施方案中,排除的B细胞一部分为所富集的B细胞的至少95%。在一些实施方案中,排除的B细胞一部分为所富集的B细胞的至少96%。在一些实施方案中,排除的B细胞一部分为所富集的B细胞的至少97%。在一些实施方案中,排除的B细胞一部分为所富集的B细胞的至少98%。在一些实施方案中,排除的B细胞一部分为所富集的B细胞的至少99%。
在一些实施方案中,所述方法还包括在步骤(c)之后进行以下步骤中的一个、两个、三个、四个、五个或更多个以排除抗原结合单元克隆型的一部分:选择富集频率高于1的克隆型;选择或排除来自于表达IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和/或IgG4的B细胞的克隆型;通过细胞分型排除非B细胞克隆型;通过细胞分型排除幼稚B细胞克隆型;通过细胞分型排除未经转换的B细胞;通过细胞分型排除耗尽的B细胞克隆型;通过细胞分型排除单核细胞;通过细胞分型排除树突状细胞;通过细胞分型排除T细胞;通过细胞分型排除自然杀伤细胞;以及排除可变区突变率小于1%、1.5%或2%的克隆型。在一些实施方案中,所述方法还包括在步骤(c)之后选择富集频率高于1的克隆型以排除抗原结合单元克隆型的一部分。在一些实施方案中,所述方法还包括在步骤(c)之后选择或排除来自于表达IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和/或IgG4的B细胞的克隆型以排除抗原结合单元克隆型的一部分。在一些实施方案中,所述方法还包括在步骤(c)之后选择来自于表达IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和/或IgG4的B细胞的克隆型以排除抗原结合单元克隆型的一部分。在一些实施方案中,所述方法还包括在步骤(c)之后排除来自于表达IgA1、IgA2、IgD、IgM、IgG1、IgG2、 IgG3和/或IgG4的B细胞的克隆型以排除抗原结合单元克隆型的一部分。在一些实施方案中,所述方法还包括在步骤(c)之后通过细胞分型排除非B细胞克隆型以排除抗原结合单元克隆型的一部分。在一些实施方案中,所述方法还包括在步骤(c)之后通过细胞分型排除幼稚B细胞克隆型以排除抗原结合单元克隆型的一部分。在一些实施方案中,所述方法还包括在步骤(c)之后通过细胞分型排除未经转换的B细胞以排除抗原结合单元克隆型的一部分。在一些实施方案中,所述方法还包括在步骤(c)之后通过细胞分型排除耗尽的B细胞克隆型以排除抗原结合单元克隆型的一部分。在一些实施方案中,所述方法还包括在步骤(c)之后通过细胞分型排除单核细胞以排除抗原结合单元克隆型的一部分。在一些实施方案中,所述方法还包括在步骤(c)之后通过细胞分型排除树突状细胞以排除抗原结合单元克隆型的一部分。在一些实施方案中,所述方法还包括在步骤(c)之后通过细胞分型排除T细胞以排除抗原结合单元克隆型的一部分。在一些实施方案中,所述方法还包括在步骤(c)之后通过细胞分型排除自然杀伤细胞以排除抗原结合单元克隆型的一部分。在一些实施方案中,所述方法还包括在步骤(c)之后排除可变区突变率小于1%、1.5%或2%的克隆型以排除抗原结合单元克隆型的一部分。
在一些实施方案中,可以选择或者排除来自于表达IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和/或IgG4的B细胞的克隆型。在一些实施方案中,所述方法包括选择来自IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和IgG4中的一种的B细胞的克隆型。在一些实施方案中,所述方法包括选择来自IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和IgG4中的两种的B细胞的克隆型。在一些实施方案中,所述方法包括选择来自IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和IgG4中的三种的B细胞的克隆型。在一些实施方案中,所述方法包括选择来自IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和IgG4中的四种的B细胞的克隆型。在一些实施方案中,所述方法包括选择来自IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和IgG4中的五种的B细胞的克隆型。在一些实施方案中,所述方法包括选择来自IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和IgG4中的六种 的B细胞的克隆型。在一些实施方案中,所述方法包括选择来自IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和IgG4中的七种的B细胞的克隆型。在一些实施方案中,所述方法包括排除来自IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和IgG4中的一种的B细胞的克隆型。在一些实施方案中,所述方法包括排除来自IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和IgG4中的两种的B细胞的克隆型。在一些实施方案中,所述方法包括排除来自IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和IgG4中的三种的B细胞的克隆型。在一些实施方案中,所述方法包括排除来自IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和IgG4中的四种的B细胞的克隆型。在一些实施方案中,所述方法包括排除来自IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和IgG4中的五种的B细胞的克隆型。在一些实施方案中,所述方法包括排除来自IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和IgG4中的六种的B细胞的克隆型。在一些实施方案中,所述方法包括排除来自IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和IgG4中的七种的B细胞的克隆型。
在一些实施方案中,所排除的单元克隆型为全部单元克隆型的至少10%、20%、30%、40%、50%、60%、70%、80%、90%、95%、96%、97%、98%、99%。在一些实施方案中,所排除的单元克隆型为全部单元克隆型的至少50%、60%、70%、80%、90%、95%、96%、97%、98%、99%。
在一些实施方案中,所述方法还包括在步骤(c)之后进行以下步骤中的一个、两个、三个、四个、五个或更多个的选择,从而使得所选择的克隆型的一部分在步骤(d)中被确认为所述抗原结合单元:选择富集频率高于1的克隆型;选择或排除来自于表达IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和/或IgG4的B细胞的克隆型;通过细胞分型排除非B细胞克隆型;通过细胞分型排除幼稚B细胞克隆型;通过细胞分型排除耗尽的B细胞克隆型;通过细胞分型排除单核细胞;通过细胞分型排除树突状细胞;通过细胞分型排除T细胞;通过细胞分型排除自然杀伤细胞;以及排除可变区突变率小于1%、1.5%或2%的克隆型。在一些实施方案中,所述方法还包括在步骤(c)之后进行选择富集频率高于1的克隆型, 从而使得所选择的克隆型的一部分在步骤(d)中被确认为所述抗原结合单元。在一些实施方案中,所述方法还包括在步骤(c)之后进行选择或排除来自于表达IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和/或IgG4的B细胞的克隆型,从而使得所选择的克隆型的一部分在步骤(d)中被确认为所述抗原结合单元。在一些实施方案中,所述方法还包括在步骤(c)之后进行通过细胞分型排除非B细胞克隆型,从而使得所选择的克隆型的一部分在步骤(d)中被确认为所述抗原结合单元。在一些实施方案中,所述方法还包括在步骤(c)之后进行通过细胞分型排除幼稚B细胞克隆型,从而使得所选择的克隆型的一部分在步骤(d)中被确认为所述抗原结合单元。在一些实施方案中,所述方法还包括在步骤(c)之后进行通过细胞分型排除耗尽的B细胞克隆型,从而使得所选择的克隆型的一部分在步骤(d)中被确认为所述抗原结合单元。在一些实施方案中,所述方法还包括在步骤(c)之后进行通过细胞分型排除单核细胞,从而使得所选择的克隆型的一部分在步骤(d)中被确认为所述抗原结合单元。在一些实施方案中,所述方法还包括在步骤(c)之后进行通过细胞分型排除树突状细胞,从而使得所选择的克隆型的一部分在步骤(d)中被确认为所述抗原结合单元。在一些实施方案中,所述方法还包括在步骤(c)之后进行通过细胞分型排除T细胞,从而使得所选择的克隆型的一部分在步骤(d)中被确认为所述抗原结合单元。在一些实施方案中,所述方法还包括在步骤(c)之后进行通过细胞分型排除自然杀伤细胞,从而使得所选择的克隆型的一部分在步骤(d)中被确认为所述抗原结合单元。在一些实施方案中,所述方法还包括在步骤(c)之后进行排除可变区突变率小于1%、1.5%或2%的克隆型,从而使得所选择的克隆型的一部分在步骤(d)中被确认为所述抗原结合单元。
在一些方案中,在步骤(d)中被确认为所述抗原结合单元的所选择的克隆型的一部分为全部克隆型的至少10%、20%、30%、40%、50%、60%、70%、80%、90%、95%、96%、97%、98%、99%。在一些实施方案中,在步骤(d)中被确认为所述抗原结合单元的所选择的克隆型的一 部分为全部克隆型的至少50%、60%、70%、80%、90%、95%、96%、97%、98%、99%。
在一些实施方案中,所述方法还包括根据所获得的序列信息进行轻重链匹配。在一些实施方案中,所述轻重链匹配通过计算机算法实施。在一些实施方案中,所述方法还包括根据所获得的序列信息进行谱系分析。在一些实施方案中,所述谱系分析通过计算机算法实施。在一些实施方案中,所述方法还包括将所述克隆型信息与一个或多个参比序列进行对比。在一些实施方案中,所述方法还包括可视化细胞簇。在一些实施方案中,所述可视化细胞簇通过计算机算法实施。在一些实施方案中,所述方法包括对重叠群进行组装、注释和克隆型分析。在一些实施方案中,通过计算机算法实施对重叠群的组装、注释和克隆型分析。在一些实施方案中,所述方法包括对轻链和重链的CDR区域的结构进行注释。在一些实施方案中,所述对轻链和重链的CDR区域的结构进行注释通过计算机算法实施。在一些实施方案中,所述方法包括对CDR3结构进行预测。在一些实施方案中,所述对CDR3结构的预测通过计算机算法实施。在一些实施方案中,所述方法包括包括映射V(D)J序列读取。在一些实施方案中,所述V(D)J序列读取的映射通过计算机算法实施。在一些实施方案中,所述方法包括通过下式计算高频突变率:
其中缺口为在插入或删除区域的碱基对数量。在一些实施方案中,所述方法包括将预测的CDR3H结构与参比序列的CDR3H结构进行对比。在一些实施方案中,所述对比通过计算机算法实施。
可用于本文所述的方法的算法或者计算机软件包括但不限于以下各种:
在一些实施方案中,所述参比序列为特异性结合所述抗原的抗体或其片段。在一些实施方案中,所述参比序列特异性结合SARS-CoV的抗原。在一些实施方案中,所述参比序列特异性结合SARS-CoV-2的抗原。在一些实施方案中,所述参比序列特异性结合SARS-CoV-2的S蛋白。在一些实施方案中,所述参比序列特异性结合SARS-CoV-2 S蛋白的受体结合结构域(RBD)。任何本领域已知的抗体或其片段可作为本申请中的参比序列。在一些实施方案中,所述参比序列为本领域已知的针对SARS-CoV的抗体或其片段。在一些实施方案中,所述参比序列为本领域已知的针对SARS-CoV-2的抗体或其片段。在一些实施方案中,所述参比序列为本领域已知的针对SARS-CoV-2的S蛋白的抗体或其片段。在一些实施方案中,所述参比序列为本领域已知的针对SARS-CoV-2的S蛋白结合结构域(RBD)的抗体或其片段。在一些实施方案中,所述参比序列来自PDB(Protein Data Bank)数据库。
在一些实施方案中,所述参比序列为抗体或其片段,并且所述对比包括根据所述转录组序列信息预测克隆型的CDR3H结构,并将所述克隆型的预测的CDR3H结构与所述抗体或其片段的CDR3H结构进行对比。在一些实施方案中,所述参比序列为抗体或其片段,并且所述对比包括根据所述转录组序列信息预测克隆型的CDR1H结构,并将所述克隆型的预测的CDR3H结构与所述抗体或其片段的CDR1H结构进行对比。在一些实施方案中,所述参比序列为抗体或其片段,并且所述对比包括根据所述转录组序列信息预测克隆型的CDR2H结构,并将所述克隆型的预测的CDR3H结构与所述抗体或其片段的CDR2H结构进行对比。
在一些实施方案中,所述参比序列为已知的针对SARS-CoV-2的S蛋白的抗体或其片段,并且所述对比包括根据所述转录组序列信息预测克隆型的CDR3H结构,并将所述克隆型的预测的CDR3H结构与所述抗体或其片段的CDR3H结构进行对比。在一些实施方案中,所述参比序列为已知的针对SARS-CoV-2的S蛋白结合结构域(RBD)的抗体或其片段,并且所述对比包括根据所述转录组序列信息预测克隆型的CDR3H结构,并将所述克隆型的预测的CDR3H结构与所述抗体或其片段的CDR3H结构进行对比。
在一些实施方案中,所述方法还包括在宿主细胞中表达所述抗原结合单元。任何本领域已知的宿主细胞均可用于表达本申请中的抗原结合单元。在一些实施方案中,所述宿主细胞包括真核细胞和原核细胞。在一些实施方案中,所述宿主细胞包括但不限于细菌细胞、真菌细胞、动物细胞、昆虫细胞、植物细胞等。
可用于本申请的细菌宿主细胞的实例包括属于埃希氏菌属(Escherichia)、沙雷氏菌属(Serratia)、杆菌属(Bacillus)、短杆菌属(Brevibacterium)、棒杆菌属(Corynebacterium)、微杆菌属(Microbacterium)、假单胞菌属(Pseudomonas)等的微生物。例如,细菌宿主细胞可以包括但不限于大肠杆菌(Escherichia coli)XL1-Blue、XL2-Blue、DH1、MC1000、KY3276、W1485、JM109、HB101、No.49、iW3110、NY49、G1698、BL21或TB1。其它细菌宿主细胞可以包括但不限于无花果沙雷氏菌(Serratia ficaria)、居泉沙雷氏菌(Serratia fonticola)、液化沙雷氏菌(Serratia liquefaciens)、粘质沙雷氏菌(Serratia marcescens)、枯草芽孢杆菌(Bacillus subtilis)、解淀粉芽孢杆菌(Bacillusamyloliquefaciens)、产氨短杆菌(Brevibacteriumammoniagenes)、Brevibacteriumimmariophilum ATCC 14068、解糖短杆菌(Brevibacterium saccharolyticum)ATCC14066、黄色短杆菌(Brevibacterium flavum)ATCC 14067、乳糖发酵短杆菌(Brevibacterium lactofermentum)ATCC 13869、谷氨酸棒杆菌(Corynebacteriumglutamicum)ATCC 13032、谷氨酸棒杆菌(Corynebacterium glutamicum)ATCC 13869、嗜乙酰乙酸棒杆菌(Corynebacterium acetoacidophilum)ATCC 13870、嗜氨微杆菌(Microbacterium ammoniaphilum)ATCC15354;恶臭假单胞菌(Pseudomonas putida)、假单胞菌(Pseudomonas sp.)D-0110等。
可用于本申请的酵母宿主细胞可以包括属于克鲁维酵母属(Kluyveromyces)、丝孢酵母属(Trichosporon)、酵母属(Saccharomyces)、裂殖酵母属(Schizosaccharomyces)、许旺酵母属(Schwanniomyces)、毕赤酵母属(Pichia)、假丝酵母属(Candida)等的微生物,例如酿酒酵母(Saccharomyces cerevisiae)、粟酒裂殖酵母(Schizosaccharomyces pombe)、乳酸克鲁维酵母(Kluyveromyces lactis)、茁芽丝孢酵母(Trichosporon pullulans)、河岸许旺酵母属(Schwanniomyces alluvius)、产朊假丝酵母(Candida utilis)等的微生物。
可用于本申请的真核细胞的实例包括动物细胞,如哺乳动物细胞。例如,宿主细胞包括但不限于中国仓鼠卵巢细胞(CHO)或猴细胞,例如COS细胞、HepG2细胞、A549细胞,和可通过ATCC或其它保藏机构获得的任何细胞。
在一些实施方案中,所述方法还包括纯化所述抗原结合单元。任何本领域已知的纯化方式均可用于纯化本申请中所述的抗原结合单元。在一些实施方案中,所述纯化包括但不限于离子交换层析、疏水层析和亲和层析。
在一些实施方案中,还包括评价所述抗原结合单元结合所述抗原的能力。在一些实施方案中,所述抗原结合单元结合所述抗原的能力通过KD平衡解离常数(KD)评价。
在一些实施方案中,至少大约10%、20%、30%、40%、50%、60%、70%、80%或90%的所述抗原结合单元的结合所述抗原的速率高于与所述抗原解离的速率。
在一些实施方案中,至少大约10%、20%、30%、40%、50%、60%、70%、80%或90%的所述抗原结合单元以小于100nM、小于50nM、小于20nM、小于15nM、小于10nM、小于5nM、小于4nM、小于3nM、小于2nM、小于1nM、小于0.5nM、小于0.1nM、小于0.05nM、或小于0.01nM的平衡解离常数(KD)结合所述抗原。
在一些实施方案中,至少大约10%、20%、30%、40%、50%、60%、70%、80%或90%的所述抗原结合单元通过ELISA验证具有结合所述抗原的能力。在一些实施方案中,至少大约10%、20%、30%、40%、50%、60%、70%、80%或90%的所述抗原结合单元能够中和所述抗原。在一些实施方案中,至少大约10%的所述抗原结合单元以小于20μg/ml、小于10μg/ml、小于9μg/ml、小于8μg/ml、小于7μg/ml、小于6μg/ml、小于5μg/ml、小于4μg/ml、小于3μg/ml、小于2μg/ml、小于1μg/ml、小于0.5μg/ml、小于0.25μg/ml、小于0.2μg/ml、小于0.1μg/ml、小于0.05μg/ml、或小于0.001μg/ml的IC
50中和所述抗原。在一些实施方案中,至少大约20%的所述抗原结合单元以小于20μg/ml、小于10μg/ml、小于9μg/ml、小于8μg/ml、小于7μg/ml、小于6μg/ml、小于5μg/ml、小于4μg/ml、小于3μg/ml、小于2μg/ml、小于1μg/ml、小于0.5μg/ml、小于0.25μg/ml、小于0.2μg/ml、小于0.1μg/ml、小于0.05μg/ml、或小于0.001μg/ml的IC
50中和所述抗原。在一些实施方案中,至少大约30%的所述抗原结合单元以小于20μg/ml、小于10μg/ml、小于9μg/ml、小于8μg/ml、小于7μg/ml、小于6μg/ml、小于5μg/ml、小于4μg/ml、小于3μg/ml、小于2μg/ml、小于1μg/ml、小于0.5μg/ml、小于0.25μg/ml、小于0.2μg/ml、小于0.1μg/ml、小于0.05μg/ml、或小于0.001μg/ml的 IC
50中和所述抗原。在一些实施方案中,至少大约40%的所述抗原结合单元以小于20μg/ml、小于10μg/ml、小于9μg/ml、小于8μg/ml、小于7μg/ml、小于6μg/ml、小于5μg/ml、小于4μg/ml、小于3μg/ml、小于2μg/ml、小于1μg/ml、小于0.5μg/ml、小于0.25μg/ml、小于0.2μg/ml、小于0.1μg/ml、小于0.05μg/ml、或小于0.001μg/ml的IC
50中和所述抗原。在一些实施方案中,至少大约50%的所述抗原结合单元以小于20μg/ml、小于10μg/ml、小于9μg/ml、小于8μg/ml、小于7μg/ml、小于6μg/ml、小于5μg/ml、小于4μg/ml、小于3μg/ml、小于2μg/ml、小于1μg/ml、小于0.5μg/ml、小于0.25μg/ml、小于0.2μg/ml、小于0.1μg/ml、小于0.05μg/ml、或小于0.001μg/ml的IC
50中和所述抗原。在一些实施方案中,至少大约60%的所述抗原结合单元以小于20μg/ml、小于10μg/ml、小于9μg/ml、小于8μg/ml、小于7μg/ml、小于6μg/ml、小于5μg/ml、小于4μg/ml、小于3μg/ml、小于2μg/ml、小于1μg/ml、小于0.5μg/ml、小于0.25μg/ml、小于0.2μg/ml、小于0.1μg/ml、小于0.05μg/ml、或小于0.001μg/ml的IC
50中和所述抗原。在一些实施方案中,至少大约70%的所述抗原结合单元以小于20μg/ml、小于10μg/ml、小于9μg/ml、小于8μg/ml、小于7μg/ml、小于6μg/ml、小于5μg/ml、小于4μg/ml、小于3μg/ml、小于2μg/ml、小于1μg/ml、小于0.5μg/ml、小于0.25μg/ml、小于0.2μg/ml、小于0.1μg/ml、小于0.05μg/ml、或小于0.001μg/ml的IC
50中和所述抗原。在一些实施方案中,至少大约80%的所述抗原结合单元以小于20μg/ml、小于10μg/ml、小于9μg/ml、小于8μg/ml、小于7μg/ml、小于6μg/ml、小于5μg/ml、小于4μg/ml、小于3μg/ml、小于2μg/ml、小于1μg/ml、小于0.5μg/ml、小于0.25μg/ml、小于0.2μg/ml、小于0.1μg/ml、小于0.05μg/ml、或小于0.001μg/ml的IC
50中和所述抗原。在一些实施方案中,至少大约90%的所述抗原结合单元以小于20μg/ml、小于10μg/ml、小于9μg/ml、小于8μg/ml、小于7μg/ml、小于6μg/ml、小于5μg/ml、小于4μg/ml、小于3μg/ml、小于2μg/ml、小于1μg/ml、小于0.5μg/ml、小于0.25μg/ml、小于0.2μg/ml、小于0.1μg/ml、小于0.05μg/ml、或小于0.001μg/ml的IC
50中和所述抗原。
在一些实施方案中,可在若干天内通过本文所述的方法获得所述抗原结合单元。在一些实施方案中,可在1天、2天、3天、4天、5天、6天、7天、8天、9天、10天、两周、三周、四周内通过本文所述的方法获得所述抗原结合单元。
在另一个方面,本文提供一种制备针对预先确定的抗原的抗原结合单元的方法,包括根据任一前述权利要求所述的方法鉴定针对所述抗原的抗原结合单元,在宿主细胞中表达所述抗原结合单元,以及收获并纯化所述抗原结合单元。
抗原结合单元
一方面,本文所述的抗原结合单元包含重链可变区(VH)和轻链可变区(VL),所述重链可变区包含VH CDR1、VH CDR2和VH CDR3,且所述轻链可变区包含VL CDR1、VL CDR2和VL CDR3。
本文所述的抗原结合单元的VH可包含选自SEQ ID NO.:721-1080和3111-3145的序列,与选自SEQ ID NO:721-1080和3111-3145的序列相比包含一个或多个氨基酸添加、删除、或取代的序列,或者与选自SEQ ID NO:721-1080和3111-3145的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列。当本文所述的抗原结合单元的VH与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VH与参考多肽相比可存在1个、2个、3个、4个、5个、6个、7个、8个、9个、10个、11个、12个、13个、14个、15个、16个、17个、18个、19个或20个添加、删除或取代。当本文所述的抗原结合单元的VH与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VH与参考多肽相比可存在多于1个、2个、3个、4个、5个、6个、7个、8个、9个、10个、11个、12个、13个、14个、15个、16个、17个、18个、19个或20个添加、删除或取代。当本文所述的抗原结合单元的VH与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VH与参考多肽相比可存在少于2个、3个、4个、5个、6个、7个、8 个、9个、10个、11个、12个、13个、14个、15个、16个、17个、18个、19个或20个添加、删除或取代。
本文所述的抗原结合单元的VH CDR1可包含选自SEQ ID NO.:1461-1820和2901-2935的序列,与选自SEQ ID NO:1461-1820和2901-2935的序列相比包含一个或多个氨基酸添加、删除、或取代的序列,或者与选自SEQ ID NO:1461-1820和2901-2935的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列。当本文所述的抗原结合单元的VH CDR1与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VH CDR1与参考多肽相比可存在1个、2个、3个、4个、或5个添加、删除或取代。当本文所述的抗原结合单元的VH CDR1与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VH CDR1与参考多肽相比可存在多于1个、2个、3个、4个、或5个添加、删除或取代。当本文所述的抗原结合单元的VH CDR1与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VH CDR1与参考多肽相比可存在少于2个、3个、4个、或5个添加、删除或取代。
本文所述的抗原结合单元的VH CDR2可包含选自SEQ ID NO.:1821-2180和2936-2970的序列,与选自SEQ ID NO:1821-2180和2936-2970的序列相比包含一个或多个氨基酸添加、删除、或取代的序列,或者与选自SEQ ID NO:1821-2180和2936-2970的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列。当本文所述的抗原结合单元的VH CDR2与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VH CDR2与参考多肽相比可存在1个、2个、3个、4个、或5个添加、删除或取代。当本文所述的抗原结合单元的VH CDR2与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VH CDR2与参考多肽相比可存在多于1个、2个、3个、4个、或5个添加、删除或取代。当本文所述的抗原结合单元的VH CDR2与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VH CDR2与参考多 肽相比可存在少于2个、3个、4个、或5个添加、删除或取代。
本文所述的抗原结合单元的VH CDR3可包含选自SEQ ID NO.:1-360和2971-3005的序列,与选自SEQ ID NO:1-360和2971-3005的序列相比包含一个或多个氨基酸添加、删除、或取代的序列,或者与选自SEQ ID NO:1-360和2971-3005的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列。当本文所述的抗原结合单元的VH CDR3与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VH CDR3与参考多肽相比可存在1个、2个、3个、4个、或5个添加、删除或取代。当本文所述的抗原结合单元的VH CDR3与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VH CDR3与参考多肽相比可存在多于1个、2个、3个、4个、或5个添加、删除或取代。当本文所述的抗原结合单元的VH CDR2与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VH CDR3与参考多肽相比可存在少于2个、3个、4个、或5个添加、删除或取代。
本文所述的抗原结合单元的VL可包含选自SEQ ID NO.:1081-1440和3146-3180的序列,与选自SEQ ID NO:1081-1440和3146-3180的序列相比包含一个或多个氨基酸添加、删除、或取代的序列,或者与选自SEQ ID NO:1081-1440和3146-3180的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列。当本文所述的抗原结合单元的VL与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VL与参考多肽相比可存在1个、2个、3个、4个、5个、6个、7个、8个、9个、10个、11个、12个、13个、14个、15个、16个、17个、18个、19个或20个添加、删除或取代。当本文所述的抗原结合单元的VL与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VL与参考多肽相比可存在多于1个、2个、3个、4个、5个、6个、7个、8个、9个、10个、11个、12个、13个、14个、15个、16个、17个、18个、19个或20个添加、删除或取代。当本文所述的抗原结合单元的VL与参 考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VL与参考多肽相比可存在少于2个、3个、4个、5个、6个、7个、8个、9个、10个、11个、12个、13个、14个、15个、16个、17个、18个、19个或20个添加、删除或取代。
本文所述的抗原结合单元的VL CDR1可包含选自选自SEQ ID NO.:2181-2540和3006-3040的序列,与选自SEQ ID NO:2181-2540和3006-3040的序列相比包含一个或多个氨基酸添加、删除、或取代的序列,或者与选自SEQ ID NO:2181-2540和3006-3040的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列。当本文所述的抗原结合单元的VL CDR1与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VL CDR1与参考多肽相比可存在1个、2个、3个、4个、或5个添加、删除或取代。当本文所述的抗原结合单元的VL CDR1与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VL CDR1与参考多肽相比可存在多于1个、2个、3个、4个、或5个添加、删除或取代。当本文所述的抗原结合单元的VL CDR1与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VL CDR1与参考多肽相比可存在少于2个、3个、4个、或5个添加、删除或取代。
本文所述的抗原结合单元的VL CDR2可包含选自SEQ ID NO.:2541-2900和3041-3075的序列,与选自SEQ ID NO:2541-2900和3041-3075的序列相比包含一个或多个氨基酸添加、删除、或取代的序列,或者与选自SEQ ID NO:2541-2900和3041-3075的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列。当本文所述的抗原结合单元的VL CDR2与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VL CDR2与参考多肽相比可存在1个、2个、3个、4个、或5个添加、删除或取代。当本文所述的抗原结合单元的VLCDR2与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VL CDR2与参考多肽相比可存在多于1个、2个、3个、4个、或5个添加、删除或取代。当 本文所述的抗原结合单元的VL CDR2与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VL CDR2与参考多肽相比可存在少于2个、3个、4个、或5个添加、删除或取代。
本文所述的抗原结合单元的VL CDR3可包含选自SEQ ID NO.:361-720和3076-3110的序列,与选自SEQ ID NO:361-720和3076-3110的序列相比包含一个或多个氨基酸添加、删除、或取代的序列,或者与选自SEQ ID NO:361-720和3076-3110的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列。当本文所述的抗原结合单元的VL CDR3与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VL CDR3与参考多肽相比可存在1个、2个、3个、4个、或5个添加、删除或取代。当本文所述的抗原结合单元的VLCDR3与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VL CDR3与参考多肽相比可存在多于1个、2个、3个、4个、或5个添加、删除或取代。当本文所述的抗原结合单元的VL CDR3与参考多肽序列相比存在氨基酸添加、删除或取代时,本文所述的抗原结合单元的VL CDR3与参考多肽相比可存在少于2个、3个、4个、或5个添加、删除或取代。
本文所述的抗原结合单元的VH CDR1可包含选自SEQ ID NO.:1461-1820和2901-2935的序列,与选自SEQ ID NO:1461-1820和2901-2935的序列相比包含一个或多个氨基酸添加、删除、或取代的序列,或者与选自SEQ ID NO:1461-1820和2901-2935的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列;并且本文所述的抗原结合单元的VL CDR1可包含选自SEQ ID NO.:2181-2540和3006-3040的序列,与选自SEQ ID NO:2181-2540和3006-3040的序列相比包含一个或多个氨基酸添加、删除、或取代的序列,或者与选自SEQ ID NO:2181-2540和3006-3040的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列。
本文所述的抗原结合单元的VH CDR2可包含选自SEQ ID NO.:1821- 2180和2936-2970的序列,与选自SEQ ID NO:1821-2180和2936-2970的序列相比包含一个或多个氨基酸添加、删除、或取代的序列,或者与选自SEQ ID NO:1821-2180和2936-2970的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列;并且本文所述的抗原结合单元的VL CDR2可包含选自SEQ ID NO.:2541-2900和3041-3075的序列,与选自SEQ ID NO:2541-2900和3041-3075的序列相比包含一个或多个氨基酸添加、删除、或取代的序列,或者与选自SEQ ID NO:2541-2900和3041-3075的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列。
本文所述的抗原结合单元的VH CDR3可包含选自SEQ ID NO.:1-360和2971-3005的序列,与选自SEQ ID NO:1-360和2971-3005的序列相比包含一个或多个氨基酸添加、删除、或取代的序列,或者与选自SEQ ID NO:1-360和2971-3005的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列;并且本文所述的抗原结合单元的VL CDR3可包含选自SEQ ID NO.:361-720和3076-3110的序列,与选自SEQ ID NO:361-720和3076-3110的序列相比包含一个或多个氨基酸添加、删除、或取代的序列,或者与选自SEQ ID NO:361-720和3076-3110的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列。
本文所述的抗原结合单元的VH可包含VH CDR1、VH CDR2和VH CDR3,其中所述VH CDR1选自SEQ ID NO.:1461-1820和2901-2935的序列,与选自SEQ ID NO:1461-1820和2901-2935的序列相比包含一个或多个氨基酸添加、删除、或取代的序列,或者与选自SEQ ID NO:1461-1820和2901-2935的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列;其中所述VH CDR2选自SEQ ID NO.:1821-2180和2936-2970的序列,与选自SEQ ID NO:1821-2180和2936-2970的序列相比包含一个或多个氨基酸添加、删除、或取代的序列,或者与选自SEQ ID NO:1821-2180和2936-2970的 序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列;且其中所述VH CDR3选自SEQ ID NO.:1-360和2971-3005的序列,与选自SEQ ID NO:1-360和2971-3005的序列相比包含一个或多个氨基酸添加、删除、或取代的序列,或者与选自SEQ ID NO:1-360和2971-3005的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列。
本文所述的抗原结合单元的VL可包含VL CDR1、VL CDR2和VL CDR3,其中所述VL CDR1选自SEQ ID NO.:2181-2540和3006-3040的序列,与选自SEQ ID NO:2181-2540和3006-3040的序列相比包含一个或多个氨基酸添加、删除、或取代的序列,或者与选自SEQ ID NO:2181-2540和3006-3040的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列;其中所述VL CDR2选自SEQ ID NO.:2541-2900和3041-3075的序列,与选自SEQ ID NO:2541-2900和3041-3075的序列相比包含一个或多个氨基酸添加、删除、或取代的序列,或者与选自SEQ ID NO:2541-2900和3041-3075的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列;且其中所述VL CDR3选自SEQ ID NO.:361-720和3076-3110的序列,与选自SEQ ID NO:361-720和3076-3110的序列相比包含一个或多个氨基酸添加、删除、或取代的序列,或者与选自SEQ ID NO:361-720和3076-3110的序列具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或99%的同一性的序列。
本文所述的抗原结合单元的VH可包含选自以下CDR1、CDR2、和CDR3的组合的序列:
在本文所述的抗原结合单元中,所述VH可包含选自以下CDR1、CDR2、和CDR3的组合的序列:
本文所述的抗原结合单元的所述的VH CDR1可包含与SEQ ID NO:721-1080和3111-3145中所包含的CDR1相同的序列;本文所述的抗原结合单元的所述的VH CDR2可包含与SEQ ID NO:721-1080和3111-3145中所包含的CDR2相同的序列;本文所述的抗原结合单元的所述的VH CDR3可包含与SEQ ID NO:721-1080和3111-3145中所包含的CDR3相同的序列;所述抗原结合单元的所述VL CDR1可包含与SEQ ID NO:1081-1440和3146-3180中所包含的CDR1相同的序列;所述抗原结合单元的所述VLCDR2可包含与SEQ ID NO:1081-1440和3146-3180中所包含的CDR2相同的序列;和/或所述抗原结合单元的所述VL CDR3可包含与SEQ ID NO:1081-1440和3146-3180中所包含的CDR3相同的序列。
在一个实施方式中,本文提供的抗体包含一个、两个、三个、四个、五个、或六个氨基酸序列,其中每个氨基酸序列独立地选自于以下所列氨基酸序列:
a.轻链可变区CDR1氨基酸序列:SEQ ID NO:2354、SEQ ID NO:2355、SEQ ID NO:2370、SEQ ID NO:2477、及SEQ ID NO:3012;
b.轻链可变区CDR2氨基酸序列:SEQ ID NO:2714、SEQ ID NO:2715、SEQ ID NO:2730、SEQ ID NO:2837、及SEQ ID NO:3047;
c.轻链可变区CDR3氨基酸序列:SEQ ID NO:534、SEQ ID NO:535、SEQ ID NO:550、SEQ ID NO:657、及SEQ ID NO:3082;
d.重链可变区CDR1氨基酸序列:SEQ ID NO:1634、SEQ ID NO:1635、SEQ ID NO:1650、SEQ ID NO:1757、及SEQ ID NO:2907;
e.重链可变区CDR2氨基酸序列:SEQ ID NO:1994、SEQ ID NO:1995、SEQ ID NO:2010、SEQ ID NO:2117、及SEQ ID NO:2942;及
f.重链可变区CDR3氨基酸序列:SEQ ID NO:174、SEQ ID NO:175、SEQ ID NO:190、SEQ ID NO:297、及SEQ ID NO:2977。
在一个实施方式中,本文提供的抗体包含一个、两个、三个、四个、五个、或六个氨基酸序列,其中每个氨基酸序列独立地选自于以下所列氨基酸序列:
a.轻链可变区CDR1氨基酸序列:SEQ ID NO:2354;
b.轻链可变区CDR2氨基酸序列:SEQ ID NO:2714;
c.轻链可变区CDR3氨基酸序列:SEQ ID NO:534;
d.重链可变区CDR1氨基酸序列:SEQ ID NO:1634;
e.重链可变区CDR2氨基酸序列:SEQ ID NO:1994;及
f.重链可变区CDR3氨基酸序列:SEQ ID NO:174。
在一个实施方式中,本文提供的抗体包含一个、两个、三个、四个、五个、或六个氨基酸序列,其中每个氨基酸序列独立地选自于以下所列氨基酸序列:
a.轻链可变区CDR1氨基酸序列:SEQ ID NO:2355;
b.轻链可变区CDR2氨基酸序列:SEQ ID NO:2715;
c.轻链可变区CDR3氨基酸序列:SEQ ID NO:535;
d.重链可变区CDR1氨基酸序列:SEQ ID NO:1635;
e.重链可变区CDR2氨基酸序列:SEQ ID NO:1995;及
f.重链可变区CDR3氨基酸序列:SEQ ID NO:175。
在一个实施方式中,本文提供的抗体包含一个、两个、三个、四个、五个、或六个氨基酸序列,其中每个氨基酸序列独立地选自于以下所列氨基酸序列:
a.轻链可变区CDR1氨基酸序列:SEQ ID NO:2370;
b.轻链可变区CDR2氨基酸序列:SEQ ID NO:2730;
c.轻链可变区CDR3氨基酸序列:SEQ ID NO:550;
d.重链可变区CDR1氨基酸序列:SEQ ID NO:1650;
e.重链可变区CDR2氨基酸序列:SEQ ID NO:2010;及
f.重链可变区CDR3氨基酸序列:SEQ ID NO:190。
在一个实施方式中,本文提供的抗体包含一个、两个、三个、四个、五个、或六个氨基酸序列,其中每个氨基酸序列独立地选自于以下所列氨基酸序列:
a.轻链可变区CDR1氨基酸序列:SEQ ID NO:2477;
b.轻链可变区CDR2氨基酸序列:SEQ ID NO:2837;
c.轻链可变区CDR3氨基酸序列:SEQ ID NO:657;
d.重链可变区CDR1氨基酸序列:SEQ ID NO:1757;
e.重链可变区CDR2氨基酸序列:SEQ ID NO:2117;及
f.重链可变区CDR3氨基酸序列:SEQ ID NO:297。
在一个实施方式中,本文提供的抗体包含一个、两个、三个、四个、五个、或六个氨基酸序列,其中每个氨基酸序列独立地选自于以下所列氨基酸序列:
a.轻链可变区CDR1氨基酸序列:SEQ ID NO:3012;
b.轻链可变区CDR2氨基酸序列:SEQ ID NO:3047;
c.轻链可变区CDR3氨基酸序列:SEQ ID NO:3082;
d.重链可变区CDR1氨基酸序列:SEQ ID NO:2907;
e.重链可变区CDR2氨基酸序列:SEQ ID NO:2942;及
f.重链可变区CDR3氨基酸序列:SEQ ID NO:2977。
在一个实施方式中,本文提供的抗体包含一个、或两个氨基酸序列,其中每个氨基酸序列独立地选自于以下所列氨基酸序列:
a.轻链可变区氨基酸序列:SEQ ID NO:1377、及SEQ ID NO:3152;及
b.重链可变区氨基酸序列:SEQ ID NO:1017、及SEQ ID NO:3117。
在一个实施方式中,本文提供的抗体包含一个、或两个氨基酸序列,其中每个氨基酸序列独立地选自于以下所列氨基酸序列:
a.轻链可变区氨基酸序列:SEQ ID NO:1254;及
b.重链可变区氨基酸序列:SEQ ID NO:894。
在一个实施方式中,本文提供的抗体包含一个、或两个氨基酸序列,其中每个氨基酸序列独立地选自于以下所列氨基酸序列:
a.轻链可变区氨基酸序列:SEQ ID NO:1255;及
b.重链可变区氨基酸序列:SEQ ID NO:895。
在一个实施方式中,本文提供的抗体包含一个、或两个氨基酸序列,其中每个氨基酸序列独立地选自于以下所列氨基酸序列:
a.轻链可变区氨基酸序列:SEQ ID NO:1270;及
b.重链可变区氨基酸序列:SEQ ID NO:910。
在一个实施方式中,本文提供的抗体包含一个、或两个氨基酸序列,其中每个氨基酸序列独立地选自于以下所列氨基酸序列:
a.轻链可变区氨基酸序列:SEQ ID NO:1377;及
b.重链可变区氨基酸序列:SEQ ID NO:1017。
在一个实施方式中,本文提供的抗体包含一个、或两个氨基酸序列,其中每个氨基酸序列独立地选自于以下所列氨基酸序列:
a.轻链可变区氨基酸序列:SEQ ID NO:3152;及
b.重链可变区氨基酸序列:SEQ ID NO:3117。
本文所述的抗原结合单元可与新型冠状病毒(SARS-CoV-2)S蛋白结合。本文所述的抗原结合单元可与新型冠状病毒(SARS-CoV-2)S蛋白的受体结合结构域(RBD)。抗原结合单元与RBD的结合可的结合可通过本领域已知的任何方法来表征或表示。例如,结合可以用结合亲和力来表征,结合亲和力可以是抗原结合单元与抗原之间的相互作用的强度。结合亲和力可通过本领域中已知的任何方法,如体外结合试验来确定。本文抗原结合单元的结合亲和力可按照KD来表示,KD被定义为两个动力学速率常数Ka/Kd的比率,其中“Ka”指抗体与抗原结合的速率常数,“Kd”指抗体从抗体/抗原复合物中解离的速率常数。如本文公开的抗原结合单元以约10μM至约1fM范围内的KD特异性结合新型冠状病毒(SARS-CoV-2)S蛋白的受体结合结构域(RBD)。例如,抗原结合单元可以以小于约10μM、1μM、0.1μM、50nM、20nM、15nM、10nM、5nM、4nM、3nM、2nM、1nM、0.5nM、0.1nM、50pM、10pM、1pM、0.1pM、10fM、1fM、0.1fM或小于0.1fM的KD特异性结合新型冠状病毒(SARS-CoV-2)S蛋白的受体结合结构域(RBD)。本文公开的抗原结合单元可以以小于100nM、小于50nM、小于20nM、小于15nM、小于10nM、小于5nM、小于4nM、小于3nM、小于2nM、小于1nM、小于0.5nM、小于0.1nM、小于0.05nM、或小于0.01nM的平衡解离常数(KD)结合新型冠状病毒(SARS-CoV-2)S蛋白的受体结合结构域(RBD)。
本文所述的抗原结合单元对新型冠状病毒(SARS-CoV-2)具有中和活性。本文所述的抗原结合单元对新型冠状病毒(SARS-CoV-2)的中和活性可通过假病毒进行分析。假病毒具有与疹病毒相似的细胞感染特点,能够模拟真病毒感染细胞的早期过程,并且可以安全、快速地进行检测分析。本文所述的抗原结合单元对新型冠状病毒(SARS-CoV-2)的中和活性可通过本领域已知的方法检测,如采用微孔细胞中和试验,参照Temperton N J等人,Emerg Infect Dis,2005,11(3),411-416的描述进行。
本文所述的抗原结合单元对新型冠状病毒(SARS-CoV-2)的中和活性可采用实验细胞如Huh-7细胞以及假病毒SARS-CoV-2病毒检测。本文所述的抗原结合单元可以以例如小于100μg/ml、小于50μg/ml、小于20μg/ml、小于10μg/ml、小于9μg/ml、小于8μg/ml、小于7μg/ml、小于6μg/ml、小于5μg/ml、小于4μg/ml、小于3μg/ml、小于2μg/ml、小于1μg/ml、小于0.5μg/ml、小于0.25μg/ml、小于0.2μg/ml、小于0.1μg/ml、小于0.05μg/ml、小于1ng/ml、小于0.5ng/ml、小于0.25ng/ml、小于0.2ng/ml、小于0.1ng/ml、小于50pg/ml、小于25pg/ml、小于20pg/ml、小于10pg/ml、小于5pg/ml、小于2.5pg/ml、小于2pg/ml、或小于1pg/ml的IC50中和新型冠状病毒(SARS-CoV-2)假病毒。
本文所述的抗原结合单元对新型冠状病毒(SARS-CoV-2)的中和活性可采用SARS-CoV-2真病毒通过空斑减少中和试验(Plaque Reduction Neutralization Test,PRNT)进行检测,通过孵育后空斑(plaque)的减少计算本文所述中的抗原结合单元中和SARS-CoV-2真病毒的IC50。本文所述的抗原结合单元可以以例如小于100μg/ml、小于50μg/ml、小于20μg/ml、小于10μg/ml、小于9μg/ml、小于8μg/ml、小于7μg/ml、小于6μg/ml、小于5μg/ml、小于4μg/ml、小于3μg/ml、小于2μg/ml、小于1μg/ml、小于0.5μg/ml、小于0.25μg/ml、小于0.2μg/ml、小于0.1μg/ml、小于0.05μg/ml、小于1ng/ml、小于0.5ng/ml、小于0.25ng/ml、小于0.2ng/ml、小于0.1ng/ml、小于50pg/ml、小于25pg/ml、小于20pg/ml、小于10pg/ml、小于5pg/ml、小于2.5pg/ml、小于2pg/ml、或小于1pg/ml的IC50中和新型冠状病毒(SARS-CoV-2)真病毒。
抗原结合单元的制备
本文提供了产生任何本文公开的抗原结合单元的方法,其中该方法包括在适于表达抗原结合单元的条件下培养表达抗原结合单元的宿主细胞,以及分离由宿主细胞表达的抗原结合单元。
所表达的抗原结合单元可以使用本领域已知的多种蛋白质纯化技术分离。通常,抗原结合单元作为分泌的多肽从培养基中分离,尽管它们也可在无信号肽的情况下直接产生时从宿主细胞裂解物或细菌周质中回收。如果抗原结合单元是膜结合的,它们可以通过本领域技术人员常用的适当去污剂溶液溶解。回收的抗原结合单元可以通过盐沉淀(例如,用硫酸铵)、离子交换色谱法(例如在中性pH下在阳离子或阴离子交换柱上运行并用离子强度增加的步骤梯度洗脱)、凝胶过滤色谱法(包括凝胶过滤HPLC)以及标签亲和柱色谱法,或亲和树脂如蛋白A、蛋白G、羟基磷灰石和抗免疫球蛋白进一步纯化。
在本文所述的方法和组合物中可以使用添加了以下部分的衍生免疫球蛋白:化学连接体,可检测部分如荧光染料,酶,底物,化学发光部分,特异性结合部分如链霉亲和素、亲和素或生物素,或药物缀合物。
本文还提供与化学功能部分缀合的抗原结合单元。通常,该部分是能够产生可检测信号的标记。这些缀合的抗原结合单元可用于例如检测系统,如病毒感染严重程度、感染灶的成像等。此类标记是本领域已知的,并且包括但不限于放射性同位素、酶、荧光化合物、化学发光化合物、生物发光化合物底物辅因子和抑制剂。教导使用此类标签的专利的实例参见美国专利3,817,837;3,850,752;3,939,350;3,996,345;4,277,437;4,275,149;和4,366,241。该部分可以与抗原结合单元共价连接、重组连接或通过第二试剂如第二抗体、蛋白A或生物素-亲和素复合物与抗原结合单元缀合。
其它功能部分包括信号肽、增强免疫反应性的试剂、促进与固体支持物偶联的试剂、疫苗载体、生物反应调节剂、顺磁标记和药物。 信号肽是短氨基酸序列,其引导新合成的蛋白质通过细胞膜(通常是真核细胞中的内质网)以及细菌的内膜或内膜和外膜二者。信号肽可以位于多肽的N-末端部分或多肽的C-末端部分,并且信号肽可以在多肽的生物合成与分泌之间从细胞酶促除去。这类肽可以被引入抗原结合单元中,以允许合成分子的分泌。
增强免疫反应性的试剂包括但不限于细菌超抗原。促进与固体支持物偶联的试剂包括但不限于生物素或亲和素。免疫原载体包括但不限于任何生理学上可接受的缓冲液。生物反应调节剂包括细胞因子,特别是肿瘤坏死因子(TNF)、白介素-2、白介素-4、粒细胞巨噬细胞集落刺激因子和γ-干扰素。
化学功能部分可以重组制备,例如通过产生编码抗原结合单元和功能部分的融合基因。或者,抗原结合单元可以通过各种熟知的化学程序中的任何一种化学键合到该部分。例如,当该部分是蛋白质时,连接可以通过异双官能交联剂,例如,SPDP、碳二亚胺戊二醛等。该部分可以通过第二试剂,如第二抗体、蛋白A或生物素-亲和素复合物共价连接或缀合。顺磁部分及其与抗体的缀合在本领域中是公知的。参见,例如,Miltenyi等人(1990)Cytometry 11:231-238。
核酸
在一个方面,本文提供了编码本文所述的抗原结合单元的分离的多核苷酸。对应于现有抗体的L或H链的各个区域的核苷酸序列可以使用常规技术(包括但不限于杂交、PCR和DNA测序)容易地获得并进行测序。产生单克隆抗体的杂交瘤细胞用作抗体核苷酸序列的优选来源。可以从公共或私人储存库获得产生一系列单克隆抗体的大量杂交瘤细胞。最大的储藏机构是美国典型培养物保藏中心(American Type Culture Collection),它提供了多种不同的充分表征的杂交瘤细胞系。或者,抗体核苷酸可以从免疫的或未免疫的啮齿动物或人,以及从诸如脾和外周血淋巴细胞的器官获得。适用于提取和合成抗体核苷酸的具体技术描述于Orlandi等人(1989)Proc.Natl.Acad.Sci.U.S.A 86: 3833-3837;Larrick等人1989)biochem.Biophys.Res.Commun.160:1250-1255;Sastry等人(1989)Proc.Natl.Acad.Sci.,U.S.A.86:5728-5732;以及美国专利号5,969,108。
还可以修饰抗体核苷酸序列,例如,通过用编码序列取代人重链和轻链恒定区从而代替同源非人序列。以这种方式,制备嵌合抗体,其保留原始抗体的结合特异性。
另外,可以对编码抗原结合单元的重链和/或轻链的多核苷酸进行密码子优化,以实现受试者抗原结合单元在所需宿主细胞中的优化表达。例如,在一种密码子优化方法中,天然密码子被来自参考基因组的最常见密码子所取代,其中每种氨基酸的密码子翻译速率被设计得较高。用于生成用于表达所需蛋白质的密码子优化的多核苷酸的另外的示例性方法描述于Kanaya等人,Gene,238:143-155(1999),Wang等人,Mol.Biol.Evol.,18(5):792-800(2001),美国专利号5,795,737,美国公开号2008/0076161和WO 2008/000632中,所述方法可应用于抗原结合单元的重链和/或轻链。
本文内容的多核苷酸包括编码示例性多肽的功能等同物及其片段的多核苷酸。
由于遗传密码的简并性,L和H序列的核苷酸以及适于构建本文所述的多核苷酸和载体的异二聚化序列可以有相当大的变异。这些变异包含在本文内容中。
治疗方法
本文提供了使用本文所述的抗原结合单元来预防或治疗受试者的新型冠状病毒(SARS-CoV-2)感染的方法,包括向所述受试者给予本文所述的抗原结合单元。
本文提供了使用本文所述的抗原结合单元与第二药剂联合治疗哺乳动物的疾病、病况或病症的方法。第二药剂可以与抗体一起、在抗体之前或之后施用。所述第二药剂可以是抗病毒剂。抗病毒剂包括但不限于特拉匹韦(telaprevir)、波普瑞韦(boceprevir)、西美瑞韦 (semiprevir)、索菲布韦(sofosbuvir)、达拉他韦(daclastavir)、阿那匹韦(asunaprevir)、拉米夫定(lamivudine)、阿德福韦(adefovir)、恩替卡韦(entecavir)、替诺福韦(tenofovir)、替比夫定(telbivudine)、干扰素α和PEG化干扰素α。所述第二药剂可以选自羟氯喹、氯喹、法维拉韦、金西单抗(Gimsilumab)、AdCOVID(University of Alabama at Birmingham)、AT-100(Airway Therapeutics)、TZLS-501(Tiziana Life Sciences)、OYA1(OyaGen)、BPI-002(BeyondSpring)、INO-4800(Inovio Pharmaceutical)、NP-120(ifenprodil)、瑞德西韦(GS-5734)、Actemra(Roche)、加利地韦(BCX4430)、SNG001(Synairgen Research)、或其组合。
所述第二药剂可以是用于缓解受试者并发的炎性病况的症状的药剂。所述抗炎剂包括非甾体抗炎药(NSAID)和皮质类固醇。NSAID包括但不限于水杨酸盐,如乙酰水杨酸;二氟尼柳、水杨酸和双水杨酯;丙酸衍生物,如布洛芬;萘普生;右布洛芬、右酮洛芬、氟比洛芬、奥沙普嗪、非诺洛芬、洛索洛芬和酮洛芬;乙酸衍生物,如吲哚美辛、双氯芬酸、托美汀、醋氯芬酸、舒林酸、萘丁美酮、依托度酸和酮咯酸;烯醇酸衍生物,如吡罗昔康、氯诺昔康、美洛昔康、伊索昔康、替诺昔康、苯基丁氮酮和屈恶昔康;邻氨基苯甲酸衍生物,如甲芬那酸、氟芬那酸、甲氯芬那酸和托芬那酸;选择性COX-2抑制剂,如塞来昔布、罗美昔布、罗非昔布、艾托考昔、伐地考昔、非罗考昔和帕瑞考昔;磺胺尼西林,如尼美舒利;和其他非甾体抗炎药如氯尼辛和利考非隆。皮质类固醇包括但不限于可的松、地塞米松、氢化可的松、甲泼尼龙、泼尼松和泼尼松龙。
所述第二药剂可以是免疫抑制剂。可与抗原结合单元组合使用的免疫抑制剂包括但不限于羟氯喹、柳氮磺胺吡啶、来氟米特、依那西普、英夫利昔单抗、阿达木单抗、D-青霉胺、口服金化合物、可注射金化合物(肌内注射)、米诺环素、硫代苹果酸金钠、金诺芬、D-青霉胺、氯苯扎利、布西拉明、阿克他利、环磷酰胺、硫唑嘌呤、甲氨蝶呤、咪唑立宾、环孢菌素和他克莫司。
具体剂量将根据所选择的特定抗原结合单元、要遵循的给药方案、是否与其他药剂组合施用、施用时间、施用的组织以及携带该特定抗原结合单元的物理递送系统而变化。在一些实施方案中,在治疗周期的过程中,平均每周向受试者施用约1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28、29、30、31、32、34、35、36、37、38、39、40、41、42、43、44、45、46、47、48、49、50、51、52、53、54、55、56、57、58、59、60、61、62、63、64、65、66、67、68、69或70mg范围内的抗原结合单元。例如,每周向受试者施用约35、36、37、38、39、40、41、42、43、44、45、46、47、48、49、50、51、52、53、54或55mg范围内的抗原结合单元。在一些实施方案中,每周向受试者施用约40、41、42、43、44、45、46、47、48、49、50、51、52、53、54或55mg范围内的抗原结合单元。
在治疗周期的过程中,可以平均每天以大于1、1.5、2、2.5、3、3.5、4、4.5、5、5.5、6、6.5、7、7.5、8、8.5、9、9.5或10mg的量向受试者施用抗原结合单元。例如,在治疗周期的过程中,平均每天以约6至10mg、约6.5至9.5mg、约6.5至8.5mg、约6.5至8mg或约7至9mg的量向受试者施用抗原结合单元。
抗原结合单元的剂量可以是约、至少约或至多约0.1、0.5、1、2、3、4、5、6、7、8、9、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、125、150、175、200、225、250、275、300、325、350、375、400、425、450、475、500、525、550、575、600、625、650、675、700、725、750、775、800、825、850、875、900、925、950、975、1000mg或mg/kg,或者其中可衍生的任何范围。预期mg/kg的剂量是指每千克受试者总体重的抗原结合单元mg量。预期当给予患者多剂量时,剂量可以在量上变化或者它们可以是相同的。
药物组合物
本文提供了药物组合物,其包含受试者抗体或其功能片段和药学上可接受的载体、赋形剂或稳定剂,其包括但不限于惰性固体稀释剂和填充剂、稀释剂、无菌水溶液和各种有机溶剂、渗透促进剂、增溶剂和佐剂。(Remington′s Pharmaceutical Sciences第16版,Osol,A.编著(1980))。
药物组合物可以是适合于单次施用精确剂量的单位剂型。药物组合物可进一步包含抗原结合单元作为活性成分,并且可包括常规的药物载体或赋形剂。此外,它可包括其他药物或药剂、载体、佐剂等。示例性的肠胃外施用形式包括活性多肽和/或PEG修饰的多肽在无菌水溶液中的溶液或悬浮液,例如丙二醇水溶液或右旋糖溶液。如果需要,此类剂型可以适当地用盐如组氨酸和/或磷酸盐缓冲。
所述组合物可进一步包括一种或多种药学上可接受的添加剂和赋形剂。这些添加剂和赋形剂包括但不限于防粘剂、消泡剂、缓冲剂、聚合物、抗氧化剂、防腐剂、螯合剂、粘度调节剂(viscomodulator)、张力调节剂、调味剂、着色剂、增味剂、遮光剂、悬浮剂、粘合剂、填充剂、增塑剂、润滑剂及其混合物。
试剂盒
本文所述的试剂盒包含本文所述的抗原结合单元或如本文所述的其缀合物。还提供了本文所述的抗原结合单元在制备试剂盒中的用途,所述试剂盒用于检测新型冠状病毒或其S蛋白或S蛋白的RBD在样品中的存在或其水平,或用于诊断受试者是否感染了新型冠状病毒。
在一些实施方案中,所述样品包括但不限于来自受试者(例如哺乳动物,优选人)的排泄物、口腔或鼻腔分泌物、肺泡灌洗液等。
使用抗体或其抗原结合片段来检测目标病毒或抗原(例如,新型冠状病毒或其S蛋白或S蛋白的RBD)在样品中的存在或其水平的一般方法是本领域技术人员所熟知的。在一些实施方案中,所述检测方法可以使用酶联免疫吸附(ELISA)、酶免疫检测、化学发光免疫检测、放射免疫检测、荧光免疫检测、免疫色谱法、竞争法及类似检测方法。
实施例
现参照下列意在举例说明本发明(而非限定本发明)的实施例来描述本发明。
除非特别指明,本文中所使用的分子生物学实验方法和免疫检测法,基本上参照J.Sambrook等人,分子克隆:实验室手册,第2版,冷泉港实验室出版社,1989,以及F.M.Ausubel等人,精编分子生物学实验指南,第3版,John Wiley&Sons,Inc.,1995中所述的方法进行;限制性内切酶的使用依照产品制造商推荐的条件。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规产品。本领域技术人员知晓,实施例以举例方式描述本发明,且不意欲限制本发明所要求保护的范围。
实施例1:B细胞的分离与富集
采集感染SARS-CoV-2病毒且痊愈出院的人员的血液(由北京佑安医院提供)。出院标准为(1)体温恢复正常超过三天;(2)呼吸道症状缓解;以及(3)以一天的采样间隔连续两次进行痰的SARS-CoV-2 RT-PCR检测,结果为阴性。
PBMC细胞采集以及B细胞富集:在P2+生物安全实验室中,利用STEMCELL SepMate
TM-15(Stemcell Technologies,产品目录号:86415)进行PBMC的提取。随后,根据制造商的说明书,使用STEMCELL EasySep Human Memory B Cell Isolation Kit(Stemcell Technologies,产品目录号:17864)对提取的PBMCs进行记忆B细胞的富集。
CD27+记忆B细胞富集:根据制造商的说明书,使用STEMCELL EasySep Human Memory B Cell Isolation Kit(Stemcell Technologies),采用EasySep
TM磁体对结合CD27抗体的CD27+B细胞进行分离,并计数(Countess Automated Cell Counter)。
抗原结合B细胞富集:采用购自Sino Biology的生物素化的Spike/RBD重组蛋白。在每次B细胞富集前制备新鲜的抗原/链霉亲和素M-280 Dynabeads(Thermofisher)复合物。将100μl包含6.5 x 107珠子的M-280珠子涡旋30秒钟,静置至室温。然后在磁力架上用1ml 1x PBS洗涤小珠两次,并在100μl的1x PBS中洗脱。将100μl磁珠与20μg生物素化的Spike/RBD蛋白混合,并在室温下孵育30分钟。孵育后,将复合物在磁力架上用500μl的1x PBS洗涤3次。将洗涤后的复合物在100μl的1x PBS中洗脱,置于冰上待使用。在抗原富集之前,将复合物平衡至室温。将Spike/RBD磁珠复合物直接添加到B细胞混合物中,混合并在热混合器上于4℃孵育30分钟。将混合物置于磁力架上,并除去上清液。共混合四次,将小珠洗涤后,在含有2%胎牛血清(FBS)和1mM EDTA的1x PBS中洗脱经过抗原富集的B细胞,并计数(Countess Automated Cell Counter)。
实施例2:抗原结合单元序列的获得与鉴定
根据制造商的说明书,使用Chromium Single Cell V(D)J Reagent Kits(购自10X genomics,产品目录号:100006)对上述富集后的记忆B细胞进行单细胞转录组的VDJ测序。将来自10位患者的富集的B细胞作为一个批次,共进行六个批次的测序分析。
采用10X Genomics CellRanger(3.1.0)管线处理数据。将5′基因表达谱产生的读物与GRCh38基因组进行比对,生成特征条形码矩阵。选择在超过10个细胞中表达的基因,并根据基因数量和线粒体基因百分比对细胞进行过滤,以去除可能的双峰。使用SingleR(Aran等,2019)针对人类免疫参考数据集(参见Monaco等,2019)鉴定细胞类型。图7显示经抗原富集后的B细胞测序结果的总结。
使用Seurat中的T分布随机相邻嵌入(t-SNE)可视化细胞簇(参见Satija等人,2015)。图8显示来自同一位患者的富集程度最高的25个克隆型(A)以及该患者克隆型的Ig类别分布(B)。根据该方法,从上述60位患者的富集的B细胞中共鉴定出超过8,400个抗原结合IgG+克隆型。
采用cutadapt(Martin,2011)去除3’端质量得分小于30的碱基。采用“cellranger vdj”进行重叠群组装、注释和克隆型分析。采用SAAB+管线(Kovaltsuk等,2020)对轻链和重链的CDR区域的结构进行注释,并采用内嵌的FREAD(Choi和Deane,2009)对CDR3结构进行预测。采用IgBlast-1.15.0(Ye et al.,2013)映射V(D)J序列读取。
通过DNA突变模式以及Ig类别确定每个克隆型的谱系。通过igraph(Csardi和Nepusz,2006)对谱系做图。
通过设立如下标准对克隆型进行选择(1)富集频率>1;(2)包含表达IgG1的B细胞;(3)不包含表达IgG2的B细胞;(4)可变区突变率>2%;以及(5)包含记忆B细胞。并根据此标准选择了满足标准的抗体169个,以及不满足上述标准的抗体47个。
如图9显示为对第5批次中轻链重链相匹配的生产性B细胞基于基因表达所确定的细胞分型图。图10显示为通过上述标准筛选的第5批次的B细胞的克隆型分析。其中满足上述标准的克隆型位于图中虚线右侧。图11A显示分别通过如实施例1中所述的S蛋白富集和RBD富集后所产生的满足如上标准的抗体数量以及根据本文所述测定的与RBD的结合ELISA结果和Kd值以及中和假病毒的IC50值,其中满足标准的抗体中46%与RBD结合的Kd值小于20nM,25%中和假病毒的IC50低于3μg/ml。相比之下,图11B中显示不满足不包含IgG2、可变区突变率>2%或者包含记忆B细胞的标准的克隆型与RBD的结合ELISA结果和Kd值以及中和假病毒的IC50值。
选择PDB(Protein Data Bank)数据库中的抗SARS-CoV中和抗体m396和80R(参见Prabakaran et al.,2006和Hwang et al.,2006),并将其晶体结构与通过FREAD预测的CDR3结构进行对比,鉴定出12个与这两种抗体具有结构相似性的IgG1克隆型,经验证,其中10个具有强的RBD结合亲和力以及强的对假病毒SARS-CoV-2中和能力(其中7个的IC50低于0.05μg/ml)。图12显示为抗体m396Fab与SARS-CoV-RBD复合物的晶体结构(PDB ID:2DD8)。其中下方为RBD,上方左侧为m396-H结构域,上方右侧为m396-L结构域。
对测序结果进行分析,获得395株抗原结合单元,分别命名为ABU1-395。其中所获得的抗原结合单元的序列信息如下表1所示。
表1 本文中获得的示例性抗原结合单元
ABU No. | VH SEQ ID No. | VL SEQ ID NO. |
ABU-1 | 721 | 1081 |
ABU-2 | 722 | 1082 |
ABU-3 | 723 | 1083 |
ABU-4 | 724 | 1084 |
ABU-5 | 725 | 1085 |
ABU-6 | 726 | 1086 |
ABU-7 | 727 | 1087 |
ABU-8 | 728 | 1088 |
ABU-9 | 729 | 1089 |
ABU-10 | 730 | 1090 |
ABU-11 | 731 | 1091 |
ABU-12 | 732 | 1092 |
ABU-13 | 733 | 1093 |
ABU-14 | 734 | 1094 |
ABU-15 | 735 | 1095 |
ABU-16 | 736 | 1096 |
ABU-17 | 737 | 1097 |
ABU-18 | 738 | 1098 |
ABU-19 | 739 | 1099 |
ABU-20 | 740 | 1100 |
ABU-21 | 741 | 1101 |
ABU-22 | 742 | 1102 |
ABU-23 | 743 | 1103 |
ABU-24 | 744 | 1104 |
ABU-25 | 745 | 1105 |
ABU-26 | 746 | 1106 |
ABU-27 | 747 | 1107 |
ABU-28 | 748 | 1108 |
ABU-29 | 749 | 1109 |
ABU-30 | 750 | 1110 |
ABU-31 | 751 | 1111 |
ABU-32 | 752 | 1112 |
ABU-33 | 753 | 1113 |
ABU-34 | 754 | 1114 |
ABU-35 | 755 | 1115 |
ABU-36 | 756 | 1116 |
ABU-37 | 757 | 1117 |
ABU-38 | 758 | 1118 |
ABU-39 | 759 | 1119 |
ABU-40 | 760 | 1120 |
ABU-41 | 761 | 1121 |
ABU-42 | 762 | 1122 |
ABU-43 | 763 | 1123 |
ABU-44 | 764 | 1124 |
ABU-45 | 765 | 1125 |
ABU-46 | 766 | 1126 |
ABU-47 | 767 | 1127 |
ABU-48 | 768 | 1128 |
ABU-49 | 769 | 1129 |
ABU-50 | 770 | 1130 |
ABU-51 | 771 | 1131 |
ABU-52 | 772 | 1132 |
ABU-53 | 773 | 1133 |
ABU-54 | 774 | 1134 |
ABU-55 | 775 | 1135 |
ABU-56 | 776 | 1136 |
ABU-57 | 777 | 1137 |
ABU-58 | 778 | 1138 |
ABU-59 | 779 | 1139 |
ABU-60 | 780 | 1140 |
ABU-61 | 781 | 1141 |
ABU-62 | 782 | 1142 |
ABU-63 | 783 | 1143 |
ABU-64 | 784 | 1144 |
ABU-65 | 785 | 1145 |
ABU-66 | 786 | 1146 |
ABU-67 | 787 | 1147 |
ABU-68 | 788 | 1148 |
ABU-69 | 789 | 1149 |
ABU-70 | 790 | 1150 |
ABU-71 | 791 | 1151 |
ABU-72 | 792 | 1152 |
ABU-73 | 793 | 1153 |
ABU-74 | 794 | 1154 |
ABU-75 | 795 | 1155 |
ABU-76 | 796 | 1156 |
ABU-77 | 797 | 1157 |
ABU-78 | 798 | 1158 |
ABU-79 | 799 | 1159 |
ABU-80 | 800 | 1160 |
ABU-81 | 801 | 1161 |
ABU-82 | 802 | 1162 |
ABU-83 | 803 | 1163 |
ABU-84 | 804 | 1164 |
ABU-85 | 805 | 1165 |
ABU-86 | 806 | 1166 |
ABU-87 | 807 | 1167 |
ABU-88 | 808 | 1168 |
ABU-89 | 809 | 1169 |
ABU-90 | 810 | 1170 |
ABU-91 | 811 | 1171 |
ABU-92 | 812 | 1172 |
ABU-93 | 813 | 1173 |
ABU-94 | 814 | 1174 |
ABU-95 | 815 | 1175 |
ABU-96 | 816 | 1176 |
ABU-97 | 817 | 1177 |
ABU-98 | 818 | 1178 |
ABU-99 | 819 | 1179 |
ABU-100 | 820 | 1180 |
ABU-101 | 821 | 1181 |
ABU-102 | 822 | 1182 |
ABU-103 | 823 | 1183 |
ABU-104 | 824 | 1184 |
ABU-105 | 825 | 1185 |
ABU-106 | 826 | 1186 |
ABU-107 | 827 | 1187 |
ABU-108 | 828 | 1188 |
ABU-109 | 829 | 1189 |
ABU-110 | 830 | 1190 |
ABU-111 | 831 | 1191 |
ABU-112 | 832 | 1192 |
ABU-113 | 833 | 1193 |
ABU-114 | 834 | 1194 |
ABU-115 | 835 | 1195 |
ABU-116 | 836 | 1196 |
ABU-117 | 837 | 1197 |
ABU-118 | 838 | 1198 |
ABU-119 | 839 | 1199 |
ABU-120 | 840 | 1200 |
ABU-121 | 841 | 1201 |
ABU-122 | 842 | 1202 |
ABU-123 | 843 | 1203 |
ABU-124 | 844 | 1204 |
ABU-125 | 845 | 1205 |
ABU-126 | 846 | 1206 |
ABU-127 | 847 | 1207 |
ABU-128 | 848 | 1208 |
ABU-129 | 849 | 1209 |
ABU-130 | 850 | 1210 |
ABU-131 | 851 | 1211 |
ABU-132 | 852 | 1212 |
ABU-133 | 853 | 1213 |
ABU-134 | 854 | 1214 |
ABU-135 | 855 | 1215 |
ABU-136 | 856 | 1216 |
ABU-137 | 857 | 1217 |
ABU-138 | 858 | 1218 |
ABU-139 | 859 | 1219 |
ABU-140 | 860 | 1220 |
ABU-141 | 861 | 1221 |
ABU-142 | 862 | 1222 |
ABU-143 | 863 | 1223 |
ABU-144 | 864 | 1224 |
ABU-145 | 865 | 1225 |
ABU-146 | 866 | 1226 |
ABU-147 | 867 | 1227 |
ABU-148 | 868 | 1228 |
ABU-149 | 869 | 1229 |
ABU-150 | 870 | 1230 |
ABU-151 | 871 | 1231 |
ABU-152 | 872 | 1232 |
ABU-153 | 873 | 1233 |
ABU-154 | 874 | 1234 |
ABU-155 | 875 | 1235 |
ABU-156 | 876 | 1236 |
ABU-157 | 877 | 1237 |
ABU-158 | 878 | 1238 |
ABU-159 | 879 | 1239 |
ABU-160 | 880 | 1240 |
ABU-161 | 881 | 1241 |
ABU-162 | 882 | 1242 |
ABU-163 | 883 | 1243 |
ABU-164 | 884 | 1244 |
ABU-165 | 885 | 1245 |
ABU-166 | 886 | 1246 |
ABU-167 | 887 | 1247 |
ABU-168 | 888 | 1248 |
ABU-169 | 889 | 1249 |
ABU-170 | 890 | 1250 |
ABU-171 | 891 | 1251 |
ABU-172 | 892 | 1252 |
ABU-173 | 893 | 1253 |
ABU-174 | 894 | 1254 |
ABU-175 | 895 | 1255 |
ABU-176 | 896 | 1256 |
ABU-177 | 897 | 1257 |
ABU-178 | 898 | 1258 |
ABU-179 | 899 | 1259 |
ABU-180 | 900 | 1260 |
ABU-181 | 901 | 1261 |
ABU-182 | 902 | 1262 |
ABU-183 | 903 | 1263 |
ABU-184 | 904 | 1264 |
ABU-185 | 905 | 1265 |
ABU-186 | 906 | 1266 |
ABU-187 | 907 | 1267 |
ABU-188 | 908 | 1268 |
ABU-189 | 909 | 1269 |
ABU-190 | 910 | 1270 |
ABU-191 | 911 | 1271 |
ABU-192 | 912 | 1272 |
ABU-193 | 913 | 1273 |
ABU-194 | 914 | 1274 |
ABU-195 | 915 | 1275 |
ABU-196 | 916 | 1276 |
ABU-197 | 917 | 1277 |
ABU-198 | 918 | 1278 |
ABU-199 | 919 | 1279 |
ABU-200 | 920 | 1280 |
ABU-201 | 921 | 1281 |
ABU-202 | 922 | 1282 |
ABU-203 | 923 | 1283 |
ABU-204 | 924 | 1284 |
ABU-205 | 925 | 1285 |
ABU-206 | 926 | 1286 |
ABU-207 | 927 | 1287 |
ABU-208 | 928 | 1288 |
ABU-209 | 929 | 1289 |
ABU-210 | 930 | 1290 |
ABU-211 | 931 | 1291 |
ABU-212 | 932 | 1292 |
ABU-213 | 933 | 1293 |
ABU-214 | 934 | 1294 |
ABU-215 | 935 | 1295 |
ABU-216 | 936 | 1296 |
ABU-217 | 937 | 1297 |
ABU-218 | 938 | 1298 |
ABU-219 | 939 | 1299 |
ABU-220 | 940 | 1300 |
ABU-221 | 941 | 1301 |
ABU-222 | 942 | 1302 |
ABU-223 | 943 | 1303 |
ABU-224 | 944 | 1304 |
ABU-225 | 945 | 1305 |
ABU-226 | 946 | 1306 |
ABU-227 | 947 | 1307 |
ABU-228 | 948 | 1308 |
ABU-229 | 949 | 1309 |
ABU-230 | 950 | 1310 |
ABU-231 | 951 | 1311 |
ABU-232 | 952 | 1312 |
ABU-233 | 953 | 1313 |
ABU-234 | 954 | 1314 |
ABU-235 | 955 | 1315 |
ABU-236 | 956 | 1316 |
ABU-237 | 957 | 1317 |
ABU-238 | 958 | 1318 |
ABU-239 | 959 | 1319 |
ABU-240 | 960 | 1320 |
ABU-241 | 961 | 1321 |
ABU-242 | 962 | 1322 |
ABU-243 | 963 | 1323 |
ABU-244 | 964 | 1324 |
ABU-245 | 965 | 1325 |
ABU-246 | 966 | 1326 |
ABU-247 | 967 | 1327 |
ABU-248 | 968 | 1328 |
ABU-249 | 969 | 1329 |
ABU-250 | 970 | 1330 |
ABU-251 | 971 | 1331 |
ABU-252 | 972 | 1332 |
ABU-253 | 973 | 1333 |
ABU-254 | 974 | 1334 |
ABU-255 | 975 | 1335 |
ABU-256 | 976 | 1336 |
ABU-257 | 977 | 1337 |
ABU-258 | 978 | 1338 |
ABU-259 | 979 | 1339 |
ABU-260 | 980 | 1340 |
ABU-261 | 981 | 1341 |
ABU-262 | 982 | 1342 |
ABU-263 | 983 | 1343 |
ABU-264 | 984 | 1344 |
ABU-265 | 985 | 1345 |
ABU-266 | 986 | 1346 |
ABU-267 | 987 | 1347 |
ABU-268 | 988 | 1348 |
ABU-269 | 989 | 1349 |
ABU-270 | 990 | 1350 |
ABU-271 | 991 | 1351 |
ABU-272 | 992 | 1352 |
ABU-273 | 993 | 1353 |
ABU-274 | 994 | 1354 |
ABU-275 | 995 | 1355 |
ABU-276 | 996 | 1356 |
ABU-277 | 997 | 1357 |
ABU-278 | 998 | 1358 |
ABU-279 | 999 | 1359 |
ABU-280 | 1000 | 1360 |
ABU-281 | 1001 | 1361 |
ABU-282 | 1002 | 1362 |
ABU-283 | 1003 | 1363 |
ABU-284 | 1004 | 1364 |
ABU-285 | 1005 | 1365 |
ABU-286 | 1006 | 1366 |
ABU-287 | 1007 | 1367 |
ABU-288 | 1008 | 1368 |
ABU-289 | 1009 | 1369 |
ABU-290 | 1010 | 1370 |
ABU-291 | 1011 | 1371 |
ABU-292 | 1012 | 1372 |
ABU-293 | 1013 | 1373 |
ABU-294 | 1014 | 1374 |
ABU-295 | 1015 | 1375 |
ABU-296 | 1016 | 1376 |
ABU-297 | 1017 | 1377 |
ABU-298 | 1018 | 1378 |
ABU-299 | 1019 | 1379 |
ABU-300 | 1020 | 1380 |
ABU-301 | 1021 | 1381 |
ABU-302 | 1022 | 1382 |
ABU-303 | 1023 | 1383 |
ABU-304 | 1024 | 1384 |
ABU-305 | 1025 | 1385 |
ABU-306 | 1026 | 1386 |
ABU-307 | 1027 | 1387 |
ABU-308 | 1028 | 1388 |
ABU-309 | 1029 | 1389 |
ABU-310 | 1030 | 1390 |
ABU-311 | 1031 | 1391 |
ABU-312 | 1032 | 1392 |
ABU-313 | 1033 | 1393 |
ABU-314 | 1034 | 1394 |
ABU-315 | 1035 | 1395 |
ABU-316 | 1036 | 1396 |
ABU-317 | 1037 | 1397 |
ABU-318 | 1038 | 1398 |
ABU-319 | 1039 | 1399 |
ABU-320 | 1040 | 1400 |
ABU-321 | 1041 | 1401 |
ABU-322 | 1042 | 1402 |
ABU-323 | 1043 | 1403 |
ABU-324 | 1044 | 1404 |
ABU-325 | 1045 | 1405 |
ABU-326 | 1046 | 1406 |
ABU-327 | 1047 | 1407 |
ABU-328 | 1048 | 1408 |
ABU-329 | 1049 | 1409 |
ABU-330 | 1050 | 1410 |
ABU-331 | 1051 | 1411 |
ABU-332 | 1052 | 1412 |
ABU-333 | 1053 | 1413 |
ABU-334 | 1054 | 1414 |
ABU-335 | 1055 | 1415 |
ABU-336 | 1056 | 1416 |
ABU-337 | 1057 | 1417 |
ABU-338 | 1058 | 1418 |
ABU-339 | 1059 | 1419 |
ABU-340 | 1060 | 1420 |
ABU-341 | 1061 | 1421 |
ABU-342 | 1062 | 1422 |
ABU-343 | 1063 | 1423 |
ABU-344 | 1064 | 1424 |
ABU-345 | 1065 | 1425 |
ABU-346 | 1066 | 1426 |
ABU-347 | 1067 | 1427 |
ABU-348 | 1068 | 1428 |
ABU-349 | 1069 | 1429 |
ABU-350 | 1070 | 1430 |
ABU-351 | 1071 | 1431 |
ABU-352 | 1072 | 1432 |
ABU-353 | 1073 | 1433 |
ABU-354 | 1074 | 1434 |
ABU-355 | 1075 | 1435 |
ABU-356 | 1076 | 1436 |
ABU-357 | 1077 | 1437 |
ABU-358 | 1078 | 1438 |
ABU-359 | 1079 | 1439 |
ABU-360 | 1080 | 1440 |
ABU-361 | 3111 | 3146 |
ABU-362 | 3112 | 3147 |
ABU-363 | 3113 | 3148 |
ABU-364 | 3114 | 3149 |
ABU-365 | 3115 | 3150 |
ABU-366 | 3116 | 3151 |
ABU-367 | 3117 | 3152 |
ABU-368 | 3118 | 3153 |
ABU-369 | 3119 | 3154 |
ABU-370 | 3120 | 3155 |
ABU-371 | 3121 | 3156 |
ABU-372 | 3122 | 3157 |
ABU-373 | 3123 | 3158 |
ABU-374 | 3124 | 3159 |
ABU-375 | 3125 | 3160 |
ABU-376 | 3126 | 3161 |
ABU-377 | 3127 | 3162 |
ABU-378 | 3128 | 3163 |
ABU-379 | 3129 | 3164 |
ABU-380 | 3130 | 3165 |
ABU-381 | 3131 | 3166 |
ABU-382 | 3132 | 3167 |
ABU-383 | 3133 | 3168 |
ABU-384 | 3134 | 3169 |
ABU-385 | 3135 | 3170 |
ABU-386 | 3136 | 3171 |
ABU-387 | 3137 | 3172 |
ABU-388 | 3138 | 3173 |
ABU-389 | 3139 | 3174 |
ABU-390 | 3140 | 3175 |
ABU-391 | 3141 | 3176 |
ABU-392 | 3142 | 3177 |
ABU-393 | 3143 | 3178 |
ABU-394 | 3144 | 3179 |
ABU-395 | 3145 | 3180 |
实施例3:本文中抗原结合单元的制备和纯化
根据实施例2中获得的抗原结合单元的序列信息,委托北京义翘神州有限公司表达和纯化所获得的抗原结合单元,并检测了它们的抗原反应性。
简言之,在体外合成编码抗体重链和轻链的核酸分子,然后分别克隆至表达载体中,从而得到分别编码抗体重链和轻链的重组表达载体。将上 述得到的分别编码抗体重链和轻链的重组表达载体共转染HEK293细胞。转染4-6小时后,将细胞培养液更换成无血清的培养基,并且继续在37℃下培养6天。培养结束后,通过亲和纯化柱从培养物中纯化细胞所表达的抗体蛋白。随后,通过还原性和非还原性SDS-PAGE检测所纯化的目的蛋白。其中,以ABU-174、ABU-175和ABU190为例,其制备后的电泳结果分别如图1A-1C所示。结果显示,经纯化的ABU-174、ABU-175和ABU190的纯度分别为95.9%、96.4%、98.2%。
随后,使用重组表达的S蛋白RBD作为包被抗原,使用辣根过氧化物酶(HRP)标记的Goat anti-human IgG Fc作为二抗,通过ELISA实验,检测经纯化的待测抗体的抗原反应性。简言之,用重组表达的S蛋白RBD(其氨基酸序列如SEQ ID NO:1459所示,浓度为0.01μg/ml或1μg/ml)包被96孔板,随后用封闭液对96孔板进行封闭。然后,分别加入待测单抗(对照抗体、ABU-174、ABU-175和ABU190;浓度分别为0.1μg/ml),并孵育。用ELISA洗涤液进行洗涤后,加入辣根过氧化物酶(HRP)标记的Goat anti-human IgG Fc作为二抗(以1∶500稀释),并继续孵育。然后,用PBST洗涤酶标板,并加入显色剂显色。随后在酶标仪上读取OD450nm的吸收值。结果如表2所示。由表2可知,ABU-174、ABU-175和ABU190均能够特异性识别并结合S蛋白RBD。
表2:通过ELISA检测的ABU-174、ABU-175和ABU190抗原结合单元与S蛋白RBD的反应性(OD450读数)
实施例4:本文中的抗原结合单元与S蛋白的结合能力的评估
本实施例采用表面等离子体共振技术(SPR)检测抗体与Spike蛋白RBD区域的亲和力。使用Biacore T200进行测量,先将生物素标记的SARS-COV-2 RBD结构域偶联到SA芯片(GE公司)上,信号共振单位RU值上升100个单位。运行缓冲液是PH 7.4的PBS加上0.005%P20,确保分析物(如抗体)中的缓冲液与运行缓冲液一致。3倍梯度稀释纯化好的抗体,使其浓度在50-0.78125nM间。测量结果使用Biacore Evaluation软件进行分析,1∶1模型拟合所有曲线,获得抗体与抗原结合的速率常数Ka以及抗体从抗体/抗原复合物中解离的速率常数Kd,并计算解离平衡常数KD,其中KD=Kd/Ka,结果如下表3所示。
表3列举了本文中示例性抗原结合单元与Spike蛋白RBD区域的结合亲和力,其中各抗原结合单元的KD值均小于20nM。
表3.本文示例性抗原结合单元与Spike蛋白RBD区域的结合亲和力的KD值
图2A-2进一步示例性地显示了ABU-174、ABU-175、ABU190、ABU297和ABU367与Spike蛋白RBD区域的结合亲和力。由图2A-2C可见,ABU-174的KD值为0.29nM,ABU-175的KD值为0.039nM,ABU190的KD值为2.8nM,ABU297的KD值为0.824nM,以及ABU的KD值为0.18nM。图2A-2E表明,ABU-174、ABU-175、ABU190、ABU297和ABU367与新型冠状病毒S蛋白均具有良好的亲和力。
实施例5:本文抗原结合单元中和SARS-CoV-2假病毒的能力的评估
在本实施例中,参照Temperton N J等人,Emerg Infect Dis,2005,11(3),411-416的描述,利用微孔细胞中和实验法,检测了本文中的抗原结合单元对SARS-CoV-2假病毒的中和活性。本实施例所应用的SARS-CoV-2假病毒由中国食品药品检定研究院提供,其具有与真病毒相似的细胞感染特点,能够模拟真病毒感染细胞的早期过程,并且携带报告基因luciferase,可以快速方便地进行检测分析。操作假病毒的安全性高,在P2级实验室内就可完成中和实验,检测抗体的中和活性(Neutralization titer)。实验方法的具体步骤如下。
1.平衡试剂
将保存于2-8℃的试剂(0.25%胰酶-EDTA,DMEM完全培养基)取出,室温平衡30分钟以上。
2.试验操作
(1)取96孔板,按照表4所示,设置样品的排布方式;其中,A2-H2的孔设置为细胞对照孔(CC),其仅含有实验细胞;A3-H3的孔设置为病毒对照孔(VV),其含有实验细胞和假病毒;A4-A11、B4-B11、C4-C11、D4-D11、E4-E11、F4-F11、G4-G11、H4-H11的孔设置为实验孔,其含有实验细胞、假病毒以及不同浓度的待测抗体;其余的孔设置为空白。本实施例中所使用的实验细胞和假病毒分别为Huh-7细胞和SARS-CoV-2病毒(均由中国食品药品检定研究院提供)。
表4. 96孔板中样品的排布方式
1 | 2 | 3 | 4 | 5-10 | 11 | 12 | |
A | - | CC | VV | 稀释度1 | 稀释度1 | 稀释度1 | - |
B | - | CC | VV | 稀释度2 | 稀释度2 | 稀释度2 | - |
C | - | CC | VV | 稀释度3 | 稀释度3 | 稀释度3 | - |
D | - | CC | VV | 稀释度4 | 稀释度4 | 稀释度4 | - |
E | - | CC | VV | 稀释度5 | 稀释度5 | 稀释度5 | - |
F | - | CC | VV | 稀释度6 | 稀释度6 | 稀释度6 | - |
G | - | CC | VV | 稀释度7 | 稀释度7 | 稀释度7 | - |
H | - | CC | VV | 稀释度8 | 稀释度8 | 稀释度8 | - |
(2)在细胞对照孔中加入100μl/孔的DMEM完全培养基(含有1%的抗生素,25mM HEPES,10%FBS);在病毒对照孔中加入100μl/孔的DMEM完全培养基;并且,在实验孔中加入50μl/孔的指定浓度的、稀释于DMEM完全培养基中的待测抗体。表4中所使用的稀释度1-8的抗体浓度分别为1/30μg/μl,1/90μg/μl,1/270μg/μl,1/810μg/μl,1/2430μg/μl,1/7290μg/μl,1/21870μg/μl,1/65610μg/μl。
(3)用DMEM完全培养基将SARS-CoV-2假病毒稀释至约1.3×10
4/ml (TCID50);然后向病毒对照孔和实验孔中添加50μl/孔的SARS-CoV-2假病毒。
(4)将96孔板置于细胞培养箱中(37℃,5%CO
2)孵育1小时。
(5)用DMEM完全培养基将预先培养好的Huh-7细胞稀释至2×10
5个/ml。在前一步骤的孵育结束后,向细胞对照孔、病毒对照孔和实验孔中添加100μl/孔的细胞。
(6)将96孔板置于细胞培养箱中(37℃,5%CO
2)培养20-28小时。
(7)从细胞培养箱中取出96孔板,从每个孔中吸弃150μl上清,然后加入100μl荧光素酶检测试剂,室温避光反应2min。
(8)反应结束后,用移液器将各个孔中的液体反复吹吸6~8次,使细胞充分裂解。然后,从每孔中吸出150μl液体,转移至对应的96孔化学发光检测板中,用化学发光检测仪(Perkinelmer EnSight多功能酶标仪)读取发光值。
(9)计算中和抑制率:
抑制率=[1-(实验孔的发光强度均值-CC孔的发光强度均值)/(VV孔的发光强度均值-CC孔的发光强度均值)]×100%。
(10)根据中和抑制率的结果,利用Reed-Muench法计算待测抗体的IC50。
表5列举了本文中示例性抗原结合单元中和SARS-CoV-2假病毒的IC
50,其中各抗原结合单元的IC50值均小于1μg/ml。
表5.本文示例性抗原结合单元中和SARS-CoV-2假病毒的IC50
ABU No. | IC50(μg/ml) |
ABU-174 | <0.1 |
ABU-175 | <0.1 |
ABU-190 | <0.1 |
ABU-207 | <0.5 |
ABU-208 | <0.5 |
ABU-257 | <0.5 |
ABU-290 | <0.1 |
ABU-291 | <0.5 |
ABU-296 | <0.1 |
ABU-297 | <0.1 |
ABU-308 | <0.5 |
ABU-322 | <0.1 |
ABU-340 | <0.5 |
ABU-341 | <0.1 |
ABU-344 | <1 |
ABU-349 | <0.1 |
ABU-351 | <0.1 |
ABU-352 | <0.1 |
ABU-354 | <0.1 |
ABU-355 | <0.1 |
ABU-356 | <0.1 |
ABU-357 | <1 |
ABU-358 | <0.1 |
ABU-359 | <0.1 |
ABU-360 | <0.1 |
ABU-361 | <0.5 |
ABU-362 | <0.5 |
ABU-365 | <0.1 |
ABU-367 | <0.1 |
ABU-368 | <0.5 |
ABU-369 | <0.1 |
ABU-371 | <1 |
ABU-372 | <0.5 |
ABU-373 | <0.5 |
ABU-375 | <0.1 |
ABU-376 | <0.1 |
ABU-377 | <0.5 |
ABU-379 | <0.5 |
ABU-380 | <0.1 |
ABU-381 | <0.1 |
ABU-382 | <0.1 |
ABU-386 | <0.1 |
ABU-391 | <1 |
ABU-392 | <0.1 |
ABU-395 | <0.1 |
图3A-3C进一步示例性地显示了ABU-174、ABU-175和ABU190对SARS-CoV-2假病毒的中和活性。由图3A-3C可见,ABU-174、ABU-175和ABU190均具有良好的中和活性,其IC50分别为0.026μg/ml(ABU-174)、0.0086μg/ml(ABU-175)、0.039μg/ml(ABU190)。
实施例6:本文中的抗原结合单元中和SARS-CoV-2真病毒的能力的评估
在本实施例中,分别通过细胞病变(CPE)测定和空斑减少中和试验(PRNT)来评估待测抗体的中和活性。所使用的SARS-CoV-2病毒由军事医学研究院提供,其滴度(TCID50)为10
5/ml,并且,所有实验操作均在BSL-3实验室内完成。
6.1细胞病变(CPE)测定
(1)以5×10
4/ml的浓度,向96孔培养板的每孔中加入100μl Vero E6细胞,并在37℃,5%CO
2的条件下培养24小时。
(2)将待测抗体稀释成10个浓度:为1/10μg/μl,1/30μg/μl,1/90μg/μl,1/270μg/μl,1/810μg/μl,1/2430μg/μl,1/7290μg/μl,1/21870μg/μl,1/65610μg/μl,1/196830μg/μl。取100μl指定浓度的待测抗体,加入等体积的SARS-CoV-2真病毒(100TCID50),并在37℃,5%CO
2的条件下孵育1h。
(3)在步骤(1)的培养结束后,弃去96孔培养板中的细胞培养液,加入步骤(2)制备的含有待测抗体和真病毒的混合液(200μl),作为实验组。孵育1h后,从孔中吸出上清,每孔加入200μl DMEM培养基(含有2%抗生素和16μg/ml胰蛋白酶)。
在实验过程中,平行设置细胞对照组和病毒对照组。在细胞对照组(4个复孔)中,弃去孔中的细胞培养液后,每孔添加200μl DMEM培养基(含有2%抗生素和16μg/ml胰蛋白酶)。在病毒对照组(3个复孔)中,弃去孔中的细胞培养液后,每孔添加100TCID50的真病毒(100μl),并在37℃孵育1h;孵育结束后,从孔中吸出上清,每孔加入200μl DMEM培养基(含有2%抗生素和16μg/ml胰蛋白酶)。
(4)在37℃,5%CO
2的条件下培养细胞4-5天。
(5)在光学显微镜下观察细胞病变(CPE),并根据细胞病变情况,评估不同浓度的单抗对CPE的抑制活性。
抗原结合单元ABU-174的检测结果如下表6所示,结果表明抗原结 合单元ABU-174在细胞上对病毒有抑制效果,中和抗体滴度为1.6ng/μl。
表6.抗原结合单元ABU-174对SARS-CoV-2的中和活性效果
“+”为细胞有CPE变化,“-”为细胞无CPE变化或正常细胞形态
抗原结合单元ABU-175的检测结果如下表7及图4所示,结果表明抗原结合单元ABU-175在细胞上对病毒有抑制效果,中和抗体滴度为0.7ng/μl。
表7.抗原结合单元ABU-175对SARS-CoV-2的中和活性效果
“+”为细胞有CPE变化,“-”为细胞无CPE变化或正常细胞形态
6.2空斑减少中和试验(PRNT):
(1)以5×10
4/ml的浓度,向96孔培养板的每孔中加入100μl Vero E6细胞,并在37℃,5%CO
2的条件下培养24小时。
(2)将待测抗体稀释成5个浓度:为50μg/ml,10μg/ml,2μg/ml,0.4 μg/ml,0.08μg/ml。
(3)在步骤(1)的培养结束后,弃去96孔培养板中的细胞培养液,加入步骤(2)制备的含有待测抗体和真病毒的混合液(200μl),作为实验组。孵育1h后,从孔中吸出上清,每孔加入200μl DMEM培养基(含有2%抗生素和16μg/ml胰蛋白酶)。
在实验过程中,平行设置细胞对照组和病毒对照组。在细胞对照组中,弃去孔中的细胞培养液后,每孔添加200μl DMEM培养基(含有2%抗生素和16μg/ml胰蛋白酶)。在病毒对照组(4个复孔)中,弃去孔中的细胞培养液后,每孔添加100TCID50的真病毒(100μl),并在37℃孵育1h;孵育结束后,从孔中吸出上清,每孔加入200μl DMEM培养基(含有2%抗生素和16μg/ml胰蛋白酶)。
(4)在37℃,5%CO
2的条件下培养细胞4天。
(5)细胞甲醛固定后,利用兔抗SARS-COV血清(sino生物)和过氧化物酶标记的山羊抗兔IgG(Dako)标记。利用TMB(True Blue,KPL)显色后观测空斑,计算抑制率并绘制剂量-反应曲线。
图5显示了本文示例性的抗原结合单元ABU-174、ABU-175和ABU190的剂量-反应曲线。由图5可见,抗原结合单元ABU-174、ABU-175和ABU190对SARS-CoV-2真病毒均具有良好的中和活性,能够有效抑制病毒感染和侵入细胞,IC50分别为0.5μg/ml(ABU-174),0.3μg/ml(ABU-175)和0.8μg/ml(ABU-190)。
实施例7.本文中的抗原结合单元的体内效力
SARS-CoV-2通过与hACE2受体的相互作用感染细胞。在两种不同的动物模型中评估了文中的抗原结合单元在体内对SARS-CoV-2的中和效力。
7.1抗原结合单元在hACE2转基因小鼠体内的效力
在第一个模型中,使用了hACE2转基因小鼠作为动物模型,并以暴露前预防或暴露后预防2种不同模式进行了治疗。具体而言,将hACE2 转基因小鼠经鼻内感染SARS-CoV-2种病毒(2019-nCoV Beta CoV/Wuhan/AMMS01/2020),剂量为105TCID50。
在暴露前预防治疗模式中,在病毒感染前24小时,将20mg/kg剂量的本文中的抗原结合单元腹膜内注射到hACE2转基因小鼠中,并检测了所述抗原结合单元作为暴露前预防干预的功效。
在暴露后预防治疗模式中,病毒感染后2小时,将20mg/kg剂量的抗原结合单元注射至小鼠中。使用HG1K(抗H7N9病毒的IgG1抗体)作为阴性对照,在病毒感染后2小时以20mg/kg注射。连续5天每天记录能够反映受感染小鼠健康状况的体重。
7.2抗原结合单元在仓鼠体内的效力
在第二个模型中,使用仓鼠(Mesocricetus auratus)作为动物模型,并以暴露前预防或暴露后预防2种不同模式进行了治疗。具体而言,类似于hACE2转基因小鼠,在仓鼠鼻内感染SARS-CoV-2原病毒(SARS-COV-2/WH-09/human/020/CHN),剂量为105 TCID50。
在仓鼠暴露前预防治疗模式中,在病毒感染前1天,将20mg/kg剂量的本文中的抗原结合单元注射到仓鼠中。对照组中,感染后2小时向动物注射PBS。
在仓鼠暴露后预防治疗模式中,感染后2小时,将本文中的抗原结合单元根据体重以不同剂量(包括20、10、5和2mg/kg)腹膜内注射到仓鼠中。同时将注射了磷酸盐缓冲液(PBS)的仓鼠作为对照。连续7天每天记录受感染仓鼠的体重。感染后7天将仓鼠处死,收集肺用于病毒载量分析。
序列信息
本文所涉及的部分序列的信息如下表8所示。
表8.序列表
尽管本文所述的具体实施方式已经得到详细的描述,但本领域技术人员将理解:根据已经公布的所有教导,可以对细节进行各种修改和变动,并且这些改变均在本文所述的保护范围之内。本文所述的全部分为由所附权利要求及其任何等同物给出。
Claims (27)
- 一种提供针对预先确定的抗原的抗原结合单元的方法,包括(a)获得来自个体的血液样品,其中所述个体在第一时间经确认携带所述抗原,并在所述第一时间之后的第二时间经确认不携带所述抗原或者所携带的所述抗原的量减少;(b)富集所述血液样品中的B细胞;(c)对包含多个所述个体的富集的B细胞的样品进行单细胞转录组的VDJ测序,以提供抗原结合单元的克隆型信息;以及(d)基于所述对比确认所述针对所述抗原的抗原结合单元。
- 根据权利要求1所述的方法,其中所述步骤(b)还包括选择所述血液样品中的记忆B细胞。
- 根据任一前述权利要求所述的方法,其中所述步骤(c)之前还包括通过以下步骤中的一个、两个、三个或四个来排除至少30%、40%、50%、60%、70%、80%、90%、95%的所述富集的B细胞:选择CD27+B细胞;排除幼稚B细胞;排除耗尽的B细胞;排除非B细胞;以及选择其中能够结合所述抗原的细胞。
- 根据任一前述权利要求所述的方法,还包括在步骤(c)之后进行以下步骤中的一个、两个、三个、四个、五个或更多个以排除至少30%、40%、50%、60%、70%、80%、90%、95%的抗原结合单元克隆型:选择富集频率高于1的克隆型;选择或排除来自于表达IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和/或IgG4的B细胞的克隆型;通过细胞分型排除非B细胞克隆型;通过细胞分型排除幼稚B细胞克隆型;通过细胞分型排除未经转换的B细胞;通过细胞分型排除耗尽的B细胞克隆型;通过细胞分型排除单核细胞;通过细胞分型排除树突状细胞;通过细胞分型排除T细胞;通过细胞分型排除自然杀伤细胞;以及排除可变区突变率小于1%、1.5%或2%的克隆型。
- 根据任一前述权利要求所述的方法,还包括在步骤(c)之后进行以下步骤中的一个、两个、三个、四个、五个或更多个的选择,从而使得至少大约10%、20%、30%、40%、50%、60%、70%、80%或90%的所选择的克隆型在步骤(d)中被确认为所述抗原结合单元:选择富集频率高于1的克隆型;选择或排除来自于表达IgA1、IgA2、IgD、IgM、IgG1、IgG2、IgG3和/或IgG4的B细胞的克隆型;通过细胞分型排除非B细胞克隆型;通过细胞分型排除幼稚B细胞克隆型;通过细胞分型排除耗尽的B细胞克隆型;通过细胞分型排除单核细胞;通过细胞分型排除树突状细胞;通过细胞分型排除T细胞;通过细胞分型排除自然杀伤细胞;以及排除可变区突变率小于1%、1.5%或2%的克隆型。
- 根据任一前述权利要求所述的方法,还包括根据所获得的序列信息进行轻重链匹配。
- 根据任一前述权利要求所述的方法,还包括根据所获得的序列信息进行谱系分析。
- 根据任一前述权利要求所述的方法,其中所述第二时间是在所述第一时间之后大约1天、2天、3天、4天、5天、6天、7天、8天、9天、10天、11天、12天、13天、14天、15天、20天、25天、30天。
- 根据任一前述权利要求所述的方法,其中所述个体在所述第二 时间经确认不携带所述抗原。
- 根据任一前述权利要求所述的方法,其中所述个体在所述第二时间经确认不携带所述抗原或者所携带的所述抗原的量减少。
- 根据任一前述权利要求所述的方法,其中所述个体在多个不同的第二时间经确认不携带所述抗原或者所携带的所述抗原的量减少。
- 根据权利要求11所述的方法,其中所述多个第二时间间隔大约1天、2天、3天、4天、5天、6天、7天、8天、9天、10天、11天、12天、13天、14天、15天、20天、25天、30天。
- 根据权利要求11所述的方法,其中所述个体在多个不同的第二时间经确认所携带的所述抗原的量逐渐减少。
- 根据任一前述权利要求所述的方法,其中所述抗原为病毒抗原。
- 根据任一前述权利要求所述的方法,其中所述抗原为新型冠状病毒(SARS-CoV-2)。
- 根据任一前述权利要求所述的方法,其中所述抗原为新型冠状病毒(SARS-CoV-2)S蛋白的受体结合结构域(RBD)。
- 根据任一前述权利要求所述的方法,还包括将所述克隆型信息与一个或多个参比序列进行对比。
- 根据权利要求17所述的方法,其中所述参比序列为特异性结合所述抗原的抗体或其片段。
- 根据权利要求17或18所述的方法,其中所述参比序列特异性结合SARS-CoV。
- 根据权利要求17至19之一所述的方法,其中所述参比序列特异性结合SARS-CoV S蛋白的受体结合结构域(RBD)。
- 根据权利要求17至20之一所述的方法,其中所述参比序列为抗体或其片段,并且所述对比包括根据所述转录组序列信息预测克隆型的CDR3H结构,并将所述克隆型的预测的CDR3H结构与所述抗体或其片段的CDR3H结构进行对比。
- 根据任一前述权利要求所述的方法,还包括在宿主细胞中表 达所述抗原结合单元。
- 根据任一前述权利要求所述的方法,还包括纯化所述抗原结合单元。
- 根据任一前述权利要求所述的方法,还包括评价所述抗原结合单元结合所述抗原的能力。
- 根据任一前述权利要求所述的方法,其中至少大约10%、20%、30%、40%、50%、60%、70%、80%或90%的所述抗原结合单元的结合所述抗原的速率高于与所述抗原解离的速率。
- 根据任一前述权利要求所述的方法,其中至少大约10%、20%、30%、40%、50%、60%、70%、80%或90%的所述抗原结合单元以小于100nM、小于50nM、小于20nM、小于15nM、小于10nM、小于5nM、小于4nM、小于3nM、小于2nM、小于1nM、小于0.5nM、小于0.1nM、小于0.05nM、或小于0.01nM的平衡解离常数(KD)结合所述抗原。
- 一种制备针对预先确定的抗原的抗原结合单元的方法,包括根据任一前述权利要求所述的方法鉴定针对所述抗原的抗原结合单元,在宿主细胞中表达所述抗原结合单元,以及收获并纯化所述抗原结合单元。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/924,307 US20230183322A1 (en) | 2020-05-13 | 2021-05-12 | Method for preparing antigen-binding unit |
CN202180002029.1A CN114174516A (zh) | 2020-05-13 | 2021-05-12 | 制备抗原结合单元的方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010403873 | 2020-05-13 | ||
CN202010403873.2 | 2020-05-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021228135A1 true WO2021228135A1 (zh) | 2021-11-18 |
Family
ID=78526011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/093305 WO2021228135A1 (zh) | 2020-05-13 | 2021-05-12 | 制备抗原结合单元的方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20230183322A1 (zh) |
CN (2) | CN114174516A (zh) |
WO (1) | WO2021228135A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024096742A1 (en) * | 2022-11-06 | 2024-05-10 | Leyden Laboratories B.V. | SARS-CoV-2 BINDING POLYPEPTIDE |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100279352A1 (en) * | 2009-04-30 | 2010-11-04 | Rafi Ahmed | Rapid Generation of Antibodies |
WO2017109721A1 (en) * | 2015-12-21 | 2017-06-29 | Zumutor Biologics, Inc. | A method of generating an antibody naïve library, said library and application(s) thereof |
CN107760690A (zh) * | 2017-10-25 | 2018-03-06 | 珠海泰诺麦博生物技术有限公司 | 一种高通量全人源抗体的制备方法及应用 |
CN108752472A (zh) * | 2018-06-13 | 2018-11-06 | 中国科学院广州生物医药与健康研究院 | 一种抗h7n9抗体及其制备方法和应用 |
CN109666070A (zh) * | 2017-10-13 | 2019-04-23 | 清华大学 | 单克隆抗体mers-4v2及其编码基因和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111074007A (zh) * | 2020-02-15 | 2020-04-28 | 上海迪飞医学检验实验室有限公司 | 一种检测sars-cov-2病毒的恒温扩增试剂盒及引物探针组 |
CN110974950B (zh) * | 2020-03-05 | 2020-08-07 | 广州恩宝生物医药科技有限公司 | 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗 |
CN110951756B (zh) * | 2020-02-23 | 2020-08-04 | 广州恩宝生物医药科技有限公司 | 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用 |
-
2021
- 2021-05-12 US US17/924,307 patent/US20230183322A1/en active Pending
- 2021-05-12 WO PCT/CN2021/093305 patent/WO2021228135A1/zh active Application Filing
- 2021-05-12 CN CN202180002029.1A patent/CN114174516A/zh active Pending
- 2021-05-13 CN CN202110521323.5A patent/CN113667011B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100279352A1 (en) * | 2009-04-30 | 2010-11-04 | Rafi Ahmed | Rapid Generation of Antibodies |
WO2017109721A1 (en) * | 2015-12-21 | 2017-06-29 | Zumutor Biologics, Inc. | A method of generating an antibody naïve library, said library and application(s) thereof |
CN109666070A (zh) * | 2017-10-13 | 2019-04-23 | 清华大学 | 单克隆抗体mers-4v2及其编码基因和应用 |
CN107760690A (zh) * | 2017-10-25 | 2018-03-06 | 珠海泰诺麦博生物技术有限公司 | 一种高通量全人源抗体的制备方法及应用 |
CN108752472A (zh) * | 2018-06-13 | 2018-11-06 | 中国科学院广州生物医药与健康研究院 | 一种抗h7n9抗体及其制备方法和应用 |
Non-Patent Citations (3)
Title |
---|
BIN JU; ZHANG QI; GE XIANGYANG; WANG RUOKE; YU JIAZHEN; SHAN SISI; ZHOU BING; SONG SHUO; TANG XIAN; YU JINFANG; GE JIWAN; LAN JUN;: "Potent human neutralizing antibodies elicited by SARS-CoV-2 infection", 26 March 2020 (2020-03-26), pages 1 - 42, XP055737104, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.03.21.990770v2.full.pdf> * |
CAO YUNLONG; SU BIN; GUO XIANGHUA; SUN WENJIE; DENG YONGQIANG; BAO LINLIN; ZHU QINYU; ZHANG XU; ZHENG YINGHUI; GENG CHENYANG; CHAI: "Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells", CELL, vol. 182, 9 July 2020 (2020-07-09), pages 73 - 84+16, XP086211425, ISSN: 0092-8674, DOI: 10.1016/j.cell.2020.05.025 * |
LEONARD D GOLDSTEIN; YING-JIUN J CHEN; JIA WU; SUBHRA CHAUDHURI; YI-CHUN HSIAO; KELLEN SCHNEIDER; KAM HON HOI; ZHONGHUA LIN; STEVE: "Massively parallel single-cell B-cell receptor sequencing enables rapid discovery of diverse antigen-reactive antibodies", COMMUNICATIONS BIOLOGY, vol. 2, no. 1, 1 December 2019 (2019-12-01), pages 1 - 10, XP055758874, DOI: 10.1038/s42003-019-0551-y * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024096742A1 (en) * | 2022-11-06 | 2024-05-10 | Leyden Laboratories B.V. | SARS-CoV-2 BINDING POLYPEPTIDE |
Also Published As
Publication number | Publication date |
---|---|
CN113667011A (zh) | 2021-11-19 |
CN113667011B (zh) | 2024-03-29 |
US20230183322A1 (en) | 2023-06-15 |
CN114174516A (zh) | 2022-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021180218A1 (zh) | 一种抗新型冠状病毒的单克隆抗体及其应用 | |
US9321830B2 (en) | Anti-RSV G protein antibodies | |
CN113354729B (zh) | 一种抗新型冠状病毒的单克隆抗体及其应用 | |
WO2021218947A1 (zh) | 一种抗新型冠状病毒的单克隆抗体及其应用 | |
US20230348571A1 (en) | Cross-reactive coronavirus antibodies and uses thereof | |
CN115710311A (zh) | 冠状病毒的抗体或其抗原结合片段 | |
CN113943368A (zh) | 一种新型冠状病毒及其突变体的单克隆抗体及其应用 | |
CN113444169B (zh) | 新型冠状病毒的人源单克隆抗体及其应用 | |
CN113929774A (zh) | 一种新型冠状病毒及其突变体的单克隆抗体及其应用 | |
CN113354730B (zh) | 一种抗新型冠状病毒的单克隆抗体及其应用 | |
MX2010009885A (es) | Composiciones y métodos para la terapia y diagnóstico de citomegalovirus. | |
CN116836269A (zh) | 抗呼吸道合胞病毒的单克隆抗体及其应用 | |
US10611827B2 (en) | Non-human primate-derived pan-ebola and pan-filovirus monoclonal antibodies directed against envelope glycoproteins | |
WO2021228135A1 (zh) | 制备抗原结合单元的方法 | |
TW202144405A (zh) | 抗新型冠狀病毒(SARS-CoV-2)之新穎單株抗體及其應用 | |
US20240002477A1 (en) | Polypeptides for detection and treatment of coronavirus infection | |
US20240239874A2 (en) | Fully Human Monoclonal Antibodies that Broadly Neutralize SARS-COV-2 | |
WO2024054822A1 (en) | Engineered sars-cov-2 antibodies with increased neutralization breadth | |
CN118406140A (zh) | 针对SARS-CoV-2及其突变株的广谱单克隆抗体及其用途 | |
KR20220113346A (ko) | 칸디다에 대한 항체 및 이의 용도 | |
CN116419972A (zh) | 抗SARS-CoV-2抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21804019 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21804019 Country of ref document: EP Kind code of ref document: A1 |